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THE SYNTHSEQ APPROACH TO PERSONAL GENOTYPING
Abstract
Inspired by the Archon X Prize for Genomics, our research project involves implementing a novel strategy
for sequencing the human genome. This prize worth $10 million will be awarded to the first company to
sequence 100 human genomes with 99.999% accuracy in less than 10 days for under $10,000 each.
However, the possibility of winning the X Prize is secondary to the prospect of revolutionizing medical
diagnostics. Currently, the genomic state of‐the‐art involves identifying SNPs (single nucleotide
polymorphisms) that are correlated to certain diseases. Compared to such existing diagnostics, the
genome‐wide, sequence‐based biomarkers that will be made possible by fast and affordable human
genome sequencing are staggering.
After six months of thorough investigation and development, we are pleased to present SynthSeq, a
cutting‐edge, whole‐genome sequencing venture based on the novel sequencing‐bysynthesis technology.
In contrast to high‐priced competitors, our inexpensive and comparatively error‐free whole genome
sequencing solution will prove to be an invaluable diagnostic resource, and it will only become more
valuable as advances are made in the field of molecular diagnostics. At our intended retail price of $5,000,
series A investors can expect a worst‐case MIRR of 22%, and the ultimate NPV should be no less than
$700 thousand. We are confident that our innovative SynthSeq technology will deliver high‐fidelity,
low‐cost whole genome sequencing to as many as 3,000 customers per year as currently envisioned, with
the potential for scale‐up to millions.
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A BSTRACT
Inspired by the Archon X Prize for Genomics, our research project involves implementing a
novel strategy for sequencing the human genome. This prize worth $10 million will be awarded to
the first company to sequence 100 human genomes with 99.999% accuracy in less than 10 days for
under $10,000 each. However, the possibility of winning the X Prize is secondary to the prospect of
revolutionizing medical diagnostics. Currently, the genomic state‐of‐the‐art involves identifying
SNPs (single nucleotide polymorphisms) that are correlated to certain diseases. Compared to such
existing diagnostics, the genome‐wide, sequence‐based biomarkers that will be made possible by
fast and affordable human genome sequencing are staggering.
After six months of thorough investigation and development, we are pleased to present
SynthSeq, a cutting‐edge, whole‐genome sequencing venture based on the novel sequencing‐by‐
synthesis technology. In contrast to high‐priced competitors, our inexpensive and comparatively
error‐free whole genome sequencing solution will prove to be an invaluable diagnostic resource,
and it will only become more valuable as advances are made in the field of molecular diagnostics.
At our intended retail price of $5,000, series A investors can expect a worst‐case MIRR of 22%, and
the ultimate NPV should be no less than $700 thousand. We are confident that our innovative
SynthSeq technology will deliver high‐fidelity, low‐cost whole genome sequencing to as many as
3,000 customers per year as currently envisioned, with the potential for scale‐up to millions.
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1. INTRODUCTION
__________________________________________________________________________________________________________________

P URPOSE OF G ENETIC S EQUENCING
The first successful sequencing of the human genome began in 1990 with the Human
Genome Project. It took until 2003 for the results of the project – the full sequence of the human
genome – to be released.

The project cost approximately $3 billion. 1

Since then, Sanger

Sequencing, the method used by the Human Genome Project, has been replaced by newer, better
sequencing methods. These “next generation” techniques have reduced the sequencing time of a
full human genome from the decade‐long scale to the week‐long scale and have moved closer to
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making the “thousand dollar genome” a reality.

The prospect of fast, cheap access to any

individual’s entire genetic sequence has opened the door for exciting new possibilities in promoting
human health.
One of the biggest goals of the Human Genome Project, and of genomic research in the years
since the first successful sequencing, has been to link physical conditions, including many diseases,
to their genetic roots. This could provide doctors and scientists with the opportunity to diagnose
and treat patients for specific ailments that are identified as risks based on that individual’s genetic
code.

As access to genetic information becomes easier to obtain, and science gains an

understanding of the genetic causes of many conditions, a new approach to the diagnosis and
treatment of disease is gaining prevalence – personalized medicine. In the near future, access to
such information could mean that certain revealing sequences within each patient’s individual
genome will be used to authorize the use of specialized medical treatments. While affordable entire
genome sequencing and the full implications of personalized medicine are not yet a reality,
medicine has already incorporated genetic screening into many facets of patient care.
While the average consumer does not have access to a service that will give them their
entire genome at a reasonable cost, there are services that will sequence small parts of the human
genome containing small nucleotide polymorphisms (SNPs). SNPs are the most common genetic
variations in the human genome. Disease genetics studies aim to link specific SNPs to increased
risk for disease, thus allowing services to focus on specific locations in the genome that represent
potential markers. 2 About 3,669 DNA variants associated with diseases and traits have been
identified; screening specifically for these variants could provide insight into patient risk for
disease without the need for whole‐genome sequencing. Companies such as 23andMe, Navigenics
and deCode Genetics provide services that will test for genetic variations and give information on
susceptibility to some diseases. While sequencing these segments of the genome provides some
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insight into the risk factors, this approach is handicapped by our limited knowledge of which genes
contribute to disease and their precise mechanisms of action. 3
Perhaps a more tangible effect of genome sequencing in current medicine comes in the area
of pharmacogenomics, a field that investigates the effects of genetic variations on the body’s
response to drugs. All people respond to drugs differently, and many drug responses appear to be
linked to genetics. Finding the links between genetic polymorphisms and differences in drug
metabolizing enzymes and drug transporters allows for the use of genetic tests to predict
individuals’ responses to different treatments. 4 Pharmacogenomics could lead to drugs that are
prescribed for and administered to each patient depending on his or her genetic makeup. This
predictive genomic information could help optimize drug selection and dosing, while avoiding
adverse responses by offering advance knowledge of which patients would benefit from a
particular drug and how that drug should be administered. 5
A recent example of the increased prevalence and importance of pharmacogenomics comes
in the marketing and administration of the anticoagulant Warfarin. Warfarin is a widely prescribed
drug that helps prevent blood clots and heart attacks, but dosing the drug for individual patients is
difficult. If a patient is given too high a dose, Warfarin can cause massive bleeding in the brain; in
2007, the drug was the second leading cause of emergency room admissions related to adverse
drug response. In 2007, information on genetic testing was incorporated into the drug’s product
label, and the FDA authorized the marketing of a genetic test associated with the drug. Prior to the
approval of additional information on Warfarin’s label and the associated genetic test, the only way
to attempt to prevent such reactions was trial and error – patients would be given a dose of the
drug, which would be adjusted depending on its observed effects. However, data suggesting that
patients with certain variations within the CYP2C9 and VKORC1 regions of the genome require
lower doses of Warfarin (and are therefore more prone to adverse effects when given the usual
dose) led to the use of genetic tests to fine‐tune dosage of the drug in high‐risk patients. 6
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The increased utility of genetic screening for drug therapies has prompted the FDA to begin
thinking about how to approach drugs manufactured for particular genetic groups. Clinical trials
are currently designed to test therapies on large and diverse groups of patients to identify an
average response that gauges both safety and efficacy. Pharmacogenomics seeks to bring this type
of analysis down to a sample size of one. The FDA has begun to add recommendations for tests, as
evidenced by the Warfarin case; however, there is still no standard approach for approving a
diagnostic test to be used in concert with a given therapy. The FDA has indicated that it is in the
process of developing guidelines to tackle this issue. In the meantime, pharmacogenomics will
continue to strengthen its foothold in the pharmaceutical industry. There are already a wide range
of drugs on the market with associated pharmacogenomic tests, some of which are summarized in
Table 1.1 below. 7
Drug
Atomoxetine HCI
(Strattera)
Clopidogrel (Plavix)
Cetuximab (Erbitux)
Panitumumab (Vectibix)
Gefitinib (Iressa)
Irinotecan (Camptosar)
Tamoxifen (Nolvadex)
Warfarin (Coumadin)

Purpose
ADHD
treatment
Heart attack
prevention
Colorectal
cancer drug

Gene Factor
Patients with a mutation in the CYP2D6 gene are at risk of
suffering serious liver damage.
A variation of the CYP2C19 gene interferes with the way the
drug is metabolized, rendering it ineffective.
The drugs indicated only in patients whose tumors express a
normal KRAS gene.

Lung cancer
drug
Colorectal
cancer drug
Breast cancer
drug
Blood
thinner

Indicated primarily in the treatment of patients whose tumors
have a mutation in the EGFR gene.
People with a genetic variant suffer side effects because they
have fewer liver enzymes to break down the drug.
Variations in the CYP2D6 gene can make a person metabolize
the drug too quickly or not at all.
In certain patients, the drug can cause excessive bleeding.
Genetic testing can reveal the right dose.

Table 1.1 Drugs on the market with associated pharmacogenomic tests

Genetic screening’s most significant impact in the field of medicine has arguably been in
cancer treatment. One application of genetic analysis in cancer treatment is evaluating risk of
developing certain cancers. Mutations in specific genes have been implicated in many kinds of
cancer. For example, mutations in BRCA1 and BRCA2 are positively correlated with a woman’s risk
of developing breast and ovarian cancer. 8 Genetic screening – either whole genome sequencing or,
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more commonly at this point, SNP analysis to identify specific mutations – could be used to gauge a
patient’s risk and take an appropriate action to prevent cancer or catch it in its early stages.
Another application of genetic screening in oncology has been to develop specialized
therapies to fight specific tumors. Historically, cancer treatment has been dominated by broadly
acting cytotoxins that attack all fast‐growing cells, in an approach known as chemotherapy.
However, in recent decades the molecular basis of many cancers has been studied and elucidated.
Specific sets of genetic defects lead to various types of cancer in many different parts of the body,
and two patients with seemingly similar cancers often have dissimilar underlying molecular causes.
Thus, many modern therapies are targeted to cancers with very particular genetic mutations. As a
result, genetic screening has become increasingly important in oncology. An example of applying
genetic screening to discover and apply treatment options is in the tyrosine kinase inhibitor,
Imatinib, and its use in fighting Chronic Myeloid Leukemia. The drug is effective against cancer
whose specific cause is the fusion of the BCR and ABL genes, and it represents a powerful tool for
patients fighting this cancer. 9

This novel, individualized approach to treatment requires the

discovery and development of tests for biological indicators that help doctors determine how to
treat each individual patient. As screening methods become increasingly fast and affordable,
genetic screening is sure to assume an even bigger role in cancer treatment. 10
A very recent example of the advances in genetic sequencing with implications for cancer
treatment has come in the identification of personalized tumor biomarkers. Using advanced
genome sequencing, researchers have reported that they are able to detect mutant DNA in patient
plasma isolated from blood samples, and that the genetic rearrangements in this DNA proved to be
identical to those found in tumor samples from the same patients. This allows for the detection of
chromosomal rearrangement – which has been long recognized as a universal feature of cancer – in
a way that was previously impossible. Whereas conventional approaches to genetic sequencing in
cancer treatment have looked for single‐letter mutations, this “personalized analysis of rearranged
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ends” (PARE) approach identifies entire rearrangements in DNA sequences. This has been made
possible by the ability to perform massive, parallel, and near‐complete sequencing of individual
tumor genomes. Identifying the specific mutations behind a patient’s cancer provides valuable
information needed to provide appropriate treatment. While the cost of this sequencing is still too
high to be widely applied, advancements in cost and throughput of genome sequencing could make
it possible to bring this tool into hospitals in the near future. 11
While science and medicine have made great strides toward the realization of personalized
medicine, challenges persist.

Although genetic screening has become increasingly fast and

affordable and promises to soon become widely accessible, the great difficulty in analyzing the data
it provides has become apparent. Little is known about the links between genes and disease, and
even those links that have been found generally account for a small percentage of the overall risk of
disease.7 A recent study comparing the results of two DNA screening companies, Navigenics and
23andME, which predicted risk of thirteen diseases in five individuals, found that for seven of the
diseases, 50% or fewer of the predictions made by the two companies agreed. 12
There is still work to be done on both fronts of the pursuit of personalized medicine – the
accessibility of genetic data and the understanding of the genetic causes of disease. However, it is
conceivable that as the price of sequencing the genome decreases and large amounts of genomic
data become available, correlational analyses of genetic sequences and diseases will become easier
to conduct and will provide more accurate forecasts. One can imagine a day when pharmaceutical
companies sequence the entire genome of each patient in phase III trials in order to identify genetic
causes of different reactions to a drug. With the average cost per patient hovering around $26,000
and the cost of sequencing the human genome nearing $1000, this seems fully plausible 13. It seems
clear that advancements in genetic sequencing are poised to transform medicine in the near future.
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T HE S YNTH S EQ A PPROACH
The SynthSeq approach strives to deliver superior, accurate whole genome sequencing to its
customers. The main goal of the project is to develop a process that will sequence human genomes
at exceptional throughput and low cost. The process has been designed to meet the demand of
3000 genomes per year. The incremental operating costs per genome must be $10,000 or less
apiece, and the start‐up capital for the process cannot exceed $25 million. These parameters were
inspired by the Archon X Prize for Genomics, which calls for the sequencing of 100 different human
genomes, for less than $10,000 each, in less than 10 days, with an error rate below ten per million
Project Name

The SynthSeq Approach Toward Personal Genotyping

Project Champion
Project Leaders
Specific Goals

Dr. John Crocker
Stephanie Amato, Alan Futran, Kevin Krebs, Brian Recchione
Sequence 3000 human genomes per year for less than $10,000 per sequenced
genome, with a start‐up cost of $25 million or less.
In‐Scope:
 Identify and investigate high throughput screening techniques
 Provide in‐house whole genome sequencing through application of
the most promising technology
 Characterize the biological, optical, and computational methods
underlying this technology
 Select appropriate equipment and staff
 Develop a working and profitable business model centered around
the aforementioned production level, investment, and genome price
Out‐of‐Scope
 Fabrication of flow cells
 Synthesis of reversible terminator nucleotides
 Focused screening of genome (such as SNP screening)
 The provision of genetic or medical consultation

Project Scope

Deliverables






Market assessment and competition analysis
Technical feasibility assessment
Full scale manufacturing requirements and protocol
Financial analysis over a 4‐year project life cycle

Timeline






Working sequencing prototype within 12 months
Scale‐up operations within 2 years
Full‐scale production in years 3‐4 with simultaneous R&D
Liquidate or sell the company at the conclusion of fifth year

Table 1.2 SynthSeq’s Project Charter
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bases. The first team to meet these criteria will be awarded $10 million. Outlining the company’s
specific goals, project scope, deliverables, and a timeline for developing its sequencing process, the
SynthSeq project charter is presented in Table 1.2.
The scope encompasses the development of the sequencing process in all of its aspects.
Sequencing by synthesis principles based on a technology established by Helicos BioSciences lays
the foundations of the process, while the use of novel biological, mechanical, and optical
innovations makes the SynthSeq approach unique. Once the DNA sample is extracted, purified, and
sheared, short single strand DNA templates are immobilized on the surface of a flow cell where the
sequencing chemistry occurs. The sequencing is dependent on the position of the template strands
on the flow cell surface.

The soft lithography polydimethylsiloxane (PDMS) flow cells are

purchased as one‐time use consumables from an outside vendor. They incur low consumables
costs and allow the construction of customizable PDMS gaskets that easily adhere to the glass
surface of the flow cells.
The chemistry relies heavily on reversible terminator fluorescent nucleotides, which
prevent the elongation of the template strand until two small moieties on the nucleotide are
chemically altered. This property allows time‐controlled asynchronous base pair detection because
the polymerization reaction is not occurring in real time. The synthesis of these specific nucleotides
is outsourced to a company that specializes in modified nucleotide synthesis. However, an organic
chemist will work in research and development to improve the function of these nucleotides since
they are an integral part of the sequencing design. Once base addition successfully occurs, intricate
optical techniques are used for single molecule detection and subsequent nucleotide identification.
The nucleotide fluorescence relates directly to its position on the imaging grid of the flow cell, and
the data is recorded in its corresponding fragment’s sequence. An open source genome aligner is
used to assemble the genome after all the individual DNA templates are sequenced.
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The analysis of the final sequenced genome is out of the scope of the project. Currently,
customers will not receive any medical consultation or diagnosis of elevated risks of diseases after
his or her DNA has been sequenced. The company will refer customers to other companies that
specialize in the analysis of genomic sequences. However, recognizing that this analysis can be
lucrative, SynthSeq may opt to incorporate this service into its business plan in the future.
The goal of the first year is to develop a working prototype of the process. Once the
prototype is functioning successfully, the scale‐up and commercial sequencing will commence in
the second year of operation. The number of sequencing stations will be increased to accommodate
the increased production rate of genomic sequences. After scale‐up is achieved, the company
resources will be allocated to sustaining high throughput commercial sequencing. Also, funds will
be directed to research and development for improvements in areas such as sequencing chemistry,
optimal reaction conditions, higher throughput design, and better fluorescent detection techniques.

T ECHNOLOGY R EADINESS A SSESSMENT
All next generation sequencing methods, including SynthSeq, represent an evolution of DNA
sequencing technology. These current approaches are rooted in the motivation to drive down the
cost of genome sequencing while increasing throughput and ensuring a high degree of accuracy.
SynthSeq’s ability to meet its process requirements is indebted to the considerable advances made
by previous technologies.
Advancements in nanotechnology, nucleotide chemistry, optical devices, microscopy tools,
and computational systems make the SynthSeq design successful in meeting its cost and throughput
goals. The microfluidic flow cells, where the sequencing chemistry occurs, take advantage of micro‐
fabrication techniques to create a cell on the micro scale. The soft lithography cells reduce the
reaction volume significantly compared to more traditional sequencing methods and thereby
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conserve the amount of reagents used in the process. Another nano‐technological contribution is
polyelectrolyte layer by layer assembly, which forms a polymer film that prevents non‐specific
binding of free dNTPs to the bottom of the flow cell. This reduces background fluorescence and
preempts recording the detection of a free nucleotide as a base in the sequence.

Customer Value
Proposition

Sequenced
Genome

Accuracy

Products

Technical
Differentiation

Process/
Manufacturing
Technology

Material
Technology

Shotgun
Sequencing

Double‐Barrel
Shotgun
Sequencing

Genomic
Mapping

True Single
Molecule Sequencing

Computer
DNA
aligner

EMCCD

Camera

Automated
Microscopy
Accessories

Microfluidic
Flow Cells

TIRF
Microscope

Sequencing by single molecule

Sequencing random DNA
fragments in mass

synthesis without DNA
amplification

Dideoxy Chain‐
Termination DNA
Sequencing

Restriction
Enzymes

Clinical Use

Whole‐
Genome
Shotgun

Genbank

Product
Technologies

Low
Cost

High Throughput

Layer by Layer
Assembly

Reversible Terminating
Fluorescent Nucleotides

Yeast and Bacterial Artificial
Chromosome Vectors (YAC
and BAC)

PDMS Glass Bonding

Phi29 Phi29 Soft Lithography
Polymerase
Polymeras

Figure 1.1. Innovation Map for SynthSeq Technology

The single molecule detection is made possible by the ability to suspend the DNA
polymerization reaction to identify the base added. The development of reversible terminator
fluorescent nucleotides allows the designer to control the reaction. The conversion of the 3’‐OH of
these nucleotides to a small allyl group allows the polymerase to add the base without any steric
inhibitions, but prevents the polymerization of additional bases until the hydroxyl group is
regenerated. Once the reaction is suspended, the use of a megapixel Electron Multiplying Closed‐
Coupled Device (EMCCD) camera and automated microscope stage positioners allow the
simultaneous detection of single base additions on the order of magnitude of 105 DNA templates.
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The high pixel resolution and fast frame rate serve as important parameters for high throughput
because they allow more template elongations to be observed in a shorter period of time. Further
improvements in speed and resolution will increase the throughput capabilities of the process.
Also, advancements in genome alignment algorithms will facilitate the assembly of all the collected
optical data into the genomic sequence in less time, and using less processing power.
In addition to imaging limitations, the throughput exhibits a strong dependence on the
microscope stage accessories. Advancements in stage automation allow the process to image
multiple areas in the same flow cell, which dramatically reduces the time necessary to sequence a
genome. The velocity and settle time of the stage positioner dictates the speed at which different
imaging areas on the flow cell can be analyzed. The piezo nanopositioner provides stage movement
on the nanometer scale. This instrument is able to detect the presence of more than one template
within a single pixel.
All of the above technologies are integral to the execution of the design goals. Figure 1.2
outlines the SynthSeq process. After taking into account capital, operating, and labor costs, as well
as market pressures, a SynthSeq customer can expect to pay $5000 for his or her complete genome.
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FIGURE 1.2 The SynthSeq process is outlined from the preparation stages to the product delivery.

C USTOMER R EQUIREMENTS
The customer requirements involved in human genome sequencing revolve around a few
main issues: accuracy of the sequence, quick results, and a positive customer experience. These
items help define the Critical‐to Quality (CTQ) variables for the process, which are highlighted in
Table 1.3. These variables represent the core drivers of this technology. Without achievements in
either accuracy or high throughput, the process will not meet its requirements for sequencing 12
genomes a day with a minimum error rate of 1 per 100,000 bases. The CTQ variables for the
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process can be categorized as newuniqueand difficult (NUD). NUD requirements represent basic
customer needs that must be satisfied before they will purchase our genomic sequencing service.
These requirements are not fully established in the genomic sequencing market. The developments
made with the CTQ attract customers and are novel to the field.
The accuracy of the genomic sequence is affected by the error rates in each stage of the
process. For customer ease, the genomic DNA is collected through a saliva sample, which may
introduce some bacteria into the sample, trace amounts of erroneous DNA. During sequencing,
errors are introduced through polymerase‐facilitated nucleotide addition, single‐molecule
fluorophore detection by the EMCCD cameras and the elucidation of the identity of the excited
nucleotide, and they are manifested in the alignment of the DNA sequence. A barcode system will
be instituted to prevent misidentification, with the scanning of each genome taking place prior to
sequencing to confirm that the genomic DNA sample corresponds to the correct customer.
The turnaround of the genomic data to the customer should be reasonable. This time frame
Customer Requirements

CTQ Variables

Weight

Accuracy

Sample Prep Error Rate
Polymerase Error Rate
EMCCD Single Molecule Detection Error Rate
Fluorophore Cleavage Error Rate
Sequence Aligner Error Rate
EMCCD Resolution
EMCCD Frame Rate
XY Stage Positioner Velocity
Rate of Nucleotide Addition
Rate of Fluorophore Cleavage

0.50

Sample Method
Confidentiality
Referral to Genome Analysis Service
Low Cost

0.20

Result Turnaround

Customer Experience

0.30

Table 1.3. Customer requirements satisfied by the SynthSeq technology CTQ variables addressed.

is linked directly to the process’s throughput of data generation and alignment. Since the SynthSeq
process is serial in nature, the main limitations to throughput originate in the speed of imaging the
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single molecule fluorophores and moving from one imaging area to the next on a flow cell; the
frame speed and pixel resolution of the camera and the velocity of the stage controller are key
elements.

Advancements in these technologies may significantly increase the speed of data

generation for our process. SynthSeq was designed to successfully sequence twelve genomes in a
day using four workstations. Considering both sample preparation and genome assembly, the
turnaround is less than four days, providing the customer with a relatively fast result.
Our ability to attract customers to SynthSeq is essential for the success of our company. As
aforementioned, saliva was selected as the sampling mode over other common methods such as
blood and cheek swabs. This collection method was chosen for its non‐invasiveness, simplicity and
easy purification using a basic kit, while still providing adequate genomic DNA for analysis.
SynthSeq’s customer price of $5000 is competitive with the other sequencing technologies (see
Chapter 2), so our customers are getting unparalleled value for their money.

C ONCLUSIONS
The following chapters will show that an attractive business model can be built around the
sequencing of entire human genomes using a novel single molecule Sequencing By Synthesis (SBS)
strategy. This process will succeed in sequencing twelve genomes per day for 250 days per year
using just four stations composed of reaction, imaging and fluid handling equipment. The genome
will be sequenced at a cost of $747 to the company, while our customers will be charged a
competitive price of $5000 per genome. This price significantly undercuts all current competitors
and, compounded with the unprecedented accuracy of our sequencing technology and the positive
customer experience provided by the company, should attract a majority of the genome sequencing
market to SynthSeq while still ensuring comfortable profit margins.
We will describe the basic principles behind our technology and why it is superior to its
competitors (Next Generation Sequencing Technologies, Chapter 2), highlight the components that
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made possible the unprecedented throughput achieved by the SynthSeq method (High Throughput,
Chapter 3), explain the steps required to take a human saliva sample and prepare a flow cell
containing template DNA on a novel sequencing surface (Preparation Stages, Chapter 4), describe
the chemistry behind our unique approach to single molecule SBS, the optical equipment used to
image and sequence individual DNA molecules, and the analysis that proves this method can
identify the sequence of nucleotides on the molecule (Chemistry and Detection, Chapter 5), review
the hardware and software used to assemble a full genome from billions of short sequences
(Genome Assembly, Chapter 6) and present a financial analysis proving that SynthSeq is a
worthwhile investment poised to provide high profits to investors (Financial Analysis; Chapter 7).
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2. NEXT GENERATION SEQUENCING TECHNOLOGIES
__________________________________________________________________________________________________________________

This chapter will outline the fundamentals of the SynthSeq technology, followed by an
analysis of the genotyping market and existing companies, and finally a pricing scheme. We will
demonstrate that our technology is poised to outperform any existing technology in terms of both
cost and throughput, making it a prime target for venture capitalists. Existing genotyping firms that
will be assessed include Illumina, 454 Life Sciences, Pacific Biosciences, and Knome. The former
three firms offer sequencing platforms in the form of an instrument that can be purchased and used
in private labs. Knome has a business model most similar to ours, as they provide a genotyping
service to individuals. Further analysis will be provided in the following sections, all of which
demonstrates the viability of our technology as a sound investment opportunity for angel investors.
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M ARKET A NALYSIS
The nature of the genotyping industry is quite volatile due to the constant and swift
technological innovations that characterize the field of biotechnology. Consequently, a portion of
SynthSeq’s revenue must be allocated toward staying at the forefront of these technological
advances by investing in research and development. Furthermore, the success of our business is
highly dependent upon the low cost of the service that we provide. Many competing technologies
exist, which would steal some of SynthSeq’s market share if they were competitively priced.
Fortunately, our technology is more accurate and cheaper than that of other existing firms (see the
following Competitive Analysis), so SynthSeq definitely merits investment.
Another reason that costs need to be kept down is the current state of the market. The fact
that it is nascent industry also means that the value of the personal genome is not yet obvious.
Compounded by the fact that inferior, cheaper options, such as the SNP analysis, already exist, there
is only so much that a customer would be willing to pay for what may turn out to be merely
extraneous data on top of the SNP analysis which is already available commercially. 14 Nevertheless,
it is SynthSeq’s firm belief that as more genomes are sequenced and compared, the great value of
our product for personalized medicine will be realized.
Potential consumers of SynthSeq’s genotyping service include several main types. Our
target customers run the gamut from healthcare professionals hoping to determine a patient’s risk
factors to healthy individuals who want a copy of their genome for personal reasons. Scientists in
labs across the country will want to sequence genomes cheaply and quickly to build up a
comparative database for determining the mutations that lead to various pathologies. As more and
more genomes are sequenced, the value of such a database will continually increase, incentivizing
still more individuals to reap the benefits of having access to their genomic sequence.
Specifically, individuals with a family history of certain cancers or genetic disorders for
which there is no current diagnostic might represent some of our customers. Necessary changes in
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medical practice and insurance company policies (not to mention ethical dilemmas)
notwithstanding, the technology has the potential to revolutionize the field of medicine, offering
novel insights into diseases such as cancer, as well as a plethora of other genetic maladies. The next
few years could see SynthSeq’s genotyping service become a routine medical test, ordered for
millions of individuals every year in the United States alone. 15

S EQUENCING BY S YNTHESIS
In the two decades since the Human Genome Project began, sequencing technologies have
grown increasingly more time and cost efficient. Perhaps the most significant technological leap in
the quest for the thousand‐dollar genome has been the advent of non‐Sanger sequencing. Sanger
sequencing uses modified, tagged nucleotides to terminate newly synthesized DNA fragments at
specific bases. The fragments are then size separated. Since the modified terminator nucleotides
are tagged, the sequence can be determined from this separation. Since the early 1990s, different
implementations of this biochemical method have been the main
way of sequencing DNA. However, over the past five years, new
“next‐generation” sequencing techniques have surfaced, which are
exploited in highly parallel DNA sequencing platforms that are
reducing the cost of DNA sequencing by orders of magnitude. 16
The specific advancement that has made it possible for SynthSeq
and other “next‐generation” technologies to achieve such high
throughput at such a low cost is known as Sequencing‐By‐
Synthesis (SBS).
Sanger sequencing relies on the amplification of target
DNA by polymerase chain reaction (PCR) and the ability to
terminate this process, followed by the recognition of the identity
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Figure 2.1 Sequencing centers
producing the Sanger sequence data for
mammalian genome projects are
factory‐ like outfits with a large number
of personnel.

and relative position of the ddNTP that terminated amplification. By doing this for billions of
fragments of the target DNA being sequenced, the overall genome can be reconstructed. This basic
idea has been coupled with developments such as capillary electrophoresis, laboratory automation
and process parallelization. The first attempts to sequencing the entire genome involved huge
sequencing centers run by hundreds of scientists and operators using these methods to construct
one genome, taking years at a time and costing billions of dollars (Figure 2.1). 17
SBS is fundamentally different. Instead of running a chemical reaction (PCR) on the target
DNA first and then analyzing the products to find a sequence, the methods that use single molecule
SBS detect individual DNA molecules and monitor the addition of nucleotides that incorporated
during DNA synthesis. 18 Innovations in template preparation, imaging, and genome alignment and
assembly have made it possible to directly sequence a strand of DNA as it is synthesized by tracking
which nucleotide is being added to each position of the template during the reaction. This method
of sequencing DNA has been employed in platforms that cheaply produce large amounts of
sequence data in a way that traditional (Sanger) sequencing cannot. 19 There are many platforms
that employ SBS, each using it in a unique way.

S YNTH S EQ T ECHNOLOGY – A SYNCHRONOUS , SINGLE MOLECULE SBS
SynthSeq’s technology is based on true single molecule SBS.

DNA molecules are

immobilized on a solid surface in a flow cell and are individually imaged by an EMCCD based optical
detection system as DNA synthesis is carried out. The DNA to be sequenced is denatured and
sheared and the billions of fragments of the single stranded DNA are annealed to a glass slide using
novel surface chemistry. The molecules are distributed randomly over the surface of the glass slide.
This slide is loaded into the flow cell, which is mounted on the microscope stage. Here, the
sequence of chemical reaction and imaging steps, which identify the sequence of the individual
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fragments, are carried out. DNA amplification is done using unique, modified nucleotides that
reversibly terminate the extension reaction. These nucleotides are tagged with a fluorophore
according to their identity, G, C, A or T, and have a 3’‐allyl group replacing the usual hydroxyl group
that temporarily blocks subsequent nucleotide addition. After incorporation of the nucleotides, the
reaction is stopped, allowing for the entire slide to be imaged to identify which nucleotide was
added to each template fragment on the slide. Then, the modified nucleotides are un‐blocked
(regeneration of 3’‐OH and cleavage of fluorophore), which allows the extension reaction to
continue and the identity of the next nucleotide added to be determined.
There are a few aspects of SynthSeq’s approach to SBS that set it apart from other
technologies.

Some methods PCR amplify the DNA before sequencing which introduces

amplification bias – an over‐representation of reads from areas of the genome with between 40%
and 65% G+C content. The SynthSeq approach directly sequences single molecules taken directly
from samples without any artificial amplification. Another defining characteristic of the SynthSeq
method is that it is asynchronous. DNA synthesis is blocked after each nucleotide addition and
imaging steps are carried out in between nucleotide addition steps. The next nucleotide is not
added until the reaction has been unblocked. Thus, it is known exactly how many nucleotides
should have been added and recorded as part of the sequence. This virtually eliminates insertion
and deletion errors.

Other technologies use real‐time imaging of ongoing reactions.

These

procedures often suffer from errors in reading homopolymers – stretches of DNA composed of the
same, repeated nucleotide. Since our technology pauses following each successive addition, we
know exactly how many nucleotides exist in a sequence of repeats.
Figure 2.2 below is a schematic of the steps in the SynthSeq process.
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3.

2.

Figure 2.2 SynthSeq’s single molecule SBS: 1) Nucleotides modified with 3’‐allyl group (shown in red) and fluorphore are introduced to template strands, 2) DNA
synthesis occurs and modified nucleotides are added to template strands, 3) Fluorophores are excited (different excited fluorophores shown in blue, yellow and
magenta) and molecules are imaged, 4) Fluorophores are cleaved and 3’‐OH groups (shown in green) are regenerated.

4.

1.

C OMPETITIVE A NALYSIS
Despite the unprecedented throughput of the SynthSeq technology that has been
demonstrated, it is important to consider possible competitors in the genome sequencing market.
Some of the companies that offer parallel services to ours include Illumina, Roche/454 Life
Sciences, and Pacific Biosciences. Unfortunately, due to the great amount of information that is
proprietary and protected, precise determinations of cost and throughput are often difficult to
assess. Furthermore, like all biotechnology related fields, genomic sequencing is characterized by
frequent technological advances and increases in efficiency that promote stiff competition. For this
reason we will devote 15% of our revenue to research and development, in an effort to stay at the
forefront of the industry.

In the following sections, we demonstrate the advantages of our

technology over the methods currently employed by other firms.
Illumina
Like many other next‐generation sequencing firms, Illumina relies upon the parallel
sequencing of millions of DNA fragments to determine an individual’s genomic sequence.
Specifically, they rely on a reversible terminator‐based sequencing chemistry known as Solexa.
First, randomly fragmented genomic single stranded DNA (ssDNA) strands are attached to a planar,
optically transparent surface and then extended and amplified, creating a sequencing flow cell with
millions of clusters that contain roughly one thousand copies of a certain template. Next, the
clusters are sequenced using four‐color DNA sequencing by synthesis technology that employs
reversible terminators with cleavable fluorescent dyes, in addition to an undisclosed DNA
polymerase. The tagged dNTPs then emit light at different wavelengths following laser excitation.
This light is detected using total internal reflection (TIRF) optics. Finally, the reads are aligned
against a reference genome using Illumina’s own proprietary software.
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Some of the advantages of the Solexa technology include the simplicity of their flow cell
(random array, like SynthSeq), as well as the use of DNA clusters, which intensifies the signal sent to
the imager, increasing the signal to noise ratio. Also, after completion of the first read, the
templates can be regenerated, enabling a second read from the other end of the clusters, resulting
in more data and an internal verification method.
Illumina claims their new HiSeq2000 to be the first commercially available sequencer to
enable researchers to obtain ~30x coverage of two human genomes in a single run for under
$10,000 (USD)* per sample. 20 However, as demonstrated by Figure 2.3, Illumina’s throughput
simply cannot compete with SynthSeq’s technology. Although the specific error rates of this
instrument could not be found in the Illumina HiSeq2000 brochure or datasheet, it is likely that its
increased throughput comes at the cost of accuracy. Researchers have noted that Illumina’s
sequencing reads are prone amplification bias. It is likely that this occurs as a result of Illumina’s
reliance on PCR to amplify their reads or their cluster amplification technique; SynthSeq’s
technology demonstrates no such bias. 21

Figure 2.3 Timeline of Illumina’s technology, which demonstrates their throughput deficit. (Image
from Illumina, Inc.)

Roche/454 Sequencing
More competitive than Illumina’s technology, 454 Sequencing relies on longer read lengths
to improve throughput. They employ sequencing by synthesis techniques and record light signals
using CCD cameras. As shown in Figure 2.4, DNA beads are deposited into PicoTiterPlates, allowing
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400,000 parallel reads. Their technology is highly
accurate

and

is

characterized

by

very

few

substitution errors, allowing de novo sequencing to
be performed (i.e. no reference genome is necessary).
Additionally, the accompanying software is nimble,
enabling facile data transfer and fewer IT demands.

Figure 2.4 454’s DNA beads being deposited into
a PicoTiterPlater (Image from Illumina, Inc.)

However, as shown in Figure 2.5, 454 (like Illumina’s Solexa) depends on PCR, which takes a great
deal of time and may result in amplification bias. Additionally, 454 utilizes a pyrosequencing
technique. One nucleotide species is introduced during each cycle, which is detrimental to both
throughput and reagent costs. SynthSeq allows for the introduction all of the nucleotides in concert,
while 454’s technology necessitates four separate add and wash cycles. 22

Figure 2.5. Formation of DNA coated microbeads by clonal amplification in
water‐in‐oil microreactors (Image from Roche Diagnostics)

Figure 2.6. Timeline of 454’s sequencing technology (Image from Roche Diagnostics)

The resultant timeline for the 454 Sequencing shown in Figure 2.6 indicates far lower throughput
than is possible using SynthSeq technology. For instance, the quoted run time for one million reads
is ten hours using the GS XLR70 sequencing kit, corresponding to just one billion bases per day. 23
Although this may sound like very high throughput, each of SynthSeq’s four stations will process
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over thirty billion bases per day. SynthSeq does not involve PCR, and its alignment process will
employ a reference genome rather than de novo sequencing, saving time and increasing throughput.

Pacific Biosciences
Pacific Biosciences, founded in 2004, has developed a platform that uses “Single Molecule
Real Time” (SMRT™) DNA sequencing technology. This technology is unique in that it employs
natural DNA synthesis by a DNA polymerase. Like SynthSeq technology, their approach is based on
the imaging of successive fluorescently tagged bases while a single
DNA polymerase molecule processes them. However, they employ
zero‐mode waveguides (ZMWs), tiny aluminum wells that house
the growing DNA strands, as opposed to the random array used by
the SynthSeq technology. In addition to a SMRT cell that ensures a

Figure 2.7 PacBio SMRT
Sequencing, inside ZMW (Image
from Pacific Biosciences)

high signal to noise ratio, PacBio's SMRT technology relies on
phospholinked nucleotides that produce fast, accurate reads using

DNA synthesis and a detection system that enables the real‐time detection of single molecules. The
low costs made possible by the PacBio platform (the most similar technology to SynthSeq) will
surely result in some stiff competition.

Figure 2.8 SMRT sequencing along a DNA single‐strand. (Image from Pacific Biosciences)
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PacBio asserts that their longer read lengths promote simpler, more accurate assembly
because they can fully span repetitive or structurally varied genomic regions that can present
problems for shorter read‐length platforms. The longer reads also reduce the need for high
coverage, significantly lowering operating costs and requiring lower throughput. While these are
accurate claims, our technology overcomes the read‐length issue with its relatively error‐free
process (no insertions or deletions, only no‐reads) and an aligner designed specifically for short
reads. PacBio’s SMRT sequencing technology, in contrast, is plagued by insertion and deletion
errors that lead to the need for high coverage, severely decreasing throughput.
PacBio also touts the openness of its informatics design, which facilitates “scalable
customization and integration with existing infrastructure”, as well as the versatility of their
SMRT™ Cell, which allows users to easily upgrade their setups. Similarly, they note that as detector
technology improves, increases in throughput will be possible without changes to the assay. It is
important to realize that while other companies are focused on ensuring the flexibility and user‐
friendliness of their instruments, SynthSeq does not need to concern itself with such issues. Given
that we are offering a service instead of a sequencing platform, we have certain inherent
advantages over the companies mentioned above. Our sole focus is on ensuring throughput and
customer experience, not developing an instrument that requires maintenance and optimization.

Knome
Knome is another firm that may present some competition to SynthSeq. Unlike the above
companies that peddle expensive genotyping instruments, Knome has a business model that closely
parallels our own. Like SynthSeq, Knome is focused solely on customer experience and throughput,
rather than manufacturing genotyping machines for the scientific community.
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Originally situated as a quasi boutique firm selling an expensive product to self‐proclaimed
“pioneers”, Knome now offers its genotyping service to a wider audience, as a result of downward
movement in price over the last couple of years. The identity of the sequencing technology they use
is heavily guarded, but it should be assumed that they can compete with any of our other
competitors in terms of throughput. Unfortunately, their error rates could also not be found, so
gauging their competitiveness is rather difficult. However, with a price tag of $68,500 for their
whole genome sequencing service, SynthSeq is in position to significantly undercut them.
In a savvy economic move, Knome has recently developed two separate levels of sequencing
to expand their market. In addition to the “KnomeCOMPLETE” (an individual’s entire genome
sequence), the company has also started to offer the “KnomeSELECT” option, which includes only
the exome, or the protein‐coding region of the DNA sequence. The price tag for the limited analysis
is $19,500, more than three times cheaper than the full sequence and, at this stage in personalized
medicine, almost equally useful. 24 It is important to note that much of Knome’s focus lies in
customer experience, including representatives who personally meet with clients to discuss the
findings and analysis of a team of geneticists. Customer confidentiality, access to consultation, and
providing the latest genomic interpretations are three facets of Knome’s business model (Figure
2.9) that we need to strive for in order to erode their market share, our ability to undercut their
price notwithstanding. 25

Figure 2.9 The Knome Business Model. (Image from Knome, Inc.)
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P RICING A NALYSIS
Knome’s cheaper exome sequence option is reminiscent of many other companies offering a
similar service at much lower prices. For example, Navigenics and 23andme are two such firms
offering a more limited analysis of the genes that have been linked to disease. 26 Ostensibly,
SynthSeq with its advanced chemistry, low error rates, and entire genome capabilities should
attract a wide audience if priced lower than our full genome competitors.

However, before

SynthSeq can be absolutely sure of success, the relative utility of the full genome over a “select”
analysis consisting exclusively of the protein‐coding DNA exome needs to be demonstrated. Until
some palpable advantages of full‐genome sequencing are demonstrated, a large proportion of the
personal genotyping market will continue to purchase the cheaper option. Therefore, our focus
needs to be on matching these competitors’ prices as well.
One more consideration that SynthSeq needs to make in terms of pricing is the downward
trend in cost of the human genome over time that is shown in Figure 2.10, below.

Figure 2.10. Full genome sequencing price trends (data shown for Knome), Year 1 corresponds to
2005 and remaining years follow. Predicted prices are $43,000, $26,000 and $10,500 for years 2011,
2013 and 2015 respectively.

Based on the above trend, the cost of total genome sequencing has been decreasing
exponentially over the course of the last decade. SynthSeq must consider not only the price at which
it will be competitive in the first year, but also how it might need to respond in subsequent years to
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the continuing downward trend of genotyping costs. It is important to note that the prices of our
competitors are inflated to what the market will tolerate, and do not necessarily reflect the actual
cost of producing a genome. As soon as we introduce a cheaper option, other companies may be in
a position to match our price, which is another aspect of the market that SynthSeq must take into
consideration (see Chapter 8 for more detailed financial analysis).

C ONCLUSIONS
As demonstrated in the above sections, the SynthSeq technology presents a sound
investment opportunity. Our superior throughput and very low cost compared to our competitors
is a direct result of the relatively error‐free nature of our detection strategy (discussed in Chapter
5). Starting out with the best technology is the greatest boon to our future ability to keep costs low.
Even when undercutting the closest competitors’ prices by more than half, our company will post
significant profits. However, remaining in this advantageous position over the next few years will
admittedly be a challenge, which is why SynthSeq is devoting considerable resources to continued
research and development efforts. We cannot over‐emphasize the importance of providing our
customers with a personalized experience rivaling that of Knome, including but not limited to the
latest interpretation of their genomic sequence. For the above reasons, investors should be assured
that their money will support the most viable solution to fast and inexpensive personal genotyping.
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3. OPTIMIZING SYNTHSEQ’S THROUGHPUT
__________________________________________________________________________________________________________________

The SynthSeq process aims to sequence twelve genomes per day. The technology must
generate massive amounts of data in parallel to meet this goal due to the large number of base pairs
in a human genome and the nature of sequencing by synthesis. The SynthSeq technology remains
competitive in the commercial sequencing market because of its high throughput capabilities. Since
our process is serial in nature, many unique design decisions are incorporated to transform a
typically slow and low throughput, but highly accurate process into a system that meets its desired
throughput goal.
Many of the bottlenecks in the SynthSeq design originate in the chemistry and detection of
single fluorescently tagged nucleotides after they are added to the DNA template strands. Unlike
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other technologies that sequence in real time, SynthSeq suspends the polymerization reaction to
determine which base is incorporated. This places time limitations on the process, but these
restrictions are overcome by utilizing mechanical and optical equipment in novel ways.
Many variables affect the overall throughput calculation of the SynthSeq process. The
following factors were heavily considered during the design stages: pixel size, fields of view,
kinetics of chemical reactions, read length, optical efficiency, and coverage. These parameters are
ultimately optimized to generate the throughput needed to reach SynthSeq’s goal.

EMCCD S IZE OF P IXELS AND D IMENSIONS OF P IXEL A RRAY
The pixel size and dimensions of the pixel grid for the EMCCD camera set the parameters for
the optical field of view and the detection volume. Every camera specifies the pixel size inherent to
its chip and how many pixels lie on that chip. SynthSeq utilizes a megapixel camera with 1024 by
1024 pixels to take advantage of as many pixels in a single imaging area as possible. The pixel is
ultimately where a single nucleotide fluorophore is detected and identified. Ideally, a single DNA
fragment immobilized on the surface of the reaction chamber will correspond to one pixel.
Therefore, the more pixels present on the camera’s detection chip, the more DNA templates can be
sequenced in one imaging area. The camera chosen by SynthSeq has one of the largest pixel array
dimensions on the EMCCD market. When new camera innovations arise with more pixels in the
imaging chip, that technology can be applied to the SynthSeq process to increase throughput even
further.
The size of the pixel affects the size of the imaging area, the detection volume, and the
kinetics of the nucleotide addition. The camera consists of pixels with standard 13µm by 13µm
dimensions. However, through a 60x objective and a 0.5 magnification changer built into our
detection microscope, the pixel size is reduced to 0.5µm by 0.5µm.
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Equation 3.1
The microscope used in the process offered 100x objectives and other magnification changers, but
the resulting pixel size would have been too small for SynthSeq’s design. The size of the pixel sets
the imaging area to be about 0.25mm2; this value corresponds to the field of view in the
microscope.

V IEWING M ULTIPLE I MAGING A REAS
A feature unique to SynthSeq is its ability to simultaneously sequence templates in multiple
imaging areas and then rotate through these fields of view to perform single molecule detection.
This practice increases the throughput of this overall process tremendously. If only one imaging
area is sequenced at a time, the throughput of the process would fall and sequencing a single
genome would take over 1300 hours and consume over 1600 flow cells. This time and use of
resources is not feasible for SynthSeq.

0.5 µm
0.5 µm

0.5 mm
0.5 mm

13mm

13mm
Figure 3.1. The dimensions of the pixel size, imaging area, and overall reaction chamber directly impact the
throughput. The white grid represents the reaction chamber in the flow cell that consists of 841 imaging areas. Each
imaging area, shown in orange, has 1024 by 1024 pixels, each with dimensions of 0.5µm by 0.5µm (in blue).
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To solve this problem, sequencing multiple imaging areas simultaneously is applied. A total
of 841 imaging areas fit into the 13mm by 13mm reaction chamber in the flow cell with the
0.25mm2 size of one imaging area. This increases the throughput of detection to 2.8*108 DNA
templates sequenced simultaneously in the flow cell. The time moving from one imaging area to
the next is a major factor to the throughput of the process and will be discussed in the next section.

2

1

Nucleotide Addition
Incubation – 3s

Initial Imaging – 0.111 s

Computation and
Repositioning – 0.021s

Image – 0.111 s

250nm shift ‐0.2 s

3

Fluorophore Cleave and
3’OH Regeneration – 60s

Move to next imaging
area and settling – 0.07 s

Image – 0.111 s

Figure 3.2 The outline of the chemistry and detection cycle for a single nucleotide addition to the DNA templates. (1) The
free dNTPs are incubated over the entire reaction chamber. (2) A single imaging area undergoes imaging, shifting, and
another imaging before the stage moves on to the next imaging area. (2) The cleave solution is injected into the entire
reaction chamber to allow the addition of the next free dNTP round to sequence the next base on the templates.

S INGLE N UCLEOTIDE A DDITION AND D ETECTION
The rates of polymerization and fluorophore cleave/3’‐OH regeneration reactions as well as
the imaging protocol to detect the nucleotides are major time limitations in the design and
influence the throughput. Figure 3.2 displays the time involved in every step in the chemistry and
detection process. The innovative equipment used at the sequencing station permit the
asynchronous sequencing process to work in the proper time frame to achieve our throughput goal.
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The incubation of the free dNTP reaction solution in the reaction chamber occurs for 3s.
This incubation time does not significantly change the throughput when increased. Therefore, a
conservative incubation time was chosen to ensure successful nucleotide addition. The time
needed to cleave the fluorophore from the incorporated nucleotide and wash the tags out of the
reaction chamber is only 60s. This rate also does not limit the throughput time significantly.
The imaging of the tagged nucleotides provides the most difficult challenge to maintaining
the goal of sequencing twelve genomes per day. The imaging time depends on the frame rate of the
camera, which is set at nine frames/s. Faster cameras exist on the market, but the EMCCD is chosen
for its megapixel imaging grid, not for its frame rate. The two stage automated controllers, X/Y
positioner and microscan piezo from ThorLabs move the stage to image multiple imaging areas at
once. Since the shift time (0.02s) using the piezo did not affect the throughput, two images per
imaging area are incorporated into the design to improve the optical efficiency (discussed further
below). The speed of the X/Y positioner (10mm/s) is essential for moving between imaging areas
quickly. Overall, each imaging area takes 0.444s and the total time over all imaging areas for the
asynchronous addition of one nucleotide to each template is 374s. Achieving the necessary
throughput hinges upon this imaging cycle.

R EAD L ENGTH
Another variable considered in the throughput calculation is the read length of each DNA
template. The read length is defined as the number of base pairs that are sequenced on a single
template strand. The read length sequence is then sent to the aligner to assemble the entire human
genome. DNA shearing equipment limits how small the genomic DNA can be fragmented. The
specifications of the shearer used in the SynthSeq process cut the DNA into a mean length of 100
base pairs. These fragments are immobilized on the flow cell surface. The shear‐length exceeds the
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read length of the templates to prevent reaching the end of a template strand before all cycles of
nucleotide addition have been completed.
SynthSeq’s read length is 32 base pairs, which is shorter than many other competing
technologies. A shorter read length makes identifying repeating sequences more difficult when
aligning the genome. However, SynthSeq requires a shorter read length because of the
asynchronous nature of its sequencing process. The polymerase that catalyzes nucleotide addition
can only remain attached to the DNA template strand for 4.1 hours (see Chapter 5). If the read
length is increased, the time required to sequence more bases per template would surpass that time
and new polymerases would have to be incubated into the chamber mid‐sequencing.

O PTICAL D ETECTION E FFICIENCY
Single molecule SBS relies on the detection of individual DNA strands. The pixel count and
number of imaging areas limit the number of genomic fragments that can be sequenced
asynchronously. The system would be at its ideal level of template detection throughput at
1.05x106 templates per imaging area. However, an inherent feature of the SynthSeq technology is
the random immobilization of DNA templates on the surface of the flow cell’s reaction chamber. As
a result, the templates are bound randomly on the flow cell surface at a particular area density
defined as:
Equation 3.2

The area density of template packing is restricted because the signals from different
growing strands contaminate one another when they are too close due to optical diffraction. The
intensity of a single fluorescent base appears on the pixel grid as roughly a 300nm diameter circle.
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This disc cannot interfere with other template fluorescent circles or pixel boundaries following
specific boundary conditions. If one pixel has two template circles, then the pixel becomes inactive
because the wavelength emission of a particular base cannot be assigned to the proper template.
Also, the intensity ratios from two cameras used to identify bases will not fall in acceptable ranges
when overlap occurs.

The inability to identify the emitting fluorophore would result in an

unidentified base at that position in the sequence.
The random arrangement of templates on the surface causes some pixels to be unusable.
The ratio of usable pixels to total pixels becomes the ‘efficiency factor’ of the template/pixel system
and significantly affects the throughput. Higher efficiency allows more genomic fragments to be
sequenced simultaneously in a given imaging area, resulting in fewer flow cells used per genome
and a reduced total sequencing time. The efficiency is defined by Equation 3.3.
Equation 3.3

The probability of one template optical center landing in one pixel follows a statistical
distribution. Treating templates as fluorescent points, an optimally loaded system has 36.8%
empty pixels, 36.8% pixels containing one template, and 26.4% pixels containing two or more
templates. This calculation results in an efficiency factor of 0.368, which corresponds to the
maximum yield for the pixel array efficiency when optical diffraction is neglected. 27
The optical diffraction of the fluorophores and the 250nm stage shift must be taken into
account to obtain an accurate estimate of the system’s efficiency. To adapt to this design, a
computational simulation is performed using Java code presented in Appendix D. This takes into
account the scenarios where a pixel remains usable or becomes inactive due to template‐template
and template‐pixel boundary interactions.

43

A 1024 by 1024 two‐dimensional array models the imaging area of the EMCDD. Each box in
the array is broken down further into a 50 by 50 array to evaluate the pixel boundary conditions. A
random number generator randomly places numbers within the smaller arrays. The simulation
evaluates the number’s position relative to both its position in the array and its position in
comparison to other random numbers.
The boundary conditions follow certain criteria to determine if a pixel is viable. It is
assumed that if 50% or more of the template’s area lies within a pixel its intensity ratio can still be
accurately determined, and it is labeled viable.
Therefore, if the simulated template lies anywhere in
the pixel other than the four corners, where significant
pixel overlap occurs (the red areas of Figure 3.2.), the
template is considered viable and the count for that
particular pixel is set to 1. If a template lies on one of
the four corners, it appears as a diffractive disc
straddling 3 or 4 pixels. It is improbable that more than
Figure 3.3 The 3 by 3 array represents the
larger pixel grid. Since a random coverage is
used for template immobilization,
computational simulation must be used to
determine the statistical efficiency of the pixels.
If a template lands on any red area, that data is
not usable in the first optical imaging step. The
grid is shifted by 250nm to the right shown by
the dotted lines. This shift significantly
improves the efficiency.

50% of that disc will lie in one pixel, thus making all
four pixels unusable. Only one template can lie in a
pixel at once. If the simulated pixel already has a value
of 1 (i.e. a template already resides in the pixel), the box
becomes unusable and the value of that box in the array
is set to ‐1.

Another constraint on optical detection is contamination from neighboring pixels. As long
as less than 10% of the diffractive disc from a neighboring template encroaches upon the target
pixel, the target pixel is not contaminated. If any more than 10% of that disc lies in the target pixel,
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this contaminating signal causes an intolerable spread of the intensity peaks of the target signal.
This infringement makes the target pixels unusable.

4

4
2

2

5

5
3

3
1

1
(b)

(a)

Figure 3.4 (a) The templates are randomly arranged on the pixel grid. Number 1 is a good example of a viable pixel
placement. Number 3 is still in a good place because more than 50% of it is in a pixel. Templates 4&5 are not usable
because they are both occupying the same pixel. (b) After the shift is applied, template number 2, which was unusable
previously is now able to be used in the sequencing.

Using these assumptions, the efficiency of the pixel grid becomes 0.186. This efficiency is
about half the efficiency calculated when the templates are treated as points. This drop is expected
because simulating the templates as discs imposes additional limitations to what the system can
identify and thereby reduces the number of usable pixels.
In order to compensate for this decrease in efficiency, a 250nm stage shift is performed
using the piezo positioner. The shift will increase the efficiency by making some templates
detectable although they were previously considered in an unfavorable position on the pixel grid
(Figure 3.4(b)). The efficiency calculated is also a function of the area density. The optimal area
density is determined by trial and error to see which value produces the highest efficiency. With an
n=1.15, when 1.21x106 templates are laid out randomly on the imaging surface of the flow cell, an
efficiency of 0.324 is achieved. This value is close to the ideal efficiency obtained when both the
optical diffraction and shift were not taken into account. This efficiency value is incorporated into
the overall throughput equation.
An ordered array could have been produced on the slide’s surface instead of a random
coverage of DNA fragments. There exists instrumentation that could produce such an ordered
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array at the micron scale, such as the DPN 5000 System from Nanoink, Inc. This system uses Dip
Pen Nanolithography (DPN), a technique that uses an atomic force microscope tip to transfer
molecules to a surface. 28 This could be used to “print” arrays of poly‐T tails on the surface of a glass
slide that would then produce an ordered array of template DNA fragments. There is one main
advantage to this approach; an ordered array makes it easy to track DNA fragments on the surface
after each nucleotide addition and imaging step. The templates could be ordered so one template
corresponds to exactly one pixel.
There are several reasons why random coverage of single stranded DNA template strands
was chosen instead of an ordered array. The first reason is the cost and complexity of machinery.
Dip Pen Nanolithography machines can cost up to $500,000 compared to the machinery required
for random coverage, which costs roughly $17,000. Another reason an ordered array was passed
over was that it was unclear whether or not nano‐array printing machines could print onto a bio‐
inert surface. Representatives from nanoink could not guarantee success using the DPN5000
machine in this context. Finally, the array printer would have to produce an ordered array of single
molecules; the DPN5000 cannot consistently print only one single stranded DNA oligonucleotide.
There would have been many positions on the array that contained two or more template DNA
fragments producing unusable data.

T HE C OVERAGE F ACTOR
The random nature of this process requires an over‐generation of information in order to
assemble a full genomic sequence. The target genome must be multiplied by a coverage factor to
ensure no gaps exist in the sequence. This factor increases the total length sequenced and lowers
throughput. Therefore, this coverage factor must be optimized to reach the highest throughput
while eliminating base pair gaps. At a given base pair position, a success is defined as the existence
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of a sequenced fragment containing the base pair in question with the assumption that the aligner
will position it properly into the sequence. More critically, the success of a proper base in the
sequence depends on the success of binding polymerase to the template strands and maintaining
Step in Sequencing

Probability of Success

Process

high processivity, incorporating a free dNTP into the
growing

Polymerase Binding

99%

Polymerase Remaining

99%

template

strand,

generating

a

strong

fluorophore signal for detection, and assigning the signal
to the proper nucleotide so it can be placed in the

on Template Strand
Nucleotide Incorporation

99%

Detecting
Fluorophore
Table 3.1 Probability
of success
for each 99%
possible point of Signal
error in the sequencing
process. Because SynthSeq is such a low error
Nucleotide
Identification
99%
process every step
has a 99%
chance of being
successful.

genome sequence.

Each of these steps in the single

molecule sequencing has a probability of failure that
contributes to the overall probability of gaps forming in
the genome assembly. Therefore, each of these steps
received individual probability analysis to estimate the

depth needed for whole genomic coverage. The probability of success for each of these steps is
shown in Table 3.1. These specific analyses are shown in detail in Chapter 5.
The total coverage is established using a negative binomial distribution. The purpose of
finding this distribution is to determine how many copies of the genome must be sequenced to
reach the maximum overall error rate of 10‐5 or 1 in every 100,000 bases sequenced. This function
models the probability that there will be a certain number of failures before a predetermined
number of successes can occur. One of the variables in this distribution is the probability a success
will occur. The success rates of each individual source of error in the process contribute to the
overall probability of success. The total probability is the product of the probability from each
component (Table 3.1), which equals 0.95. Equation 3.4 is the formula for the negative binomial
distribution.

Equation 3.4
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Where x is the number of failures, r is the number of successes, and p is the probability of success.
In this system, the number of failures equals mean coverage ‐ 1, and the number of successes equals
1. Every base position in the genomic sequence needs at least one a success or identified base to
add to the sequence. The coverage is how many copies are required of a particular base position.
The failures are represented by X’s, or unidentified bases, in that position when processed by the
aligner.
Data

Description

5

The failure number is varied until the

probability of error is under 10‐5.

After this

Number of failures

1

Threshold number of successes

0.95

Probability of a success

Result

Description

2.96875E07

evaluation and application of Equation 3.4, the
coverage factor is calculated as 6 (Table 3.2).
Therefore, six copies of the genome must be

Negative binomial distribution

sequenced in the process to accurately reconstruct a
Table 3.2 The coverage is determined using the
negative binomial distribution. With a probability
of success at 0.95, the error rate is well below the
desired maximum error rate. The process uses a 6‐
fold coverage.

full human genome. This coverage provides an overall
error rate of 2.97*10‐7, which is lower than the 10‐5
target.

Many commercial competitors require more than 20‐fold coverage for their sequencing
technology. This is a major advantage for SynthSeq because it allows a higher throughput. This
lower coverage is made possible by the asynchronous nature of the process. Since the total number
of nucleotide additions is known, no deletion or insertion errors exist. If a base is not properly
identified in a particular position, then an X is placed in its spot and the sequencing continues in the
proper order. Also, SynthSeq does not need to worry about homopolymers – repetitive bases in a
single template – because reversible terminator nucleotides allow for the stepwise addition of
nucleotides through those sequences. Finally, since the SynthSeq process does not rely on
amplification of the extracted consumer DNA, it avoids amplification bias inherent to PCR. The
lower number of sequencing errors gives some flexibility in the need for additional coverage.
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T HROUGHPUT O PTIMIZATION
A critical feature of this technology is that it accomplishes exceptional throughput
capabilities without sacrificing highly accurate sequencing. Many design variables are taken into
account when developing a cost‐effective process with the required twelve genomes per day
capability. These factors are optimized to achieve our throughput goal with four sequencing
stations. The variables of the process that were optimized, and the design decisions made for each
variable, are displayed in Table 3.3.
First, the pixel size is dependent on the
objectives

and

magnification

changers

available for the microscope system. The 60x
objective with the 0.5 magnification changer
sets the pixels in the imaging area to roughly
0.25µm2 and the total imaging area to
0.25mm2. The number of imaging areas in the

Throughput Variable

Optimized Value/Decision

Pixel Size

0.5µm

Reaction Chamber Dimension

13mm by 13mm

Read Length

32 base pairs

Optical Efficiency

0.324

Coverage Factor

6‐fold

Table 3.3 Many factors were optimized to determine the exact
throughput of the SynthSeq process.

13mm by 13mm flow cell reaction chamber is 841. These areas set the parameters for how many
DNA templates can be sequenced simultaneously in one flow cell. Equation 3.5 shows the ideal
number of templates that can be sequenced simultaneously in one flow cell:

Equation 3.5
Where one imaging area contains a 1024 by 1024 pixel grid. Incorporating the read length
determines how many base pairs are being sequenced in a single flow cell, which is calculated in
Equation 3.6.
Equation 3.6
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If

could be achieved, one flow cell would be more than adequate to sequence a

human genome. However, the other factors must be accounted for to get a more accurate
calculation of SynthSeq’s throughput.
The major limitations to the throughput of this process are the efficiency and coverage
factors and the cycle time associated with the identification of each nucleotide. A higher efficiency
correlates to more templates being sequenced at once and less data being discarded because of
optical detection ambiguity. A small increase or decrease in the efficiency significantly alters the
throughput results. The real number of base pairs sequencing in one flow cell includes the
efficiency factor.
Equation 3.7
The coverage factor dictates how many total base pairs must be sequenced during the
process. The 6‐fold coverage factor forces the overall sequencing time to increase as well as the
amount of equipment needed to maintain the 12 genomes/day goal. This coverage requires the
sequencing of 18*109 base pairs. Equation 3.8 confirms that two flow cells are required to ensure
that the adequate number of bases are sequenced to properly align the genome.

Equation 3.8
The completion of the chemistry and detection cycle for one nucleotide addition sets the
time for the whole process occurring at the sequencing station. These times are limited by the
polymerase and cleave kinetics, frame rate of the EMCCD, velocity of the piezo controller, and the
velocity and settle time of the X/Y stage positioner. The time required to sequence one base across
all templates in the reaction chamber is about 7.3 minutes. This includes polymerization, imaging,
and cleaving steps. This chemistry and detection cycle occurs 32 times per flow cell to sequence
each template to its read length. Consequently, each flow cell runs for 4 hours. In between flow cell
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sequencing, a technician must dispose of the finished cell, reapply oil to the microscope stage,
attach the next flow cell properly, check for errors in the automation process, and begin the
sequencing cycles. This procedure takes an estimated time of fifteen minutes.
After summing all these process times, the sequencing of one genome requires about 8.25
hours. Each sequencing station can sequence up to three genomes per day assuming operation
occurs for 24 hours a day. One night operator will be working to ensure sequencing progresses as
planned and to change the flow cells when necessary. To achieve the goal of twelve genomes per
day, SynthSeq requires four sequencing stations.

C ONCLUSIONS
SynthSeq maintains a highly accurate sequencing process with unprecedented throughput
capabilities. The process design is optimized to sequence twelve genomes per day with an error
rate on the order of 10‐7, and 6‐fold coverage. As demonstrated, random coverage is not detrimental
to the throughput of the process; the 32.4% efficiency achieved is comparable to the predetermined
efficiency value stated in the literature.

Initial
Imaging Cycle

Fluorophore Cleave

Nucleotide Addition

Change Flow Cell‐ 15
i t

0

30x
Account for
read length

30x
Account for
read length

4h

Figure 3.5 The time needed to sequence a single human genome in the SynthSeq process is outlined in this Gantt chart.
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8.25 h

The Gantt chart in Figure 3.5 displays the time needed for each step in the sequencing and
the total time found using the throughput calculation. Now that proof of the throughput has been
established, the following chapters will discuss the details of the sample and flow cell preparation,
the chemistry and detection cycle for adding a nucleotide, and the assembly of the genome.

52

4. PRE‐SEQUENCING PREPARATIONS
__________________________________________________________________________________________________________________

Before the actual sequencing of the human genome can commence, the DNA must be
purified, the reaction chamber flow cell must be assembled, and the sequencing station must be
assembled. This chapter will outline the necessary preparation stages that need to be performed
before the actual chemistry and nucleotide detection occurs. The DNA sample is received as a
saliva sample for customer ease. The DNA in this sample is extracted, purified, sheared, and
modified to fit the requirements of the SynthSeq process.

The genomic DNA fragments are

immobilized randomly on the flow cell reaction chamber surface. The bottom glass cover slip of the
flow cell undergoes layer by layer assembly to prevent the non‐specific binding of fluorescent
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nucleotides to the flow cell surface. Once the flow cell is assembled with the immobilized DNA
templates, it is attached to the sequencing station via the microscope stage.

DNA E XTRACTION , P URIFICATION , AND P REPARATION

Covaris s2 Shearing
Conditions
Base Pair Size
Duty Cycle
Intensity
Cycles per Burst
Frequency Sweep
Z Height
Temperature
Seconds (time)

End Repair Mixture Components
Reagent
DNA sample
Nuclease‐free water
t4 DNA ligase buffer with
10mM ATP
dNTP mix
T4 DNA polymerase
Klenow enzyme
T4 PNK

Volume Required
(µL)
29
46
10
4
5
1
5
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100bp
20%
5
200
yes
6mm
6 °C
480

Total Volume

Genomic sequencing begins with the

100

collection of the customer’s DNA. Since saliva is not the most pure source of genomic information,
the need for high purity sample collection is high. The DNA Genotek Oragene® kit solves this
problem with a solution that mixes with saliva samples for preservation. A kit is mailed to the
customer; he or she spits into the prepared sample and mails their DNA sample back to SynthSeq.
The sample is then loaded into the Magtration 12GC, manufactured by PSS Bio Instruments, which
uses paramagnetic‐particle technology to purify the DNA from the
Oragene® solution. The elution volume is 200μL with a median yield of

Table 4.1 Shearing conditions for DNA
samples

3.8μg/200μL of DNA and a median A260/280 ratio of 1.95. 29 The DNA is now isolated, but its length is
too long for the purpose of the design. To rectify this problem, the DNA sample is inserted into the
Covaris s2 Shearer, where Adaptive Focused Acoustics energy, more commonly used in the process
of breaking up kidney stones, shears the double stranded DNA. By using the specifications found in
Table 4.1, we can obtain a target peak for a length of 100 base pairs. 30

Adding poly‐A tail Mixture

Table 4.2 Components used to repair ends of sheared DNA.

Reagent

Volume Required
(μL)

DNA sample
Klenow buffer
dATP
Klenow exo (3' to 5' exo
minus)
Total Volume

32
5
10
3
50

Table 4.3 Components used to add poly‐A tail to DNA.
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The DNA strands are then purified using the QIAquick Purification Kit, and the ends are
repaired by mixing the DNA with the reaction mixture found in Table 4.2 and incubated. 31 The DNA
once again is purified using the QIAquick Purification Kit. The poly‐A tail with fluorescent tag is
added to the DNA fragments using the reaction mixture found in Table 4.3 and incubated. 32 The
sample is the run through a Qiagen MinElute Purification Column Kit. 33 Both Qiagen kit protocols
can be found in Appendix B.

DNA shearing
8 min

Magtration
12GC
Purification
30 min (12
samples)

QIAGEN
kit 5 min
Repair DNA ends
30 min
Purify
5 min
Add poly‐A tail
30 min

0

15

30

45

60
Minutes

75

90

QIAGEN
MinElute Kit
5 min

105

120

Figure 4.1 The Gantt chart is for the DNA sample preparation from the customer’s saliva to the 100 base pair DNA
template fragments ready to be annealed to the flow cell surface. The total time of preparation takes about 2 hours.

The Gantt chart (Figure 4.1) shows the time each step in the sample preparation takes to
complete. The Magtration purification can purify all twelve genomic DNA samples needed for daily
operation at once.

All these procedures are performed to prepare the samples sent to the

sequencing station the following day. The times depicted in the Gantt chart affect the customer
turnaround because a day is required for DNA preparation before it is sequenced. However, the
DNA extraction, purification, and shearing steps do not impact the overall throughput, as they do
not constitute the rate‐limiting stage of the entire process, which is actually the SynthSeq chemistry
and nucleotide detection (refer to Chapter 5).

L AYER  BY L AYER A SSEMBLY AND T EMPLATE A NNEALING
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In order to carry out the single molecule SBS process, the fragments of the DNA being
sequenced must be bound to the glass slide. The surface must be able to bind to these fragments
but prevent non‐specific binding of free nucleotides and other molecules during the sequencing
process to prevent imaging errors. To accomplish this, it is necessary to coat the surface of the slide
with a bio‐inert surface that can still bind to the DNA fragments. The solution to this problem
requires layer by layer deposition of polymer onto the glass followed by immobilization of single
stranded DNA strands onto that surface that serve to capture the template DNA.
The formation of a bio‐inert surface on the glass slide is accomplished using layer‐by‐layer
(LbL) deposition. LbL deposition is a method that assembles ultrathin films on a substrate by
submerging the substrate, in this case a glass slide, back and forth between two dilute baths of
oppositely charged polyelectrolytes.

There are many advantages to LbL deposition.

It is a

relatively inexpensive procedure that allows for control over the structure, composition and
thickness of the deposited film.
For this process, the two polymers being used to coat the glass slides for use in SynthSeq’s
single molecule SBS approach are poly(acrylic acid) (PAA) and poly(acrylamide) (PAAm). The LbL
process is done using an automated dipping machine, DS‐50 SLIDE STAINER 115V. The glass slide
is alternately dipped in dilute solutions of the PAA and PAAm with three rinses (2 min, 1 min, 1
min) in between each polymer application.

Dipping the substrate into each of the polymer

solutions once completes one bilayer on its surface. A polymer trilayer is used in this process, so
three cycles of polymer addition are completed in order to create the bio‐inert surface that will
prevent free nucleotide absorption. The multilayer films are thermally cross‐linked at 90C under
vacuum for eight hours. 34
After completing the bio‐inert surface, the slide must be bio‐functionalized such that the
template DNA fragments to be sequenced can be immobilized on its surface.

The sample

preparation steps of the process include DNA purification, denaturation, fragmentation and
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functionalization steps; the functionalization step is particularly important for the immobilization
of these DNA strands onto a glass slide. Single stranded poly‐A tails are added to the beginning of
each of the sequences, allowing the fragments to anneal to a complementary poly‐T oligonucleotide.
These oliginucleotides are used to bio‐functionalize the polymer surface of the glass slide.
Single stranded DNA oligonucleotides can be covalently bound to the carboxyl groups of a
PAA surface by carbodiimide activation. The aminated ssDNA oligonucleotide is diluted in acid
buffer (10 mM 2‐(N‐morpholino)ethansulfonic acid buffer (MES buffer, pH 6; Sigma‐Aldrich)
containing 10 mM MgCl2 (Sigma‐Aldrich), 5 mM 1‐ethyl‐3(3‐dimethylaminopropyl)carbodiimide
(EDC; Sigma‐ Aldrich), and 0.33 mM N‐hydroxysulfosuccinimide (NHSS; Sigma‐ Aldrich)) and the
glass substrate is submerged in the DNA solution. The concentration of the DNA in the solution and
the incubation time (approximately 1 hour) is optimized to reach the desired coverage on the
surface of the polymer‐coated slide. 35
The modified template single stranded DNA fragments are annealed to the poly‐T tails on
the bio‐functionalized, bio‐inert surface of the glass slide using standard oligonucleotide annealing
procedure. The poly‐T oligonucleotide coated slide is immersed in a solution of the template DNA
and heated to 90‐95°C for 3–5 minutes and allowed to cool to room temperature. After slides are
coated, functionalized and annealed to the template DNA they are stored at 4°C until ready to use.
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S EQUENCING R EACTION F LOW C ELL
The microfluidic flow cell serves as the sequencing reaction vessel. Because its dimensions
are on the micro scale, the reaction volume needed for the polymerization and cleaving are
significantly reduced. Technological developments in soft lithography have provided a facile route

0.5 mm

13 mm

13 mm

Figure 4.2 This drawing depicts the dimensions of the PDMS flow cell used in the sequencing.
The top and bottom of the flow cell are composed of glass. The area of the reaction chamber is
as shown. Not pictured are channels etched 58
into the PDMS, two inlet channels and one outlet,
connected to the reaction chamber.

to microfabrication of microfluidic channels in a flow cell. Soft lithography includes a family of
techniques involving a soft polymeric replica (i.e. PDMS) cured to a hard master mold to create a
soft stamp. 37 The polymer is compatible with the chemicals used in the process so the flow cell will
not corrode or degrade while sequencing. The flow cells will be externally manufactured by
CiDRA® Precision Services, LLC, using their SlipStream™ technology. They develop consumable,
custom flow cells made as per design.
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In this sequencing process, a standard microscope

coverslips serve as the top and bottom of the device. The PDMS is cut according to the design
specifications of a reaction chamber 13mm by 13mm by 0.5mm. Figure 4.2 displays a rough
representation of the flow cell dimensions.
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LbL Assembly
27 minutes

Thermal Cross Linking 8 hours
Add polydT to polymer
1 hour
PDMS
bonding

0

1
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Hours
Figure 4.3 The time required to complete the flow cell preparation is shown in this Gantt chart.

Layer‐by‐layer assembly is performed on the glass slides, and the poly‐T tails are
immobilized on the surface. The sample’s DNA is annealed to the poly‐T tails. Then, the PDMS
stamp is bonded to the surface of the slides. The bonding is done using partial curing techniques,
and requires 35 minutes. This procedure results in high average bond strength and gives the most
flexibility in time, temperature, and cleanliness considerations. 39 Two inlet channels are fabricated
into the cell, one for the nucleotide reaction solution and one for the cleave wash. The cell includes
an outlet channel to allow continuously flushing of solutions out of the system. An outline of the
entire flow cell preparation is depicted in Figure 4.3, and the steps occur over a 10 hour time
period. Like the sample preparation, the flow cell preparation is performed a day prior to the actual
genome sequencing and does not directly affect the process’s throughput, but does affect the
turnaround.
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S EQUENCING S TATION S ETUP
The

Flow Cell
Nucleotide Solution

instruments

Piezo Stage

involved in the sequencing

Motorized Stage

Cleave/ Wash Solution

Syringe Pump
TIRF Microscopy Objective

EMCCD

EMCCD
Beam‐splitter

make

the

throughput of the design
possible. The station setup

Temperature Controller

Stage Control

station

Computer/Server

Figure 4.4 The station setup is a combination of instruments all integral to
the success and throughput of SynthSeq’s process.

is depicted in Figure 4.4. An
infusion only syringe pump
with automated controls is

used to inject reaction solutions into the flow cell at specified flow rates and time increments. The
reaction chamber is maintained at 40°C for all chemical reactions using a temperature controller
connected directly to the stage. The flow cell is positioned directly on a microscan piezo controller
with is compatible with the motorized X/Y microscopy stage controller. The stage accessories are
placed on the stage of a TIRF microscope. For the design of the sequencing station, the ThorLabs
MAX201 Motorized X/Y Stage along with the ThorLabs Microscan Piezo X/Y/Z Controller was
chosen over an automated stage position with higher reproducibility. The MAX201 moves the stage
to the next imaging area at 1µm repeatability. The microscan piezo will then shift the stage to the
proper position after an initial imaging to align the templates to their original data points. The two
picture adjustment system saves capital because the stage controller with high reproducibility of
0.1µm is estimated to cost about $50,000, which is significantly higher than the roughly $17,000
costs in the chosen system.
When the lasers excite the fluorophores, the emission wavelengths are reflected back
through the objective and into the dichroic beam‐splitter, which separates the light at 576nm. The
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two ranges of wavelengths are then sent to their corresponding EMCCD cameras to detect the
spatially dependent signals of each growing template strand. The data collected is then sent to the
computer and servers for genome assembly.

C ONCLUSIONS
Although these preparation stages are not major factors in achieving the throughput goal of
the system, they are essential to the proper functioning of the design. The DNA extraction,
purification, shearing, and poly‐A addition allows the genomic DNA to anneal to the prepared flow
cell reaction chamber surface. This surface is pre‐treated with layer by layer assembly to prevent
free fluorescent nucleotides from binding to the glass surface and distorting the emission of the
incorporated nucleotides.

The sequencing stations consist of various pieces of equipment

necessary for the successful execution of the chemistry and detection sequencing cycle.
The preparation stages do affect the product turnaround. Both the sample and flow cell
preparation must be performed the day prior to sequencing a particular customer’s genome. One
day is added to the turnaround as a result of these steps.

After the completion of these

preparations, the actual sequencing of the DNA fragments takes place. This sequencing protocol
directly affects the throughput of the process.
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5. CHEMISTRY AND DETECTION
__________________________________________________________________________________________________________________

dNTP Incubation
and Addition

The bottleneck in the design’s throughput occurs
during the sequencing chemistry and detection steps.
The serial nature of base addition and optical detection
to determine the next nucleotide on the DNA template
creates the most time constraints in collecting genome

Fluorophore Cleave
and Wash

Imaging and Stage
Repositioning

Figure 5.1 The chemistry and detection cycle
starts with nucleotide addition, then continues
with optical detection, and ends with removing
the blocking group on the nucleotide.

data. For every nucleotide base addition, a rotation is
performed until the 32 base read length is reached for the template strands immobilized on the
flow cell surface. An outline of the cycle, Figure 5.1, displays the three main modules: nucleotide
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addition, stage movements and imaging for base identification, and fluorophore‐blocking group
chemical cleave.

I NITIAL I MAGING OF T EMPLATE P OSITION
Before the nucleotide reaction solution is injected in the flow cell, the initial positions of the
templates must be recorded. A fluorophore attached to the poly‐A tail of the single stranded DNA
sample is excited. Their emission is detected on the pixel grid of the EMCCD camera, and the signal
is sent to the computer to record its position. The fluorophore is not cleaved off from the template,
but instead allowed to photobleach. It is assumed that the fluorophore will completely photobleach
before the first nucleotide is added to the system. The location of each template is important for
accurately recording the sequence generated. The position of each detected fluorescent nucleotide
will correspond spatially to a particular growing strand to generate its sequence. The initial
positions will act as fiducials (i.e. landmarks) to facilitate moving the stage to the proper place when
switching between imaging areas. Cross correlation functions are applied to adjust the imaging
areas to their original positions based on the initial imaging of the flow cell. Once these positions
are recorded, the aforementioned cycle can begin.

NUCLEOTIDE ADDITION
DNA S TRUCTURE AND S YNTHESIS C ATALYZED BY DNA P OLYMERASES
Deoxyribonucleic acid (DNA) consists
of two long polynucleotide chains composed of
four different types of nucleotide subunits.
One chain is referred to as a single‐stranded

Figure 5.2 The structure of DNA has 4 nucleotide bases. The
cytosine forms 3 hydrogen bonds with guanine, and thymine
forms 2 hydrogen bonds with adenine. The negatively charged
backbone consists of alternating phosphate and deoxyribose
sugars.
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DNA, and when two chains interact through hydrogen bonding, they assume the double helix
conformation. Nucleotides are composed of a five‐carbon deoxyribose sugar with single phosphate
group on the 5’ carbon and a nitrogen‐containing base. The four bases found in DNA are adenine
(A), cytosine (C), guanine (G), and thymine (T). The two ring base purines are paired with the
single ring pyrimidines; A always pairs with T and G always pairs with C. 40 The negatively charged
backbone of DNA is comprised of alternating sugar and phosphate linkages called phosphodiester
bonds. These bonds occur at the 3’‐OH group on the deoxyribose and the phosphate group attached
to the 5’ carbon. The formation of these phosphodiester bonds is at the crux of nucleotide addition.
Enzymatic proteins called DNA polymerases
catalyze the formation of the phosphodiester bond
during in vitro DNA synthesis.

They facilitate the

formation of hydrogen bonds between the free
deoxyribonucleoside

triphosphates

and

their

complementary bases on the template DNA strand.
This synthesis proceeds in the 5’ to 3’ direction because
each subsequent nucleotide requires a free 3’‐OH group
to form the phosphodiester bond.

In order for the

synthesis to commence, a short region of double
stranded DNA with an exposed 3’‐OH group must exist
to act as a primer for the addition. Polymerases need a
primer because they attach to a double stranded DNA
before beginning base addition. The correct nucleotide
has a greater affinity for the polymerase.

Correct

complementary base binding to the template offers the
most energetically favorable pairing. With the proper

66

Figure 5.3 DNA polymerases follow specific
steps when catalyzing DNA synthesis
polymerization. Phi29 polymerase operates in
this depicted fashion when incorporating the
nucleotide analogs in this technology.

base pair, the enzyme tightens around the active site and undergoes a conformational change
immediately before addition.
Some DNA polymerases exhibit high processivity, polymerizing many nucleotides to the 3′
end of the chain before falling off the DNA template. Other DNA polymerases are distributive and
incorporate just one nucleotide and then fall off the DNA template. When a polymerase incorrectly
adds a base pair, its proofreading mechanism is utilized. The removal of the wrong base occurs
from 3’ to 5’ exonuclease properties of certain polymerases that remove nucleotides from the 3’
end. This reduces errors introduced in DNA synthesis and genome replication.

P HI 29 P OLYMERASE
Multiple DNA polymerases are found in human and bacterial cells indicating specialized
roles for the different enzymes in various aspects of DNA replication. However, they have highly
conserved structure among the species and very little variation in their catalytic mechanisms.
Polymerases are grouped into families dependent on their similarities in protein structure and
function. Many high fidelity, eukaryotic and bacterial based polymerases are found in Family B.
These polymerases, in addition to accurate nucleotide addition, intrinsically have exonuclease
proofreading activity. 41 Phi29 DNA polymerase, a member of the B‐type family, was chosen for the
process because of its high fidelity, incorporation speed, and good processivity.
Bacteriophage phi29 DNA polymerase is a small (ca. 68kDa), replicative polymerase from
the Bacilius subtilis phage phi29. It assists in DNA polymerization reactions and terminal protein
deoxynucleotidylation. Phi29 polymerase also has degradative activities, pyrophosphorolysis and
3’‐5’ exonuclease activity. This polymerase exhibits processivity of greater than 70 kilobases with
uninterrupted synthesis and strand displacement ability. Significant amino acid conservation spans
across many of the eukaryotic polymerases including phi29 to form a polymerization active site in
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several groups of nucleic acid synthesizing enzymes. The synthesis originates from the C‐terminus
domain of the enzyme. The binding of phi29 to DNA primer‐template structures is enhanced by the
presence of metal ions that are known to activate DNA polymerization. 42

The polymerase

adequately recognizes chain‐terminating agents, a property essential to the sequencing process.
The polymerase exhibits a low error rate of 10‐5, which increases the probability of a
nucleotide being successfully incorporated into the template strand. This error rate corresponds to
natural nucleotides with no additional groups attached.41 For certain dNTP analogs, they do not
incorporate due to steric or electrostatic interactions that interfere with the polymerase active site.
In the SynthSeq technology, dye‐dye interactions do not come into play because the dye is cleaved
off before the next addition is made. With these analogs, a threshold number of base incorporations
exist and the threshold increases with increasing length of the linker between the base and the dye.
Incorporations up to 40 bases have been observed. 43

This restriction is one of the factors

contributing to a shorter read length in the SynthSeq technology.
Despite these polymerization concerns when utilizing tagged dNTPs, the position of the
fluorophore on the nitrogenous base instead of the 3’‐OH and the cleavable nature of the dye makes
these incorporation issues negligible. After fluorescence detection and cleavage, the blocker group
is not involved in the subsequent reaction. The nucleotide is reverted back to its natural state, and
then base addition may continue without affecting the activity of the polymerase. 44

P ROBABILITY P OLYMERASE B INDS AND R EMAINS ON T EMPLATE
If a DNA polymerase is not bound to a template strand, that fragment of DNA cannot be
sequenced. The design, however, assumes that every template strand has a polymerase bound
initially at the polyT/polyA tail at its base. The binding coefficients typical to DNA polymerases like
phi29 are on the nanomolar scale. A Kd (Equation 5.1) on this small magnitude signifies a very tight
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Figure 5.4 The plot of the binding coefficient as a function of temperature
for Taq polymerase. At 40°C, the Kd value is 8.1nM.

bond between the polymerase and DNA because the rate constant of binding is significantly larger
than that of dissociation.

Equation 5.1
The probability of finding the double stranded DNA template occupied by a polymerase is
represented by:

Equation 5.2 45
From algebraic manipulation of Equation 5.1, the ratio of free polymerase to bound
polymerase:

Equation 5.3
The binding constant used for the phi29 polymerase is estimated to be comparable to that
of Taq polymerase at 40°C (Figure 5.4), which is 8.1nM. 46 The DNA concentration is determined by
divided the optimized area density (1210000) by the volume of one pixel observation volume
(125µm3); the concentration was calculated to be 9680 templates/ µm3. Using these values, the
ratio of free polymerases to bound polymerases is 8.37*10‐7. Since the ratio is very small, the
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majority of the polymerases are bound to the double stranded DNA templates, and the amount in
free solution is negligible.
Equations 5.2 and 5.3 were combined to establish the concentration of phi29 polymerase
needed to attain a 99% probability that the polymerase binds to the template.

The phi29

polymerase must be incubated into the system at 0.78µM to achieve this probability goal. The
polymerase at this concentration is incubated for 15 minutes with the immobilized template
strands. These actions are done to ensure polymerase attaches to all the templates.
Once the polymerase is bound to the template, a probability of detachment exists. As the
read length of the DNA fragments increases, the polymerase’s ability to remain on the DNA is
reduced.

One reason the phi29 polymerase was chosen is because of its extremely high

processivity, travelling up to 70,000 bases before dissociating from the strand. 47 However, this
processivity was determined without interruption to the polymerization process. Since SynthSeq
uses reversible terminator nucleotides and the reaction is continually suspended, the amount of
time the polymerase remains on the strand must be evaluated opposed to the number of base pairs.
Since the polymerase travels at a rate of 4.7 bases/s (see Polymerization Rate) and remains
attached to the DNA for 70,000 bases, the amount of time it is expected to remain on the strand is
4.14 hours. The amount of time each flow cell undergoes the chemistry and detection cycle is 4
hours. The constant suspension of the nucleotide addition does not affect the enzyme’s high
processivity in the context of SynthSeq sequencing.
The occurrence of the release event can be modeled by the exponential cumulative
distribution function because it describes the times between events in a process in which these
events occur continuously such as nucleotide addition using the polymerase. Since the number of
events occurring is greater than 0, the probability that the polymerase is unattached from the
strand is represented by the following equation:
Equation 5.4 48
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Where X is the variable denoting number of bases traveled, x is the read length, and

is the rate

parameter. The read length in this process is 32 base pairs, and the rate parameter is 1/70,000
base pairs‐1. With the parameters are considered, the calculated error rate is 4.57*10‐4, and the
probability of the polymerase remaining on the strand after the read length in the process is
99.95%.

R EVERSIBLY T ERMINATING T AGGED N UCLEOTIDES
Many SBS techniques struggle with the problem of counting homopolymers – DNA
sequences that repeat the same base one or more times. One way to overcome this issue is to use
nucleotides that are incorporated onto a template DNA strand but block addition of any other
nucleotides, so that they could progress through these homopolymeric regions one base pair at a
time. 49 However, in order to continue the process of SBS, the ability to add nucleotides after
blocking the extension would have to be restored. One of the most unique features of SynthSeq’s
method of single molecule SBS is that each imaging step is carried out in between nucleotide
addition steps; this is accomplished using modified, tagged nucleotides that reversibly terminate
the extension reaction of DNA synthesis.
The ideal nucleotide for this process would succeed in both of the functional modifications –
reversible termination and tagged for identity of the base – with only one physical modification.
Little information on the structure and synthesis of such a modified nucleotide exists in the public
domain; however, private companies have reported data suggesting that they have synthesized one.
Helicos Biotechnologies possesses proprietary reversible terminator nucleotides that contain only
one modification. These maintain a hydroxyl group at the 3’ position and have a base modified with
a propargylamine linked via a cleavable linker to a fluorescent dye tethered to an inhibitor. Helicos
reports efficient incorporation, blocking and regeneration of extension using these nucleotides 50.
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The nucleotides used by SynthSeq have two major modifications that make it possible for
this process to be carried out. First, the nucleotides contain a tag on the base on the 1’ position of
the five‐carbon sugar via a cleavable linker. The identity of the tag depends on the identity of the
base; each has an associated fluorophore that emits light at a specified wavelength. Second, the
nucleotides have a reversible terminator group blocking the 3’‐OH, which serves to terminate DNA
synthesis. 51

Figure 5.5 SynthSeq’s modified reversible terminator nucleotides. Modifications
label the nucleotide according to which base it contains and block the 3’‐OH group
to terminate DNA extension.44

The nucleotides are tagged on the base of the nucleotide by a fluorophore that corresponds
to that base. The four bases and their corresponding fluorophores are: Guanine/bodipy‐650,
Cytosine/bodipy‐FL‐510, Adenine/ROX, and Tyrosine/R6G.
The fluorophores are attached via a cleavable allyl linker
that enables the release of the fluorophore after imaging.
They are attached at the 5‐position of the pyrimidines (T
and C) and the 7‐ positions of the purines (G and A). 52
The 3’‐OH group of these nucleotides have been
capped with a small chemically reversible moiety. It is of
crucial importance that this modification not be too large or
bulky, so that these nucleotides will still be suitable
substrates for DNA polymerase, and that it can be
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Figure 5.6 SynthSeq’s four modified
nucleotides: 3‐O‐Allyl‐dCTP‐allyl‐bodipy‐FL‐
510, 3‐O‐allyl‐dUTP‐allyl‐R6G, 3‐O‐allyl‐
dATP‐ allyl‐, and 3‐O‐allyl‐dGTP‐allyl‐
bodipy‐65044

converted to a hydroxyl group in order to enable further extension reactions after imaging.
Replacing the hydroxyl group with a small allyl group serves to block further nucleotide addition
while preserving DNA polymerase’s ability to incorporate the nucleotide onto a DNA template.
After nucleotide addition and imaging steps, two things must be done in order to enable the
cycle to be repeated: the fluorescent label must be cleaved from the base and the 3’ allyl blocking
group must be converted to a hydroxyl group. These two actions are both accomplished in one
single deallylation step using a Palladium catalyzed reaction with Na2PdCl4 and P(PhSo3Na)3 in
Thermopol reaction buffer.

Figure 5.7 Reversible terminator nucleotides are added to the template strand
and imaged. Then, the fluorophore is cleaved and the 3’‐OH group regenerated
allowing for subsequent base addition and imaging steps.44

P OLYMERIZATION R ATE
The phi29 polymerase will serve in this technology as the enzyme catalyzing nucleotide
addition to the single stranded DNA templates immobilized in the flow cell. The polymerase
requires 0.1 to 10 µM of dNTP concentration to maintain fast, accurate, and processive synthesis. It
also shows no preference for labeled or unlabeled nucleotides and is not hindered by the additional
tag moieties of the reversible terminator labeled nucleotides used in this design.

Once the

fluorophore is cleaved, it diffuses quickly away from the DNA strand and gives the next

73

complementary base the ability to bind and interact with the polymerase. The tag will typically
diffuse away from the template in about 2 to 10 µs after cleavage.45 The cleave process provides
enough time to wash through the cell to ensure the tag is removed and will not interfere with the
next nucleotide addition.
Enzymes like phi29 polymerase are among the most selective and powerful catalysts
known. An understanding of its rate of chemical reaction and how these rates change with varying
conditions such as temperature and concentration of substrate is essential to develop an optimal
nucleotide incubation time for addition. This polymerase with the help of a manganese metal ion
activator has only one substrate, the free nucleotide analog. The polymerase has an energetic
affinity to the proper base to complement the template strand, and the polymerase and nucleotide
bind to form an enzyme‐substrate complex. Then, the chemical reaction occurs and binds the free
nucleotide to its complementary base. A common equation to model this enzymatic reaction is the
Michaelis‐Menten equation:

Equation
5.5
Where V is the velocity or rate of the reaction;
constant;

is the enzyme complex dissociation rate

is the initial enzyme concentration; [S] is the substrate concentration;

is the

Michaelis‐Menten constant.39
This chemical system deviates from the traditional enzyme kinetics. The polymerase is
assumed to be bound to every DNA fragment due to high concentrations of enzyme incubated with
the templates for 15 minutes. The enzyme concentration does not come into play in the rate
equation because it’s always available to bind to the free nucleotide substrates. Its concentration
remains constant. Also, the chemistry supposes the formation of the enzyme‐substrate is rapid. The
limiting reaction is the dissociation of the complex into the polymerase and bound nucleotide.
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Therefore, a first order rate law can be proposed for the nucleotide addition reaction using phi29
polymerase.
Equation 5.6
Where r is the rate of reaction; k is the rate constant;

is the concentration of free nucleotides

in the reaction solution.
This rate law is supported by kinetic data collected by Eid et al. The experimentally
determined phi29 DNA synthesis rate for a single polymerase is 4.7 ± 1.7 bases/s at 30°C. The high
standard deviation is due to the existence of two kinetic states independent of dNTP, template, or
other such experimental variations. The rate can be 2base/s or 4base/s depending on its state,
which explains possible rate fluctuations at this higher concentration. At higher temperatures, more
bases can be incorporated in a finite period of time. The temperature of the cell cannot exceed 65°C
in the flow cell because the polymerase will denature and cease to function properly. 53 This
process runs all of the sequencing chemistry at 40°C, so the data used is a conservative estimate of
the rate for this system. Experiments determined the rate of single molecule DNA synthesis
increased as the concentration of nucleotide reagents increased (Figure 5.8) 54.
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Figure 5.8 The phi29 polymerase follows a first order rate law with a rate constant of 18.356s‐1. Along with the
data point mentioned in the text, at 100nM, the rate was 1.4 ± 0.03 base/s and at 200nM, the rate was 3.75±0.10
base/s. The determination of this rate equation allows the rate to be calculated from any free dNTP concentration.

The linear relationship between the rate and various nucleotide concentrations confirms
the first order rate law of the reaction. For SynthSeq, the addition reaction is run at an individual
dNTP concentration of 0.074µM. The 0.074µM corresponds to the maximum concentration where
an average of one fluorophore is in the detection volume of 0.0075µm3 at one period of time.

Equation 5.7
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The detection volume describes the volume above the flow cell surface where the fluorophores can
be excited and their emissions’ can be detected. The detection volume will be more clearly defined
in the following section, Optical Detection of Single Molecules. The purpose of this concentration is
to reduce the background fluorescence during single molecule detection. Any lower concentrations
will further reduce background, but the phi29 polymerase rate will be negatively affected. This
concentration of 0.074µM correlates to a rate of 0.738bases/s or approximately 1s/base. To
maximize the success of the base addition, the reaction solution is incubated for 3s.

P ROBABILITY OF N UCLEOTIDE I NCORPORATION
Nucleotide addition to the fragmented genomic DNA template is integral to the sequencing
process. The phi29 polymerase’s fidelity rate is high, and its error rate is low on the order of 10‐5.
Consequently, the probability of the nucleotide successfully being incorporated into the template is
dependent on the initial nucleotide concentration, the kinetics of the polymerization reaction, and
the set incubation time before imaging takes place.
The polymerization follows a first order rate law (Equation 5.8). The differential equation
that represents the change in dNTP concentration over time is as shown below:
Equation 5.8
Where k is the rate constant of the reaction in s‐1. When this ordinary differential equation is solved
by separation of variables over time, t, the concentration profile equation in µM is formed:
Equation 5.9
Where

is the initial nucleotide concentration in µM. For this reaction, the initial dNTP

concentration used is 0.074µM and the rate constant determined in Figure 5.8 is 18.356s‐1, which
makes the concentration specific to this system:
Equation 5.10
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Typically, a reaction is adequately complete in the time when about 1/e of its initial concentration
is reacted. In this system, this occurs at a concentration of 0.027µM and a time of 1/k or 0.054s. To
reduce the error rate of the nucleotide addition, the dNTP reaction solution is incubated in the flow
cell for 3s. This incubation time is 60‐fold more than the expected incubation time to add a base.
Therefore, the error rate is represented by e‐60 or 8.76*10‐27, and the probability of the nucleotide
being successfully polymerized is 99.99%.

R EACTION C ONDITIONS
The reaction conditions of the nucleotide addition are specified for the process. The
reaction is run at 40°C throughout the entire sequencing cycle. This temperature was chosen to
increase enzymatic kinetics as well as run the deallylation chemical cleave reaction for the
reversible terminator nucleotides at an adequate temperature. The temperature of the system
cannot exceed 65°C because the enzyme will denture. The temperature of the stage and flow cell is
maintained by a temperature controller with a set point of 40°C.
Because of the small scale dimensions of the reaction chamber in the flow cell, convective
fluid flow of the injected solutions is negligible compared to the diffusion. The free dNTPs diffuse
into the detection volume to bind to the polymerase active site and undergo addition.

OPTICAL DETECTION OF SINGLE MOLECULES
S CANNER P ROBLEM
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Our initial plan was to simplify the
imaging process by making use of a scanning
instrument such as PerkinElmer’s ScanArray
ExpressHT. Such instruments are commonly
used

in

similar

applications

requiring

extensive spatial multiplexing. The flow cell
would be inserted into the confocal laser
scanner, and the DNA strands would be

Figure 5.9 The detection mechanism of the ScanArray
ExpressHT. (Image from PerkinElmer Life Sciences, Inc.)

scanned sequentially after each addition step.

Despite meeting the 5um pixel resolution requirement of the system and supporting the
simultaneous detection of four wavelengths, the scanner was simply unable to meet the throughput
demands associated with full genome sequencing. PerkinElmer reports the scan speed of its
instrument to be less than 2.5 minutes for a 20mm x 30mm area at 10 micron resolution. 55 This is
very fast. However, it does not turn out to be fast enough to sequence the roughly half a billion DNA
strands that are necessary to construct an entire human genome at six‐fold coverage in a
reasonable time frame. The following equation demonstrates the failure of the scanner to meet
throughput demands.

(2.5 minute scan / quoted area‐cycle) * (0.28 quoted areas / flow cell area) * (400 0.5um
resolution pixels / 10um resolution pixel) * (2 flow cells / genome) * (32 cycles / flow cell) * Equation 5.11
(1hr / 60min) / (0.32 pixel efficiency) = 1000 hours / genome
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Note that this staggering figure represents just the required scanning time for each genome.
As demonstrated by the above equation, the confocal laser scanner is not a viable option for
addressing SynthSeq’s considerable throughput requirements.

T OTAL I NTERNAL R EFLECTION M ICROSCOPY
Total Internal Reflection Fluorescence Microscopy (TIRFM) is an optical technique used to
observe single molecule fluorescence. The method reduces the background when detecting the
addition of a single base pair. This optical phenomenon exploits events occurring at surfaces. Light
strikes an interface between two optical media of different refractive indices.
Distance

Relative Intensity

(Nanometers)

Figure 5.10 For proper conditions, light illuminated
on a surface will totally reflect from the surface at a
critical angle. An evanescent wave propagates into the
second medium at exponentially decaying strength.
This wave can excite fluorophores. 58

1

0.99

10

0.92

100

0.43

1000

0.0002

Table 5.11 The data shows the intensity of the
evanescent wave decreases as the wave travels
further away from the surface. This intensity decays
exponentially. By a depth of 100nm, more than half
the strength of the wave is lost. At the 30nm depth
chosen for this technology, the evanescent wave
maintains about 75% of its intensity.58

A refractive index is the factor by which the velocity of propagation in a medium is decreased
relative to the velocity of light in vacuum. 56 If the light is incident at an angle greater than the
critical angle, then it undergoes total reflection.

Beyond the angle of total reflection, the

electromagnetic field of incoming light continues to extend into the second medium. The strength of
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this evanescent wave decreases exponentially from the surface, and the effects of the wave only
extend about 100nm.
In the SynthSeq process, the observational depth for
fluorophore detection is assumed to be 30nm because the wave

30nm

maintains about half of its strength at that point. This estimation may
provide more background fluorescence than expected since
fluorophores, although less likely, can be excited and fluoresce at
further distances away from the surface than 30nm. In order to
confirm the DNA template strand’s first 38 nucleotides do not exceed

0.5µm
0.5µm

Figure 5.11 The detection
volume for each incorporated
nucleotide in the template strand
is dependent on the evanescent
wave intensity depth.

the detection depth, the root mean square distance of the ssDNA from the surface is calculated
using Equation 5.12.
Equation 5.12
Where

is the Kuhn length of ssDNA (4nm) 57 and

defined as

is the contour length of the strand

. For a ssDNA of 38 base pairs, the root mean square distance of the end of

the strand to the surface is only 10nm, which is well within the observation depth of TIRFM.
The conditions for total reflection and the critical angle follow Snell’s Law when the angle of
refraction is 90°.
Equation 5.13

Where

is the critical angle,

is the refractive index of the specimen analyzed, and

is the

refractive index of the objective. The refractive index of the first medium must be larger than the
second medium’s index.
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a.

b.

Figure 5.12 (a) The laser enters the objective at an angle where TIRFM occurs, and the light is totally reflected back into
the objective lens. After it goes back into the lens, the light is sent to a dichromatic beam‐splitter and then EMCDD
cameras. (b) The configuration of a typical inverted TIRM is depicted. 58

This technique is utilized in this design for several important reasons. TIRFM provides a
limited depth for fluorophore excitation near the surface of the flow cell. Only the fluorophores
attached to the incorporated nucleotide base remain close enough to the surface to be excited by
the evanescent wave. Therefore, the background fluorescence is reduced. Less tagged nucleotides in
the reaction solution will emit light. TIRFM offers high contrast images with a good signal to noise
ratio to provide a sharper detection of single molecules. 58
SynthSeq uses an Olympus XI81 inverted microscope with TIRFM capabilities. The
microscope is equipped with 4 line TIRF lasers capable of exciting all four reversible terminator
nucleotides simultaneously. 59 The instrument uses an APO 60x objective with a 1.49 numerical
aperture (NA). The NA improves TIRF capabilities. Barrier filters are also put in place to prevent
excitation light from interfering with the detection of the specific wavelength emissions of the four
nucleotides. A 0.5 magnification changer is also put in place to adjust, along with the objective, the
pixel length of the EMCCD from its standard 13 µm to 0.5 µm. The pixel size change reduces the
imaging area and detection volume to help the throughput of the process. If the pixel size remained
larger, the concentration of dNTP needed to maintain an average of one tagged nucleotide in the
detection volume at any point in time would be too low for the polymerase to function properly.
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The X/Y stage positioner and microscan piezo controller are compatible with the stage of this
microscope model.

EMCCD C AMERA
Electron Multiplying Charged Coupled Device cameras provide the high resolution and
single molecule detection capabilities required to execute high throughput genomic sequencing. An
EMCCD is a quantitative digital camera capable of single photon events while maintaining high
quantum efficiency because of its unique electron multiplying structure built into its sensor. An
electron multiplying structure is built into the chip to allow weak signals (e.g. emission from a
single fluorophore) to be multiplied before any read out noise is incorporated into the output. This
amplification makes the read noise negligible. Since the chip does not require an image intensifier,
the approximately the full quantum efficiency of the silicon sensor can be utilized. The EMCCD
sensors use a shift and gain register. The gain can be increased and tuned so extremely weak signals
can be detected above the read noise of the camera at any readout speed. This property allows the
technology to surpass tradition CCD cameras that experience a larger read out noise detection
limits with higher pixel readout speeds. 60
This process uses Andor’s megapixel iXonEM
+888 back‐illuminated EMCCD to detect single

0.5 µm
0.5 µm

molecule events in the sequencing by synthesis
process. For the station set up and the execution of

0.5 mm

fluorophore identification, two cameras are used at
0.5 mm

each sequencing station.

This specific model is

suggested because it has a fast frame rate, on the order
of 106 pixels, and high quantum efficiency.
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Figure 5.13 A 1024 by 1024 pixel imaging
area contains pixels with dimensions of
0.5µm by 0.5µm.

The frame rate of the camera influences throughput. This camera operates at a full frame
rate of 8.9 frames/s (i.e. 0.111 s/frame). This camera parameter determines the time needed for
the camera to detect the excited fluorophores’ emitted photons and transfer them into a signal. The
speed determines time required on each imaging area before the stage can move to the next one.
Since the reaction is not detected in real time, the frame rate does not have to keep up with the
kinetics of the reaction and does not have to be significantly fast. The camera images the
fluorophores while the synthesis is suspended. Therefore, the 9 frames/s is sufficient for this
process and does not present any major time limitations in the chemistry and detection cycle.
Although the frame speed of the camera impacts the throughput, the imaging area and
number of pixels are more important for the SynthSeq process. The megapixel chip is essential to
the throughput. The camera has a 1024x1024 active pixel array where each pixel is 13µm by 13µm
in size. As mentioned previously, a 60x objective and 0.5 magnification changer in the microscope
changes the pixel size to 0.5 µm by 0.5 µm. The imaging area due to the size of the pixel array makes
one imaging area approximately 0.5mm by 0.5mm. The template strand sequencing is spatially
dependent to where the DNA is immobilized on the flow cell surface. The pixel can detect the
addition of bases to the DNA template residing solely in that pixel. Therefore, increasing the
number of pixels in each imaging area allows more templates to be sequenced at once. However,
the efficiency factor determined through the simulation described in Chapter 3 greatly limits the
throughput of a single imaging area despite the capacity for 106 templates to be sequenced
simultaneously.
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Figure 5.14 The quantum efficiency for an EMCCD camera remains over 90% for the 500nm to 700nm wavelength
range, which is applicable to the SynthSeq process.61

The detection of a fluorescent molecule relies on a high quantum efficiency (QE) and
favorable signal to noise ratio. The QE is defined as the percentage of photons that are actually
detected and then transmitted as electrons by the camera. Higher QE generally produces a better
quality reading of the fluorophores because it has a higher signal. The quantum efficiency is a
function of the emission wavelength of the light being detected. The iXonEM +888 has quantum
efficiencies greater than 95% for the emission wavelengths used in the process (Figure 5.14). Back‐
illuminated detectors have a 4‐fold greater QE than front‐illuminated cameras of the same pixel
size. A high quantum efficiency promotes a high signal to noise ratio (SNR). SNR is a measure of
how much signal is ruined by noise. The high this ratio becomes the less prominent the noise is in
an EMCCD. The overall noise is a combination of read noise, shot noise, background noise, and dark
current.

The electron multiplying gain in an EMCCD are sufficient to effectively eliminate read

noise. Since the cameras are thermoelectrically cooled to ‐95°C, the dark current is also eliminated
from the total noise. 61 Therefore, when using an EMCCD, only the shot noise and background noise
needs to be taken into account. The evaluation of signal to noise and how it pertains to the
fluorescence detection in the SynthSeq process is discussed in the section discussing the probability
of misidentifying a nucleotide.
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D ICHROIC B EAM S PLITTER FOR F LUOROPHORE R ESOLUTION
As a result of the scanner fiasco, SynthSeq needed to find an alternate imaging solution for
its technology.

A dichroic beam‐splitter is another

necessary component of our imaging setup. We plan to
resolve the four different wavelengths emitted by the
fluorophores using two CCD cameras and the dichroic
beam‐splitter, which will allow us to determine the identity
of the captured light based on differences in intensity ratios
between the two cameras. The four fluorophores transmit
at different wavelengths, so a certain wavelength is chosen
that will divide them into pairs. The emission wavelengths
of the fluorophores are 510nm, 550nm, 602nm, and

Figure 5.15 The dichroic beam‐
splitter, showing the incident, reflected
and transmitted light pathways

650nm. 62 Consequently, an intermediate cut‐off wavelength
(the incident wavelength at which 50% of light is transmitted, and 50% is reflected) of 576nm has
been chosen for the dichroic beam‐splitter. Basically, the beam‐splitter will reflect 100% of the
510nm light into the “green” camera, and only 70% of the 550nm light. At the opposite end of the
spectrum, 100% of the 650nm light and proportionally less of the 602nm light (again, perhaps 70%,
enough to differentiate the captured light based on intensity) will be sent to the “red” CCD camera.
When split optimally, the aggregate intensity of each wavelength of light across both camera
should be comparable.

The different fluorophore signals are then resolved based on their

respective “green/red” ratios, which is based on the relative intensity of the light hitting each
camera.
Thus, each fluorophore will be resolved based on its ratio of green light to red light, as
determined by the pair of CCD cameras (see Figure 5.16).
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Figure 5.16 Resolution of the four fluorophores using two EMCCD
cameras, one for green light and the other for detection of red light

In the next section we will provide an error analysis of our optics system, which demonstrates the
feasibility of the technique described above.
Unfortunately, finding an appropriate beam‐splitter that would allow our desired resolution
of the fluorophores was not as easy as we were expecting. Many optics companies are striving to
achieve higher resolution rather than a more diffuse splitter like the one our design requires. When
we investigated the R/T curves for available splitters, we found that the reflectance would allow for
a satisfactory split in intensity between the first pair of fluorophores, but then the next two
wavelengths could not be differentiated because the transmittance curve had already peaked,
resulting in the full transmission of both wavelengths of light. Before moving on to a different
approach, we asked the technical support staff at Chroma, a company that specializes in optical
technology, if they might be able to offer us some alternative. Fortunately, they informed us that
their engineers would be able to fashion a beam‐splitter to our specifications at a cost of just $250
dollars, available in 4‐6 weeks. 63 With a satisfactory solution having been reached, we were in a
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position to move forward with our intended optical setup (the R/T curve of the resulting splitter is
shown in Figure 5.17). The next step is to confirm its viability by subjecting it to error analysis.

Figure 5.17 The beam‐splitter curves allow us to predict the relative reflection and
transmittance percentages for each of the fluorophores based on their emission wavelength.

P ROBABILITY OF P ROPERLY I DENTIFYING N UCLEOTIDES
After each nucleotide addition step in the sequencing process, there is an imagining step
that seeks to find the identity of the nucleotide added to each template. The fluorophore attached
to the recently added nucleotide is excited, and the light it emits is directed towards a beam‐
splitter. Based on the wavelength of the emitted light, different fractions of the light’s total intensity
are transmitted to two different cameras, one that collects red light and the other that collects
green light. A quantity that compares the intensity of light recorded by each camera is used to
identify the nucleotide.
The quantity used to compare the intensity of light in each camera will be called the
dimensionless relative intensity (I). In order to correct for the differences in total intensity of light
emitted that occurs in each event due to differences in orientation of the template molecule, the
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quantity used is non‐dimensionalized by dividing by the total intensity light captured by both of the
cameras combined. I is defined by Equation 5.14.

Equation 5.14
Where G is the intensity of light captured in the green camera and R is the intensity of light
captured in the red camera.
For the following discussion on nucleotide identification, the following assumptions will be
used. Four nucleotides – to be called nucleotides 1, 2, 3 and 4 in order of increasing emission light
wavelength – emit at evenly spaced wavelengths and with the same intensity. A theoretical beam‐
splitter is used that separates light at a wavelength exactly in between nucleotides 2 and 3. The
splitter sends 100% of the light emitted by nucleotide 1 to the green camera, 70% of the light
emitted by nucleotide 2 to the green camera and 30% of the light emitted by nucleotide 2 to the red
camera, 30% of the light emitted by nucleotide 3 to the green camera and 70% of the light emitted
by nucleotide 3 to the red camera, and 100% of the light emitted by nucleotide 4 to the red camera.
Thus, using Equation 5.14 and the assumptions for the behavior of the four fluorophores and the
nature of the beam‐splitter, the four I values for the nucleotides when performing as expected are:

It is of crucial importance to SynthSeq’s process that nucleotides not be misidentified. Each
of the four peaks in the graph below represent the distribution of I values for each of the four types
of nucleotides in the process. If everything works correctly, each time an imaging step occurs, the
data from the fluorescence of the fluorophore on the most recently added nucleotide of a template
fragment will fall close to the average I value of the associated with that nucleotide. The case of a
misidentified nucleotide occurs when the I value for a reading falls in the range of I values for a
nucleotide other than the one that was just added. The following discussion seeks to show the
probability of this kind of an error occurring.
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Figure 5.18 Schematic of the distribution of I values for the four
fluorophores.
I4 = ‐1.0, I3 =‐0.4
‐0.4, I2 = 0.4, I1 = 00.4
‐1.0
1.0

The nature of the signal recorded by the cameras depends on a number of factors. The
number of photoelectrons (

) measured by the camera represents the signal strength. This

number depends on a number of factors. The specific absorbance (SA) is a measure of how much
energy (in this case, the number of excitation photons,

) is absorbed by the fluorophore. The

optical efficiency (OE) describes how many of the emitted photons are captured by the objective.
The quantum efficiency (QE) is a measure of how many of the photons captured by the objective are
converted into photoelectrons in the detector. The number of photoelectrons resulting from the
excitation of one fluorophore is described by Equation 5.15:
Equation 5.15
Where texp is the exposure time.
In this process, two sources contribute to noise. The first source of noise is from statistical
fluctuations in the number of photons detected due to the random nature of their emission and
capture. The number of photoelectrons that result from a signal can be described as a Binomial
distribution. Thus, this contribution to noise can be described by the standard deviation of that
distribution which is the square root of the average number of photoelectrons:
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. The

second source of noise is from background. Background is the number of photoelectrons that are
not a direct result of a signal (NBG), where signal is defined as the excitation of a fluorophore that is
attached to the last nucleotide added to a template DNA strand.

The main contribution to

background comes from fluorophores on non‐incorporated, free nucleotides. A design of the
diffusion of free nucleotides found that an average of one free nucleotide will be in one pixel of the
image during the exposure time (see Reaction Conditions section). Thus, number of photoelectrons
. The total noise is

from background equal number of photoelectrons from signal:
calculated by combining these two sources of noise, resulting in Equation 5.16.

Equation 5.16
And the signal to noise ratio (SNR) is described by Equation 5.17.

Equation 5.17
In order to calculate the probability that statistical fluctuations and background noise will
lead to the misidentification of a nucleotide (i.e. that the I value falls in the range of the wrong
nucleotide), it is necessary to calculate the standard deviation of I for each nucleotide (σI,i). If the
standard deviation is large, then there will be a large number of misidentified nucleotides, which
could cause difficulties aligning the genome sequence and, ultimately, could lead to an inaccurate
sequence. In order to calculate σI,I, the deviations in G and R must be propagated (see Equation
5.14). Doing so yields the following equation.

Equation 5.18
Where

,

,

,

, and T stands for transmittance, which equals 1 for T1, 0.7 for T2,
0.3 for T3, and 0 for T4. Plugging each of these values in and solving for
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yields Equation 5.19.

Equation 5.19
Using Equation 5.15, Equation 5.19 and the equation relating the energy of a photon to its
wavelength (

) it is possible to relate the power of the excitation laser to the standard

deviation of I. Thus, it is possible to calculate a minimum power necessary to achieve a given level
of certainty in the measurements. It was decided that if the distance halfway between the mean
values for I1 and I2 (equal to the distance between I3 and I4 and also the shortest distance between
any two mean I values) was greater than five standard deviations of I , then the number of errors
due to noise (1 in 1,744,278) would be sufficiently low. Thus, the laser used in this process must be
sufficiently powerful to provide enough photoelectrons to keep

less than .06.

Using the

, it is found that the excitation light must be strong enough to provide 1125

condition
photoelectrons.

Next, it is necessary to determine if the laser being used to excite fluorophores is powerful
enough to satisfy the condition. Equation 5.15 is used to find out how many photoelectrons the
laser can produce to strike one fluorophore. The power of the laser being used goes up to 5W.
First, this power must be converted to a number of excitation photons (

) using the equation

. With an excitation light wavelength of 550nm, it is found that 2.76x1018 photons/W are
produced by the laser. Since the ratio of the area of one pixel to the area of the entire imaging area
is 1/1000000, the number of photons striking that area can be estimated as 2.76x1012/W.

Equation 5.20
Where

is the excitation photons and

is the photons hitting the pixel.

Next, it is necessary to find the specific absorbance and quantum yield of the fluorophores.
For this, a widely used fluorophore, Rhodamine 6G, will be used to represent the four fluorophores

92

in this system. The specific absorbance is determined by first finding the absorption cross section
with Equation 5.21 and the known molar extinction coefficient of Rhodamine 6G ( = 1.16*105
L/(mol)(cm)) 64, and then dividing that value by the area of one pixel (2.25*10‐9 cm).
Equation 5.21
The specific absorbance is found to be approximately 1.8*10‐7. The quantum yield of Rhodamine 6G
is 0.95.
The only remaining terms in Equation 5.11 are QE, OY and texp. The quantum efficiency for
the Andor L888SS EMCCD at the wavelengths being used is approximately 0.95. 65 The optical
efficiency can be estimated to be 0.25. The exposure time in this process is 1/9 seconds. Putting all
of these terms into Equation 5.15 gives a value of 12500 photoelectrons/W or 62500
photoelectrons at the full power of 5W. This value is well above the 1125 photoelectrons (which
corresponds to a power of only .09 W) necessary to ensure that error due to noise is negligible.
Another difficulty in determining the identity of a nucleotide involves photobleaching – the
photochemical destruction of a fluorophore. If a fluorophore photobleaches before a strong enough
signal is produced, the result is a “dark read” and it is not possible to determine the identity of the
nucleotide.

The probability of photobleaching is a function of excitation intensity and time,

concentration of oxygen, and temperature. 66 Decreasing the power of the excitation can reduce
photobleaching, however this would also result in more noise and less certain measurements.
Thus, it is necessary to optimize the power of the laser to accomplish low noise and low rates of
photobleaching.
For common organic fluorophores, the probability of photobleaching each time the
fluorophore is hit by a photon ranges from 10‐6‐10‐5. Photobleaching can be significantly reduced
using several methods, including enzymatic deoxygenation using glucose oxidase/catalase. Using
various methods, photobleaching probabilities as low as 10‐9 have been reported. 67 For this
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analysis, it is assumed that photobleaching occurs at a rate of 1 in 5000000 events and that a dark
read occurs when a fluorophore is photobleached before half of the total imaging time has expired.
In Figure 5.19, the probability of a dark read and the standard deviation of I for fluorophores on
nucleotide 1/4 and 2/3 (nucleotides 1 and 4 have a slightly higher standard deviation of I than
nucleotides 2 and 3, see Equation 5.19) are plotted against laser power. Since the standard
deviation of I is proportional to the square root of the power, it decreases rapidly and then reaches
a relatively stable lower limit, while the probability increases linearly as the power increases.

Figure 5.19 The standard deviation of I and the probability of a dark read vs. laser power

From relationships between the probability of a dark read and standard deviation of I vs.
laser power, a laser power that minimizes dark reads and the standard deviation of I can be chosen.
At a laser power of 280mW, the less than 1% of reads will be dark reads and the standard deviation
of I is .032 for nucleotides 1 and 4 and .024 for nucleotides 2 and 3. These values are small enough
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that noise can still be neglected as a significant source of error when attempting to identify
nucleotides.
While it is encouraging that noise does not contribute to misidentification of nucleotides to
any significant extent, this is not the only possible way that this error can occur. For example, if two
template strands lie too close to one another on the surface of the slide, it is possible that emission
light from these two reactions could contaminate one another. This contaminating light could lead
to a value of I that does not correspond to the actual nucleotide on the template strand. There
needs to be a way to correct for such errors.
This problem is solved by assigning a value to each template strand that quantifies the
accuracy of its readings. This value will be termed the Z‐score. It is defined as the average distance
of I from the nearest mean I value. This quantity is defined by Equation 5.22.

Equation 5.22
The Z‐score allows the identification of template strands whose fluorescence measurements often
do not fall onto one of the four values that represents one of the four nucleotides. The data
associated with any template strand whose Z‐score is greater than three standard deviations of I
can be discarded. As a result, even if one reading from an unusable template strand gives a value of
I that corresponds to a nucleotide that is not the actual nucleotide present, this error will not be
counted since the Z‐score for that template will be high, and all of the readings associated with it
will be discarded.

O VERVIEW OF THE I MAGING P ROCESS
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After the addition of each nucleotide to the growing DNA template, a specific imaging
sequence is performed to detect the fluorescence from the base, as depicted in Figure 5.20. This
sequence path is automated before the process begins to minimize the time and labor involved.

Initial Imaging

Repositioning to
Original Position

Shift Imaging Area
250nm to Right

Image

Image

Move Stage 0.5mm to
Next Imaging Area

Figure 5.20 The procedure for gathering nucleotide identity data from a newly added base follows this sequence.

Initially, the area being analyzed is imaged to detect where templates are in relation to their
initially recorded positions. The initial positions act as fiducials to determine how much the imaging
area spatially deviated from its original position. The imaging area is readjusted using the piezo to
position the imaging area in its proper place. This step is important because the position of each
base addition detected during fluorescence corresponds to a particular DNA fragment template. If
the position references were not accurate, the correct sequences of the templates would not be
generated.
Once the stage is positioned, the nucleotide fluorophores in the imaging area are excited
using the TIRF microscopy lasers. The emission is reflected back into the objective and sent to the
dichromatic beam‐splitter. Once the splitter separates the light at the determined wavelength, the
two new beams are sent to the cameras for detection and then to the servers for genome data
assembly.
In order to increase the optical efficiency of the templates on the pixel grid, the stage is
shifted by 250nm. By performing this shift, the issues associated with multiple templates on one
pixel and templates overlapping multiple pixels are reduced.

After the shift occurs, the area is

imaged and the data is computed so the intensities detected still correspond spatially to their
original template positions. The stage must then move to the next programmed imaging area. This
movement is accomplished using the XY stage positioner on the microscope stage, which moves at a
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velocity of 10mm/s. Once the stage has settled and the flow cell is stationary, the imaging sequence
is reinitialized for the new imaging area.

FLUOROPHORE CLEAVE
TERMINATOR REMOVAL AND 3’‐OH REGENERATION
After nucleotide addition and imaging steps, the termination of the DNA synthesis reaction
must be reversed. This involves the cleaving of the fluorophore attached to the nucleotide’s base
and the regeneration of the 3’ hydroxyl group. Both of these steps are accomplished through one
Pd catalyzed deallylation reaction.
The deallylation mixture that is introduced through the flow cell consists of Thermolpol I
reaction buffer, Na2PdCl4 and P(PhSO3Na)3. This reaction is optimally run at 60C, however at this
temperature there is a risk of interfering with the binding affinity and performance of the phi29
polymerase, thus this reaction (and the entire process) is instead run at 40C. At this temperature,
the polymerase performance is not compromised. Since this reaction is being performed below its
optimal temperature, the deallylation mixture is left in the flow cell for one minute to ensure full
removal of the fluorophore and complete conversion of the 3’‐O‐allyl group to a 3’‐OH group. To
complete the deallyation/cleave step, Tris HCl buffer is introduced through the flow cell to remove
the Pd complex. After this procedure, the system is ready for the next nucleotide addition and
imaging step. 68

Thermolpol I reaction buffer/Na2PdCl4/P(PhSO3Na)3
40C, 60 seconds
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Figure 5.21 The fluorophore is cleaved and the 3’‐OH is regenerated using Pd‐catalyzed deallylation chemistry

C ONCLUSIONS
In this chapter, we described the processes that lie at the heart of SynthSeq’s technology –
the chemical addition of reversibly terminating, tagged nucleotides, their imaging, and their
identification. We outlined the initial imaging of all of the DNA strands using fluorophores attached
to the poly‐A tail of the fragments; this allowed for the mapping of the surface and establishment of
fiducials to track the position and identity of each DNA molecule. We described the chemistry
involved in our process including the polymerase used, the characteristics of the modified
nucleotides used, the rate and fidelity of nucleotide incorporation, and the regeneration of
nucleotide function. We also described the hardware and analysis used to accurately detect and
identify single molecules including a TIRF microscope, specialized stage with nano‐positioner,
EMCCD camera, and beam‐splitter. We showed that each step could be carried out with high
confidence in its success. In short, we demonstrated that SynthSeq is able to accurately carry out
direct, asynchronous, single molecule sequencing by synthesis.
The sequence of steps outlined in this chapter provided the most difficult technical
challenges in SynthSeq’s business and define the throughput capabilities of our process. Ultimately,
the chemistry and detection portions of this process are what allow for the affordable, high
throughput sequencing of the full human genome that sets SynthSeq apart from past technologies
and current competitors.
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6. GENOME ASSEMBLY
__________________________________________________________________________________________________________________

This chapter focuses on the alignment of the genome, which represents a very resource‐
intensive part of SynthSeq’s technology in terms of money and time. Just like many of the other

99

issues that SynthSeq has faced in developing its sequencing technology, the alignment of the
genome presents a fundamental trade‐off between cost and throughput.

This trade‐off is

manifested in the amount of processing power dedicated to sequencing the genomes.

If an

insufficient amount of processing capacity is available, the process will bottleneck as detected reads
continually pile up. Additionally, the method of parallelization across server cores will have a
profound effect on turnaround. Assuming enough processing power is allocated to avoid data back‐
up, the primary issue becomes turnaround. Due to the fact that the process can be made highly
parallel, the sky is the limit when it comes to the theoretical alignment speed. However, a bank of
multi‐core processors can quickly become prohibitively expensive.

We have developed our

alignment strategy with the intention of providing enough processing capacity such that the
chemistry and detection steps will be throughput‐limiting. Although this approach resulted in
higher costs for the alignment side of the operation, we believe that the throughput it allows is
worth the cost. Note that throughput is not only reliant upon the chemistry and detection steps, but
also the ability to align bases at a rate similar to that of their detection. Ample processing power
must be allocated to the genomic alignment; otherwise a bottleneck in the system will arise.
This processing allowance is separate from turnaround, which is based on how we
parallelize the sequencing itself. Each genome is sequenced by exactly one server, parallelized
across its 32 cores. This method results in a 30 hour alignment time per genome, based on our
conservative estimates (see Equation 6.1).

The following sections delineate the alignment

requirements and demonstrate its feasibility. It is important to note that the throughput estimates
in this chapter are conservative. During the start‐up year, we may find that the optimization of our
alignment strategy significantly reduces our expected processing demands, lowering operating
costs considerably.
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D E N OVO S EQUENCING VS . C OMPARATIVE G ENOME A SSEMBLY
Within the field of genotyping, there exist two different approaches to genome alignment,
and both are frequently used. De novo sequencing is characterized by the independent alignment of
multiple reads without the use of a reference genomic template, whereas comparative genome
assembly relies on an existing genome to aid in alignment. 69 Generally, longer read technologies are
better suited to de novo sequencing, while shorter read‐length systems rely heavily on comparative
genome assembly. Acknowledging that SynthSeq constitutes a short read length technology (32 base
pairs), our reassembly strategy utilizes the public‐domain human genome sequence in concert with
comparative alignment software. Aligner algorithms, such as indexDPgenomic and BFAST, which
will be discussed later in the chapter, are designed specifically for comparative genome assembly of
short reads. They can therefore carry out successful alignment of reads in a fraction of the time and
with far less complexity than would be required if employing a de novo assembly strategy. 70

D ATA C OLLECTION AND P ROCESSING
Each sequencing station direct connects to a signal acquisition server in an adjacent room.
This unit scores the frames from the two EMCCD cameras, identifies the fluorophores in each viable
pixel, and then converts the data into a form that the aligner can process. No‐reads are converted
into Xs, and any sequence that fails the Z‐score test is thrown out. The data for each genome is
translated into a nucleotide sequence using standard signal processing techniques and sent directly
to a dedicated server for alignment.
Alignment speed is primarily based on memory access rates and multithreading capability.
Optimized reassembly is achieved only by minimizing the time required by each individual task
while maximizing the number of tasks that can be performed simultaneously. In the same way that
the parallelization of steps is fundamental to the overall process design, individual genome
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fragments can be distributed to multiple cores to speed up processing. Given the complexity of
modern computing systems, the result of this parallelization cannot be perfectly predicted, which
underscores the importance of optimizing the alignment process during the start‐up period. Such
an optimization might allow us to dramatically reduce the equipment costs in series B.

R EASSEMBLY OF THE R EADS
Once the frame data is converted to nucleotide sequences, our chosen algorithm aligns this
sequence data (i.e. the reads) to the reference genome. The aligner produces a catalog of nucleotide
sequences, positioning them in the appropriate part of the genome.

After all fragments are

organized in this way, a consensus is reached for every position, and a value of A, C, T, G, or X is
assigned to each position accordingly, generating the final genome. As previously mentioned, the
primary errors associated with SynthSeq are no‐reads, which are represented by an “X” signifying
that the identity is inconclusive (see Chapter 5). Our ability to image after the addition of each
nucleotide for a known number of cycles largely precludes both insertion and deletion errors that
plague many other technologies. Note that the aligner itself does not make errors, but it will
faithfully relay any errors emanating from the detection side of the technology.

B IOINFORMATICS H ARDWARE R EQUIREMENTS
A typical bioinformatics setup for a genotyping application includes the following elements:
•

A minimum two Dual Core Intel Xeon Processor (or a single Quad Core) with a speed of 2.6GHz
(or higher) and at least 4 GB of RAM per‐core
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•

At least 250GB of hard disk space with each core, or high‐bandwidth access to a central store
as an alternative.

•

At least 10 TB of centralized storage

•

High‐performance Port Switch offering high‐bandwidth networking across all servers 71

The SynthSeq solution to each of these hardware requirements is detailed in the following sections.

Processor – IBM Power 750 Express Server
The IBM Power 750 Express Server was chosen for its immense processing power and
energy efficiency. With 32 cores, each possessing 4GB of RAM, and a 3.0 GHz processor, this server
meets all bioinformatics requirements and is more economical than competing servers possessing
fewer cores.
Central Storage – Netdisk 9010N Storage Server
In addition to highly powerful servers that are able to align the sequencing data to the
reference genome, we also need a server that can store all of the data that results. For this purpose,
we have chosen the Netdisk 9010N, a storage server with 10TB of hard drive space, meeting the
recommended minimum amount of storage capacity. When combined with the 128GB hard‐drives
on each of our processors, however, the aggregate amount of disk space far exceeds the minimum.
Server Networking Solution – Dell PowerConnect 6224 24 Port Switch
The final piece of the hardware puzzle is a port switch that allows all of the various
components to communicate with each other, promoting parallel processing and high‐bandwidth
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data transfer. We have chosen the Dell PowerConnect 6224 Port Switch for this purpose, due to its
low cost, impressive specifications, and use in similar bioinformatics setups.

A LIGNER S OFTWARE AND C OMPUTATIONAL D EMANDS
The above components represent the hardware requirements, but there also exists the
issue of which aligner software to use. Fortunately, Helicos Biosciences offers a genome aligner
that is specifically designed for short read‐lengths, called indexDPgenomic. This aligner supports
fast, mismatch tolerant indexed alignment of short reads. It is an improved version of indexDP that
is aimed at aligning reads to large reference sets, making it ideal for SynthSeq sequencing methods.
Also, because the software is open source, we do not need to worry about any costs associated with
the alignment program itself.
For the indexDPgenomic aligner, we have decided to break up the alignment of each genome
into 15‐million‐read chunks that will each be processed by one 4GB core. These jobs are completed
in parallel across the 32 cores of an individual server, reducing the alignment time significantly. A
bank of these servers is connected via broadband connection, and our 10TB storage server serves
the total processing requirements of twelve genomes per day. Using benchmarks determined for
the alignment of human genome reads with the BFAST aligner (also open‐source), we are able to
estimate our expected processing demands.
(12 genomes / day) * (18 Gigabases / genome) * (480GB RAM * 1 day / 55
Gigabases) * (1 server / 128GB RAM) = 14.7 servers required  15 servers

Equation 6.1

Studies employing the BFAST aligner report the daily alignment of 55 billion human bases
to a reference genome using processing power equivalent to four of our servers. Fortunately, our
low coverage requirement dictates that we need to align just a fraction of that number of bases per
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genome. Based on Equation 6.1 above, a bank of 15 32‐core servers with 4GB RAM per core is
sufficient to achieve our desired throughput of twelve genomes per day, and this setup may even
allow for significant throughput increases on the chemistry and detection side of SynthSeq. 72 The
calculated processing requirement translates to approximately 30 hours per genome using one of
the 32‐core servers with 128 GB RAM to align each genome.
Depending on how the processing is allocated, the actual time for each genome to be aligned
will vary, but this amount of processing power should be sufficient based on these available
conservative benchmarks. Furthermore, the researchers note that the alignment was neither multi‐
threaded nor parallel, two options that would greatly improve calculated rates and are supported
by BFAST and indexDPgenomic. 73 Starting out with just one or two servers during the series A
period will allow us to optimize the alignment protocols and gain a better understanding of the
exact processing capacity that will be required for the scale‐up in subsequent years.

P RODUCT D ELIVERY
The final piece of the puzzle is to determine how we will deliver the sequences to our
customers and at what cost. From the sources on this subject, the data file of the human genome
would be about 750MB uncompressed (Equation 6.2). Including the reference human genome
along with the customer’s genome, in addition to our analysis and recommendations or at the very
least the names of some referral companies might be desirable. Allowing for the inclusion of all of
these things, one 2GB flash drive per customer should be sufficient (smaller if we zip the
sequences). However, the low cost of such drives limits the utility of shrinking the files. If we can
compress the data files to a great enough extent, we may be able to e‐mail them in the future. This
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practice might call customer confidentiality into question, however, so we may instead upload them
to a secure server from which customers can download their sequence, the reference human
genome sequence, a FAQ sheet, and perhaps a list of referral companies that can further analyze
their genome. At least for the start‐up phase of SynthSeq’s technology, we plan to send genome
sequences to our customers using flash drives with the latest encryption technology. The equations
used to determine the size of the raw data file are below:

Equation 6.2

C ONCLUSIONS
As mentioned previously, one of the primary advantages of SynthSeq technology is its lack of
insertion and deletion errors. The fact that no‐reads are the only source of error alleviates our need
to achieve the high coverage requirements characteristic of other technologies. Researchers have
noted that indexDPgenomic is designed specifically to accommodate insertion and deletion errors,
as opposed to other aligners created under the assumption that substitutions are more
prominent. 74 IndexDPgenomic was chosen due to its use in short‐read systems such as SynthSeq,
but due to the program’s penchant for insertion and deletion errors, we will need to evaluate its
speed in relation to other aligners, including BFAST. During our start‐up period, we will have the
opportunity to optimize our alignment procedures. Fortunately, both indexDPgenomic and BFAST
are open‐source, allowing us the freedom to test them without any additional cost.

Using

conservative benchmarks and parallel processing across a single server per genome, we have
determined that we can prevent data backup and achieve 30 hour genome alignment, using a total
of fifteen servers, ensuring both the throughput of our process and a respectable turnaround.
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7. FINANCIAL ANALYSIS
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All previous chapters have dealt with the biochemical processes and technological hurdles
of this project, yet the financial analysis of the technology is equally important to the success of the
company. This analysis will reveal whether or not the project is financially feasible; without an
existing market and the ability to generate a profit, no investors will agree to fund it. The
technology would fail from a business standpoint. This financial analysis will prove that the project
is indeed viable. Both NPV and MIRR analyses will be used to gauge the project’s profitability. All
necessary calculations and figures are included herein. It is important to note that all the calculated
values in this analysis are contingent upon projected earnings that are based on stated
assumptions.
Analysis begins with the revenue projections based on genomic throughput and price. A
separate sensitivity analysis is done on the genome price because of the importance of revenue in
the financial model. Total costs and depreciation explanations follow the revenue projections and
allow us to build an income statement for the project. The income statement shows earnings, but
we want to see free cash. Therefore, we need to adjust earning figures into cash ones by examining
working capital and other cash‐affecting items.
The company’s value can then be determined by combining the terminal value analysis and
discounted cash flow analysis. This is followed by the rate of return analysis for the two series of
investors involved in this project. This section is more difficult than conventional analysis, since
there are both series A and series B investors, who participate in two separate rounds of
investment. In order to simplify these added complications, an equity stake analysis is conducted.
With all of these explanations completed, the calculations and final results will be presented on a
single page spreadsheet for convenience.
Multiple what‐if scenarios will be discussed to see how they would impact our bottom line.
The scenario analysis will include a genome price sensitivity analysis to study the project’s
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limitations on profit. Once a sales price is established from the sensitivity analysis, two final
scenarios are performed to pass final judgment on the potential success of the SynthSeq platform.

M ARKET AND R EVENUE P ROJECTION
The genomic sequencing market is a relatively new market that has so far only been
accessible to wealthy individuals. However, the efforts of various companies are working to make
the market accessible to the general public. The Archon X Prize has contributed to the technological
improvements seen in recent years. The direct result of these technological improvements is a
price drop that should drastically expand the market for personal genomic sequencing. This
expansion is uncertain due to the paucity of available data for current sales volume. Revenue
projections are therefore difficult to accurately determine for this young and unpredictable market.
The following sections will assume our genome price to be $10,000, since the Archon X Prize
for Genomics is given to the first team to successfully manufacture and sell a genome for this price. 75
A sensitivity analysis will be conducted in a later section to determine the actual sale price of each
genome. This determination is crucial for a proper financial analysis to be conducted on the
project. We must also assume that at 100% manufacturing capacity, 3000 genomes will be sold
each year. Thus, the company will gross $30 million using these initial assumptions.
There are four stages of growth and development: the research stage, the scale up stage, the
sales stage, and the termination stage. The research period encompasses the development of a
working prototype and all necessary capital is funded by series A angel investors. There is no
revenue during this research phase, and only limited staff is employed. After a working prototype
is successfully developed, the scale up stage begins with series B investors providing the rest of the
necessary capital. New staff is added, and the step up increase allows for the first sales to begin.
We will assume that the company will be at 50% manufacturing capacity during the scale up phase.
We reach 100% design capacity during the sales stage, and the company is fully functional. The
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terminal stage marks the end of the sales and a terminal value is calculated based on prior free cash
flow projections. At this time, the company will hopefully have made a profit and will either be sold
to a larger firm or liquidated for revenue.
The following time scale will be used in the following sections: the research stage will take
one year, the scale up stage will last another year, and the sales stage will continue for three
additional years. The terminal stage ends the life of the company and a terminal value can be
calculated. The five year lifetime of the company is reasonable based on the rapid technology
improvements in the genome sequencing market. The revenue projections for these four phases
are shown in Table 7.1.

Revenue Projections
Year

2011

Stage Name
Design
Capacity

Revenue

2012

2013

2014

2015

2016

Research

Scale Up

Sales

Sales

Sales

Terminal

0%

50%

100%

100%

100%

100%

$0.00

$15,000.00

$30,000.00

$30,000.00

$30,000.00

Terminal
Value

Table 7.1 Revenue Projections for the following 5 years ($ in thousands).

It is important to note that inflation will be ignored for the entirety of the financial analysis.
Inflation calculations over such a small timescale are unnecessary. Moreover, the 1986 Financial
Accounting Standards Board determined that inflation accounting is unnecessary for financial
statements, which lie at the heart of this analysis. 76

C OSTS , PPE, AND D EPRECIATION
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A number of different costs are associated with running our company. These costs fall into
four distinct categories: equipment costs for the research phase and the sales phase, annual
research costs, and annual sales costs. Equipment purchased for the research stage includes all
laboratory machines necessary for developing the working prototype.

This includes sample

preparation machines, TIRF microscopes, EMCCD cameras, and processors. The annual research
cost is essentially employee salaries and lab space rent during this stage. Equipment purchased
during the sales stage is comprised of all additional laboratory equipment needed to scale up
production and reach 100% design capacity. The annual sales cost is the yearly burn rate of the
company once it is able to generate revenue. This burn rate is substantially greater than the
research stage burn rate. Inventory, research and development, and sales costs are added to salary
and rent during this stage. These costs are summarized in Table 7.2.
series A angel investors fund the cost of the research stage equipment purchases and the
cost of research for the first year. These investors are wealthy individuals who are willing to
participate in the risky research stage for developing new technology. For this project, the series A
investment comes to about $1.7 million.
series B investors join after a working prototype is developed and the research stage is
completed, thereby avoiding the high risk shared by the series A investors. The series B investment
is used to fund the purchase of all remaining equipment necessary for scaling up, as well as three
months worth of salary, rent, and inventory. The remaining salary, rent, and inventory costs can be
funded by generated revenue, assuming the company reaches 50% design capacity by the end of
that fiscal year. This will ensure the solvency of our company during this time. The total necessary
investment during series B is $2.85 million. It will be funded one year after the series A investment,
upon completion of the research stage.
As previously stated, the labor costs during the research stage are different from labor costs
in the following stages. Workers during the research stage consist of one secretary, two interns,

111

and four senior scientists, one of which will also serve as the company’s Chief Technical Officer
(CTO). The four senior scientists will not receive their full salary during prototype development.
Instead, they will receive two‐thirds of their ordinary salary in exchange for a 10% equity stake in
the company. This decision is the result of a compromise between the series A investors and the
four scientists. The investors want to limit the risk of their capital as much as possible, so they try
to cut salary costs by agreeing to give the employees a stake in the company. Under normal
conditions, the investors receive 85% of the company and give the employees 15%, especially when
the workers lack entrepreneurial experience. However, the added financial risk associated with
biotechnology companies may warrant series A investors to demand 90% ownership in the
company instead.
During the scale up stage and sales stages, the labor costs will be significantly higher for two
reasons. First, the four senior scientists will now receive their full salaries and begin working in
research and development to keep the company competitive in a fast‐pace genomic market.
Secondly, additional staff will be hired to meet the throughput demands of the company. New staff
members include a CEO, a CFO, two junior scientists, an organic chemist, three operators, two
salespeople for marketing, an HR representative, and an IT specialist. The junior scientists will
work on sample preparations, and the organic chemist will work to develop the reagents in‐house.
To meet our genome quota, we need to hire operators to work night shifts in order to keep
production going at all times. The sequencing of 3,000 genomes can be realized if production
operates around the clock for 250 days each year, at a rate of twelve genomes per day. The
company must operate for 24 hours a day for five days a week to achieve this level of production.
No operator can work more than 40 hours in a week, and one must be on site at all times to remove
and load new flow cells to keep the sequencing running throughout the night. Since there are 120
working hours per week, three operators will be necessary to meet our throughput demands.
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Rental costs are also different during the research stage and in subsequent stages. Space is
minimized during prototype development, but expansion is necessary to meet company demands.
Based on available rental costs and room, SynthSeq will be located in Boston, MA. 77
Inventory costs for this project include flow cells, flash drives to store DNA read outs for
each customer, sample preparation kits, and reagents. The total cost of these items depends on the
exact stage in question. The research stage is only involved in building a prototype; there are no
associated inventory costs. At 100% design capacity during the sales stage, the total inventory cost
is $691,000. During the scale up stage, we operate at 50% capacity and the total cost is halved.
Lastly, the operating costs include R&D and sales costs. These costs also only exist once the
research phase is complete. Our project will use 15% of revenue on research and development
costs and 3% of revenue on sales related costs. These are typical numbers for a biotechnology
startup company.
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Table 7.2 Cost Estimates for series A and B.
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Our company will use the 5‐year MACRS depreciation schedule in order to maximize the
amount of tax savings from the accelerated tax schedule. Depreciation is a non‐cash expense that
decreases the pre‐tax income from which taxes are deducted. An accelerated depreciation schedule
is ideal for short lived projects such as this because of the significant impact the savings has on the
NPV and MIRR analyses. The 5‐year MACRs depreciation percentages in order are 20%, 31%,
19.2%, 11.52%, 11.52%, and 5.76%.

Depreciation Schedule
MACR Tax Schedule
Year
series A Equipment
Depreciation

20.00%

32.00%

19.20%

11.52%

11.52%

2011

2012

2013

2014

2015

($247.37)

($395.79)

($237.47)

($142.48)

($430.71)

($689.14)

($413.49)

$1,236.83

series B Equipment
Depreciation

$2,153.57

Initial Net PPE
PPE Purchased/(Sold)
Less: Total Depreciation

$0.00
$1,236.83
$0.00

$1,236.83
$2,153.57
($247.37)

$3,143.04
$0.00
($826.50)

$2,316.54
$0.00
($926.61)

$1,389.92
$0.00
($555.97)

Final Net PPE

$1,236.83

$3,143.04

$2,316.54

$1,389.92

$833.95

Table 7.3 Depreciation Schedule using the 5‐year MACRs schedule ($ in thousands).

The series A equipment is labeled as the research equipment purchase, while series B
equipment is labeled as the sales equipment purchase. The ending net PPE figures in Table 7.3
represent the balance sheet amounts for how much property and equipment the company owns.
Total depreciation is found on the income statement (Table 7.4) and decreases pre‐tax income,
thereby lowering taxes. During the what‐if scenarios, we will explore the effect of the research
phase taking two years instead of just one. Under these circumstances, the series B equipment and
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its depreciations begin one year later on the income statement. As a result, the total depreciations
for each year will change.

I NCOME S TATEMENT
Income Statement
Year

2011

2012

2013

2014

2015

Revenue
Cost of Sales

$0.00
($115.10)

$15,000.00
($483.85)

$30,000.00
($829.49)

$30,000.00
($829.49)

$30,000.00
($829.49)

Gross Profit
Operating, SG&A Expenses
Depreciation

($115.10)
($356.00)
$0.00

$14,516.16
($4,110.00)
($247.37)

$29,170.51
($6,810.00)
($826.50)

$29,170.51
($6,810.00)
($926.61)

$29,170.51
($6,810.00)
($555.97)

Pre‐Tax Income
Tax @ 40%

($471.10)
$188.44

$10,158.79
($4,063.52)

$21,534.01
($8,613.60)

$21,433.90
($8,573.56)

$21,804.54
($8,721.82)

Net Income

($282.66)

$6,095.27

$12,920.41

$12,860.34

$13,082.72

0%

50%

100%

100%

100%

Margins
Gross Margin

0.00%

96.77%

97.24%

97.24%

97.24%

Profit Margin

0.00%

40.64%

43.07%

42.87%

43.61%

Design Capacity

Table 7.4 The income statement showing gross and profit margins ($ in thousands).

The total costs appearing in Table 7.4 are broken down into the cost of sales and operations,
or the SG&A expenses. The cost of sales includes all costs that are directly involved in the making of
the product, both fixed and variable costs. Fixed costs include rent and utility costs because these
do not vary with the number of goods produced and sold. Variable costs are the cost of inventory
because this cost is dependent on the number of genomes sequenced each year. The gross profit is
calculated by simply subtracting our company’s revenue by the total cost of sales. The gross margin
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is the percentage of how much money is left from the revenue after paying the cost of sales. The
operating, SG&A expenses deal with selling, general, and administrative fees associated with the
company’s operation. These expenses include the fixed cost of salary, as well as the variable costs
from research and development and sales. These variable costs are based on the amount of genome
sequenced, as well as the price charged for the sequencing. The pre‐tax income can now be
calculated by subtracting the operating, SG&A expenses and depreciation from gross profit.
Federal taxes are currently set around 35%, but total taxes increase to near 40% with the
addition of state tax. Note that taxes in the first year are actually positive because the company has
only incurred losses; we receive money from the government in what is known as a tax shield. This
shield does not always apply, but for the purposes of our analysis we will make this assumption.

W ORKING C APITAL

The generated income statement allowed us to calculate net income, but this is not
equivalent to cash. We need cash figures in order to conduct an NPV and MIRR analysis, so we must
adjust net income for cash items. One of these cash items that must be adjusted for is working
capital.
Working capital is the amount of capital needed by a company for it to operate normally.
Essentially, working capital is a portion of profits allocated for daily operations; it can be described
as current assets minus current liabilities.

Current assets are anything that can quickly be

converted to cash while current liabilities are all bills and debts that need to be paid back. Thus,
working capital is the remaining money left over after the company pays off its debts.
This analysis will cover the four main working capital items: accounts receivable, inventory,
accounts payable, and cash reserve. Accounts receivable are earnings that have not been paid for in
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cash yet. We will assume that the customer will have 30 days to pay for the product. With this
being the case:

Equation 7.1
Inventory comprises the items needed to sequence the genomes. This includes reagents,
QIAGEN kits, flow cells, etc. and can be found in Table 7.2. Since new inventory will be purchased
each month:

Equation 7.2
Accounts payable are the company’s bills that have yet to be paid for in cash. These bills
will be paid every 30 days; in this way accounts payable are the opposite of accounts receivable.
Since operating costs and rent are the company’s main bills:

Equation 7.3
Cash reserves are the cash kept on hand to pay for future salaries. Since three months
salary are held on reserve:

Equation 7.4
The change in these four working capital items allows net income to be changed into cash.
These changes are detailed in Table 7.5.
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Working Capital
Year

2011

2012

2013

2014

2015

$0.00
$0.00
$9.46
$89.00

$1,232.88
$28.41
$233.28
$352.50

$2,465.75
$56.82
$455.19
$352.50

$2,465.75
$56.82
$455.19
$352.50

$2,465.75
$56.82
$455.19
$352.50

Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inv
(Increase)/Decrease in A/P
(Increase)/Decrease in C/R

$0.00
$0.00
$9.46
($89.00)

($1,232.88)
($28.41)
$223.82
($263.50)

($1,232.88)
($28.41)
$221.92
$0.00

$0.00
$0.00
$0.00
$0.00

$0.00
$0.00
$0.00
$0.00

Total Change in Working Capital

($79.54)

($1,300.97)

($1,039.37)

$0.00

$0.00

Working Capital Item Estimates
Accounts Receivable
Inventory
Accounts Payable
Cash Reserve

Table 7.5 Working Capital and Changes in Working Capital ($ in thousands).

Any increase in assets decreases cash because the company needs to spend money to buy
necessary items. Any decrease in assets increases cash because selling equipment generates cash
for the company. Any increase in liability increases cash because borrowing from a bank means
there is more cash to spend, at least temporarily. Any decrease in liabilities decreases cash since it
indicates that loans and debts were paid back in cash.
An increase in accounts receivable should decrease cash because net income sees a change
that can’t be taken into account until the company receives the cash. The following fiscal year will
see that money paid, which results in a decrease in accounts receivable, assuming no new changes
occur. An increase in inventory decreases cash because the company needs to spend more cash to
buy enough supplies. An increase in accounts payable increases cash because the company has
acquired cash in taking out loans and incurring debt. An increase in cash reserves decreases cash
because it ties up cash into holding that will be used to pay for salary in the future.
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Purchasing PPE, or plant, property, and equipment, immediately decreases cash. This is not
shown on the income statement because the income statement reflects a company’s operational
efficiency, not one‐time cash expenses. Such purchases are instead slowly amortized. Selling of
equipment follows the same rules, in that it immediately generates cash but is not part of revenue
on the income statement. Purchasing and selling equipment is not part of the company’s everyday
operations.
Issuing common stock suffers the same problem as PPE. Issuing stock for series A and B
investors immediately generates cash, but it is an isolated event, divorced from revenue.
Repurchasing stock from the public market decreases cash, but again is not seen on the income
statement. PPE and stock exchanges are accounted for on the free cash flow statement.

F REE C ASH F LOW , T ERMINAL V ALUE
Now that working capital changes have been calculated and other cash items have been
accounted for, net income can be fully converted into free cash flow. Free cash flow is thus equal to
net income plus changes in working capital plus PPE changes plus stock issuances (Table 7.6). The
free cash flows can now be used to perform an NPV and MIRR analysis because they represent the
actual cash received by the owners.
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Free Cash Flow
Year

2011

2012

2013

2014

2015

($282.66)

$6,095.27

$12,920.41

$12,860.34

$13,082.72

$0.00

$247.37

$826.50

$926.61

$555.97

Changes in Working Capital
(Increase)/Decrease in A/R
(Increase)/Decrease in Inv
(Increase)/Decrease in A/P
(Increase)/Decrease in C/R
Total Change in Working Capital

$0.00
$0.00
$9.46
($89.00)
($79.54)

($1,232.88)
($28.41)
$223.82
($263.50)
($1,300.97)

($1,232.88)
($28.41)
$221.92
$0.00
($1,039.37)

$0.00
$0.00
$0.00
$0.00
$0.00

$0.00
$0.00
$0.00
$0.00
$0.00

Cash From Investing Activities
(Purchase)/Selling of Equipment

($1,236.83)

($2,153.57)

$0.00

$0.00

$0.00

$1,707.93

$2,825.42

$0.00

$0.00

$0.00

$108.90

$5,713.52

$12,707.54

$13,786.95

$13,638.69

Net Income
Cash Flow Statement
Cash From Operating Activities
Plus: Depreciation

Cash From Financing Activities
Issuance of Common Stock
Free Cash Flow

Table 7.6 Free Cash Flow from Net Income ($ in thousands).

Before an NPV and MIRR analysis can be conducted, the terminal value of the company
must be determined. This is done using the perpetuity growth model:

Equation 7.5

In this equation, the cash flow used is the final free cash flow listed in Table 7.6. The
variable g is the growth rate of the cash flow and the company. The variable r is the discount rate.
The terminal value calculated with this formula represents the present value of all continuing
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future cash flows. This calculation is theoretical because it assumes that the free cash flow is
predictable.

NPV V ALUATION
The net present value is used to predict the present worth of an investment assuming a
certain level of future profitability. It is the sum of every cash flow, which for these purposes is the
free cash flow plus the terminal value. This theoretical model is heavily dependent on the chosen
discount rate. The discount rate varies by industry, based on the risk associated with that industry.
Since the biotechnology is one of the riskier and more unpredictable industries, the discount rate
used will be 25% and 30%. Both of these rates will be used to create a broad range of NPVs. The
sales stage is significantly less risky than the research stage. Therefore, the discount rate during
research is 50%. Table 7.7 details the calculations of present value and NPV using a discount rate of
25%.

NPV Valuation @25%
Year

2010

2011

2012

2013

2014

2015

Terminal Value

0

1

2

3

4

5

6

$0.00
0%
$0.00

$108.90
50%
$72.60

$5,713.52
25%
$3,656.65

$12,707.54
25%
$6,506.26

$13,786.95
25%
$5,647.14

$13,638.69
25%
$4,469.13

$54,554.77
25%
$14,301.21

Investments
Discount Rate
Present Value

($1,707.93)
0%
($1,707.93)

($2,825.42)
25%
($2,260.33)

Net Present Value

$30,684.71

T
Free Cash Flow
Discount Rate
Present Value

Table 7.7 NPV Analysis at 25% Discount Rate for series B (50% Rate for series A) ($ in thousands).
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To calculate NPV, all projected discounted free cash flows and the terminal value are
converted into present values and then summed together.

The present values of the initial

investments are also calculated and subtracted from the original sum. It is important to take care
when dealing with the two rounds of investment because they are not treated equally in these
calculations. series A investment is equal to its present value because it is not a future cash flow,
but an outflow that occurs in the present. The series B investment, however, occurs one year from
the series A investment and is therefore discounted to find its present value. While the first free
cash flow is discounted 50% due to the risk of series A, the series B investment is discounted by
25% because the risk involved in developing a prototype has been eliminated.
The terminal value of the company is also discounted to the present because it is a future
projected value. The growth rate for these calculations was assumed to be 0%. The sum of all
present values is the net present value, adding all positive future cash flows with negative
investments. With our previously stated assumptions, our company’s investors will make over $30
million. To provide a complete financial picture, NPV analyses will be shown for myriad scenarios.

E QUITY S HARES
One way to measure profitability is through an IRR analysis, but this is difficult to perform
due to the two sets of investors that participate in this project. These investments, done at two
different times, force us to carefully track how much of the free cash flows go to series A investors
and how much go to series B investors. First, we need to compare how much the two groups have
invested in the project. series A investors put in about $1.7 million at the project’s outset and series
B investors put in about $2.85 million one year later. To account for the time difference, series A
investment must be discounted forward by 50% to properly compare the two numbers.
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Percentage of Investments

Investment
series A
Investors
series B
Investors

FV
Investment

Percentage

$1,707.93

$2,561.90

47.6%

$2,825.42

$2,825.42

52.4%

$5,387.32

100%

Total

Table 7.8 Compares series’ Percentages of Investments ($ in thousands).

Looking at Table 7.8, we can see that series B investors should keep 52.4% of the company
once they enter, while series A investors keep the remaining 47.6%. series B investors will get
52.4% of the company, series A investors will keep 90% of the remaining 47.6%, and the scientists
will keep the last 10% of that 47.6%. The scientists have a share in the company because of the
initial trade they made in salary for company equity with the series A investors. The breakdown of
company ownership is detailed in Table 7.9.
If NPV values are calculated for each year, we can see how each owner’s share value
increases over time. The calculation of equity percentage is essential for seeing how much of the
free cash flows go to each group. This information can now be used to properly conduct a rate of
return analysis.
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Equity Percentage
Year
Scientists
series A Investors
series B Investors
Total
NPV @25%

2011
10.0%
90.0%
0.0%
100%

2012
4.8%
42.8%
52.4%
100%

2013
4.8%
42.8%
52.4%
100%

2014
4.8%
42.8%
52.4%
100%

2015
4.8%
42.8%
52.4%
100%

2016
4.8%
42.8%
52.4%
100%

($1,635.33)

($239.02)

$6,267.24

$11,914.38

$16,383.51

$30,684.71

Share Values vs. Time
Scientists
series A Investors
series B Investors

$0.00
$0.00
$0.00

$0.00
$0.00
$0.00

$298.03
$2,682.31
$3,286.90

$566.58
$5,099.22
$6,248.58

$779.11
$7,011.95
$8,592.44

$1,459.19
$13,132.71
$16,092.81

Total

$0.00

$0.00

$6,267.24

$11,914.38

$16,383.51

$30,684.71

Table 7.9 Equity Percentage and Share Values of All Company Owners ($ in thousands).

MIRR A NALYSIS
A traditional rate of return analysis uses the internal rate of revenue (IRR) figure, but in this
case it is a flawed model. An IRR analysis on our project would produce highly overstated yields
since it entails large positive cash flows. The IRR analysis assumes that free cash flows are
reinvested at the IRR being calculated. This does not describe our company, which instead has only
two rounds of investment with no free cash flow being reinvested.
The alternative modified internal rate of return (MIRR) is used instead. For this calculation,
we need to know the finance and reinvestment rates. The finance rate is annual percentage rate
(APR) that our company would have to pay back lenders with if negative cash flows are generated.
We can assume the APR to be the prime loan interest rate, which is predicted to stay at its current
value of 3.25%. 78 The reinvestment rate is the interest rate owners would receive on any positive
cash flows. We can assume this rate to be 0.5%, which is the current yield on a 6 month US
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Treasury bill. 79 This is seen as the risk‐free rate; although the biotechnology industry could assume
a higher reinvestment rate because of its inherent risk, we will remain conservative in our
assumptions. In this way, a more moderate and realistic profitability analysis is conducted.
MIRR calculations can be seen in Table 7.10. Investments are first defined; all free cash
flows are then divided by the equity corresponding equity percentages. MIRR is then determined
based on those numbers. Note that series B investors have one less cash flow term, since they
entered the project one year after the series A investors.

MIRR Calculations
Year
Free Cash Flows
Equity Percentage
series A
series B

2011

2012

2013

2014

2015

2016

$108.90

$5,713.52

$12,707.54

$13,786.95

$13,638.69

$54,554.77

90.0%
0.0%

42.8%
52.4%

42.8%
52.4%

42.8%
52.4%

42.8%
52.4%

42.8%
52.4%

$5,837.21
$28,611.64

$23,348.82

Investment
Cash Flows
series A
series B

($1,707.93)
($2,825.42)

series A MIRR

71%

series B MIRR

80%

Divided Free Cash Flows
$98.01
$2,996.49

$2,445.32
$6,664.56

$5,438.68
$7,230.66

$5,900.66
$7,152.91

Table 7.10 MIRR Calculation. The finance rate is 3.25% and the reinvestment rate is .5% ($ in thousands).

A pro forma income statement, which summarizes the first part of the financial analysis, has
been prepared for the SynthSeq process (Table 7.11). The statement shows free cash flows, NPV,
and MIRR. There are two terminal values present on the sheet, one on top for a discount rate of
30% and one on the bottom for a discount rate of 25%.
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Table 7.11 Pro Forma for a genome price of $10,000
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W HAT I F S CENARIOS
Up until now, the financial analysis has been conducted using certain assumptions about the
research stage, the scale up and sales stages, and the terminal stage. If these assumptions fail to
hold, certain deviations will greatly affect the NPV and MIRR analyses. To study how profitability
could change, different case scenarios were defined for these three different stages. Table 7.12
explains these scenarios.

What‐If Scenarios
Research Stage
Best Case
Worst Case

S1
S2

The startup stage takes one year, as planned.
The startup stage takes two years.

Best Case

D1

Worst Case

D2

The first year of sales has 50% capacity, with remaining three years at 100%.
The first year of sales has 30% capacity, the next year's capacity is 70%, and the final
two years have full capacity.

Terminal Stage
Best Case

T1

Middle Case

T2

Worst Case

T3

Scale Up and
Sales Stage

The company stays profitable. Revenue stays constant.
The company starts to decline due to rising competition. Price reduces by half after one
year in sales.
Improved rival technology cuts customer base immediately. Equipment is sold at 50%
of face value.
Table 7.12 What‐If Scenarios

Informing scenario 2 of the terminal stage, Figure 2.10 shows the recent trend in prices for
a fully sequence genome, beginning with the Human Genome Project and ending with Knome. 80, 81
This trend shows an exponential decrease in the price of genome sequencing. This trend is likely to
continue, so a price decrease in future years is an important case to consider. However, no
company has been able to produce a fully sequenced genome with acceptable accuracy rates for
less than $5,000; this price has not changed in many years. A new technology may help lower this
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price in the next 5 years, but no company will undersell their own cost of sequencing the genome.
As a result, we will use the price of $5,000 as the lower limit on price reduction in this scenario.
Table 7.13 shows the complete NPV and MIRR summary for the twelve different scenarios.

Scenario Summary
Tree
S1

D1

D2

S2

D1

D2

Case
T1
T2
T3
T1
T2
T3
T1
T2
T3
T1
T2
T3

1
2
3
4
5
6
7
8
9
10
11
12

NPV @ 30%

NPV @ 25%

$23,275.29
$10,708.19
$10,904.06
$19,741.07
$8,149.85
$7,369.84
$17,412.60
$8,102.63
$7,896.27
$14,693.96
$5,991.86
$5,177.63

series A MIRR

$30,684.71
$14,244.15
$12,808.41
$26,762.17
$11,424.12
$8,885.87
$24,095.13
$11,346.04
$9,794.09
$20,957.10
$8,928.67
$6,656.06

series B MIRR

71%
52%
44%
69%
50%
39%
58%
43%
36%
56%
41%
32%

80%
56%
46%
77%
53%
39%
80%
57%
46%
77%
53%
39%

NPV and MIRR Range
High
(Average of Top
3)

Medium

Low

(Median)

(Average of Bottom 3)

NPV
series A

$27,180.67
66%

$11,125.05
47%

$5,941.85
35%

series B

79%

55%

42%

Table 7.13 Complete NPV and MIRR Analysis of the Twelve What‐If Scenarios ($ in thousands).

Ideally, we would like to provide an MIRR of 50% for series A investors and an MIRR of 30%
for series B investors, or better. Except under worst case scenarios, these desired rates are
achieved. A copy of all twelve scenarios’ pro forma is provided in Appendix E. It is important to
remember that all of these scenarios assumed the price of the genome to be $10,000.
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P RICE S ENSITIVITY A NALYSIS
The same analysis can now be conducted for various genome prices to determine at what
price the project is no longer profitable. Table 7.14 contains these results, with genome prices
ranging from $10,000 to $1,000.

Price Sensitivity Analysis
NPV
Genome Price
$10,000.00
$9,000.00
$8,000.00
$7,000.00
$6,000.00
$5,000.00
$4,000.00
$3,000.00
$2,000.00
$1,000.00
Breakeven Price

High

Medium

Low

$27,180.67
$23,828.92
$20,477.09
$17,125.26
$13,773.43
$10,421.60
$7,069.76
$3,717.93
$200.31
($2,922.62)

$11,147.38
$9,494.89
$7,803.22
$6,086.44
$4,320.18
$2,719.42
$1,144.92
($511.99)
($1,919.85)
($3,278.05)

$5,967.79
$4,920.38
$3,872.84
$2,825.31
$1,848.37
$697.63
($453.12)
($1,565.57)
($3,025.96)
($4,704.31)

$1,935.86

$3,363.66

$4,393.76

High
A

Medium
A

66%
63%
60%
56%
52%
47%
41%
32%
21%
‐6%

47%
45%
41%
38%
34%
31%
23%
14%
4%
‐10%

MIRR
Low
High
A
B
36%
33%
30%
28%
24%
22%
16%
11%
‐5%
‐47%

79%
75%
72%
65%
59%
53%
45%
34%
19%
‐14%

Medium
B
55%
51%
47%
42%
37%
31%
22%
12%
‐1%
‐18%

Low
B
42%
39%
35%
31%
26%
22%
16%
7%
‐12%
‐100%

Table 7.14 Genome Price Sensitivity Analysis for NPV and MIRR ($ in thousands).

Under best case scenarios, a price just over $1,900 will allow us to break even. However,
the worst case scenario must be considered to determine a reasonable price to charge for the
genome. The break‐even price is just under $4,400. If we charge around $5,000 per genome, we
will still make sizable returns, especially since the chance of worst scenarios is low. This is a
comfortable price, since our closest competitor, Knome, charges $68,000 for the same service. It is
important to note that these prices are not representative of the actual cost of genome sequencing.
Since machinery is a one‐time cost and operational costs depend on revenue, this per genome cost
is calculated using labor, inventory, and rental costs alone. The resultant drop‐dead price for
genome assembly is accordingly determined to be $746.50.
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The MIRR yields we hope to achieve for series A and B investors are also important. Ideally,
series A investors, who undertook large financial risks to fund this project, would receive 50%
returns on their investment. The series B investors undertook less risk, so a 30% return on their
investments is reasonable. Looking at Table 7.14, series A investors would see an MIRR of 52% if
we sold each sequenced genome for $6,000 under best conditions; series B investors would see an
MIRR of 53% at this sales price. Although achieving an MIRR of 50% for series A is not possible
except under best case scenarios, it is important to remember that the assumptions that went into
the best case are not implausible. It is also important to remember that the actual MIRR of series A
investment is greater than 52%, since the senior scientists who took salary hits in their first year
with SynthSeq own a share of the total success. Bearing that in mind, SynthSeq will charge $5,000
per sequenced genome.
With $5,000 having been selected as the price of the SynthSeq genome, three additional case
studies can be conducted to better gauge the financial success of the platform. The first of these
cases studies the minimum throughput the company can absorb while still breaking even. The
second considers how long the company must operate in order to break even, assuming expected
throughput is achieved. The final case considers the potential for Big Pharma to utilize our
sequencing process as part of phase III clinical trials. All of these cases will be performed under
optimal conditions which assume one year for research and development, one year for scale‐up,
and maintaining original sales price for the entire operation period.
The first case considered involves a situation where unexpectedly low throughput in series
A necessitates high capital costs in series B to purchase enough machinery and rental room to still
meet minimum genome requirements. The throughput is divided by a value α, the same number
that machinery, reagents, flow cells, and rental costs are multiplied by to recover overall
throughput. Table 7.15 presents how NPV and series A and B MIRR vary with alpha.
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Reduced Throughput Factor
α
1
2
3
4
5
6

NPV @25%
$11,947.25
$9,676.93
$7,175.38
$4,673.82
$2,172.27
($329.29)

series A
52%
42%
35%
29%
24%
20%

series B
56%
43%
34%
27%
22%
17%

5.86

$0.00

21%

18%

Table 7.15 Reduced Throughput Alpha Factor’s Effect
on NPV ($ in thousands).

Based on Table 7.15, SynthSeq will not lose money unless a minimum throughput is 5.86
times less than is currently anticipated with the technology. Considering our expected throughput,
this corresponds to performing 35 times coverage on the whole genome just to get enough data to
sequence the genome. This proves that even if some unexpected failure in throughput is discovered
during series A, SynthSeq will most likely remain financially safe.
The second case considered here involves a situation where a competitor enters the market
and forces early termination of the company in order to avoid failure from revenue loss. The reality
of another start‐up biotechnology company entering the market and undercutting SynthSeq is a
possibility, considering the rapid innovations in this field each year. Table 7.15 shows how NPV
and series A and B MIRR vary with operating years for the company.

Early Termination Effects
Years Operation
5
4
3
2
2.44

NPV @25%
$11,947.25
$3,896.44
$1,473.57
($1,615.74)
$0.00

series
A
51%
27%
22%
2%
14%

series
B
54%
26%
19%
‐8%
9%

Table 7.15 Early Termination’s Effect on NPV ($ in thousands).
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Based on Table 7.15, SynthSeq will only lose money if the company is in existence for fewer
than 2.5 years. Since the first year includes the research and design period, only part of the first
year needs to be spent operating at 100% capacity to bring the company into a positive NPV.
Therefore, SynthSeq is generally well protected against threats from competitors that would hinder
profits before enough sales are made.
The final case in this financial analysis highlights a conceivable, near‐future application of
our technology that would contribute to personalized medicine. This scenario studies the financial
feasibility of entering into an agreement with Big Pharma to provide genomic sequencing for
patients in phase III clinical trials. Most phase III trials include between 500‐3,000 patients and last
for at least three years. At this point in the process, toxicity and dosage tests have been performed
for a new drug on a small test group; phase III trials study exactly how effective a drug is for a
larger population and whether or not it is better than current treatments. 82 Genetic screening in
phase III trials could serve to find a genetic link between effectiveness of a drug and/or study the
effects of genetics on pharmacokinetics. It is possible to envision large pharmaceutical companies
paying an additional amount for each patient in the clinical trial to conduct more personalized tests
to see if certain genetic material affects drug response in patients. Since the average cost per
patient of phase III clinical trials is $26,000, the relative cost of sequencing each patient’s genome
might become economically justifiable at the low prices being proposed by SynthSeq, especially if a
lower cost were negotiated for such a deal.
This financial analysis has already proven that the bottom line price for sequencing a
genome is $746.50, including inventory, rental, and labor fees. The purchased equipment from
series A and B can handle the demands of sequencing 3,000 genomes per year.

If a large

pharmaceutical company agreed to pay for continual research costs as well as $1,000 per
sequenced genome, it would be highly beneficial to enter into contract with such a company.
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SynthSeq would provide exclusive genome sequencing for a low price to the pharmaceutical
company, while getting guaranteed business and protection from outside competitors for some
negotiated time. With market security and large savings in research and development costs, such
an agreement for phase III clinical trials would be highly profitable.

C ONCLUSIONS
This financial analysis has provided strong evidence that our company is a profitable
investment. Even when considering various less‐than ideal situations, we see that investors will
still receive acceptable returns on their investment. The sensitivity analysis shows that an ample
price margin exists for our investors. Additional case studies further prove that profitability
margins greatly outweigh the risk of failure of the SynthSeq business plan, as well as provide the
potential for genome sequencing to enter the arena of personalized medicine.
It is important to remember that these financial models are hypothetical. They provide a
guide for investors and reduce as much risk as possible, but they cannot accurately produce the
future of the genome sequencing market. Financial risk exists in this project, but no more than it
would for any reasonable fiscal endeavor. This company is a biotechnology firm that lacks many
competitors due to the technology advances made in this project. Until the genomic market
tempers with time, profit margins will remain high.
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8. CONCLUSIONS
__________________________________________________________________________________________________________________

The goal of this undertaking was to design a process that would enable the sequencing of
twelve entire genomes per day for 250 days per year with less than ten errors per million bases and
incremental operating cost per genome of less than $10,000 using less than $25 million in start‐up
capital. The designed process satisfied all of these criteria, and we have shown that it does so with
a lower error rate than competitors and at a lower cost. The technology that allows SynthSeq to
provide such a highly accurate sequence with such high throughput and at such low prices is its
unique approach to single molecule sequencing by synthesis.
The advent of non‐Sanger sequencing approaches has opened up the door to sequencing
technologies that are far superior to those originally used in the Human Genome Project.
SynthSeq’s method uses those advantages, and takes it one step further. Since our method is
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asynchronous (i.e. nucleotide identification is done in between DNA synthesis steps), it makes it
possible to easily identify and eliminate errors. Since the number of nucleotides that should have
been added to the template strand is known exactly, insertion and deletion errors are eradicated.
The stepwise addition of nucleotides also avoids errors that stem from homopolymers.
Furthermore, since PCR is not employed, amplification bias is avoided. By quantifying the average
deviation from expected values with the Z‐score, data from template strands with systematic errors
is discarded. These are fundamental advantages that SynthSeq’s sequencing procedure has over its
competitors.
The cost for SynthSeq to sequence one genome – which includes labor, rental and inventory
costs – is $747. The company will charge customers $5000; this price is well below competitors’
prices. The only other company currently selling the service to sequence an entire human genome
is Knome. It costs Knome $5,000 to sequence one genome, and they charge customers $68,500 per
genome. Illumina claims it is able to sequence the genome for $10,000, and the price to a customer,
when it is released, is sure to be well above that. Thus, SynthSeq will provide an accurate genome
sequence to customers at a fraction of the cost of its competitors and provide significant returns to
investors. Charging $5000 per genome, SynthSeq expects to have a positive NPV over four years. In
the worst‐case scenario, the NPV of the company is $700 thousand and in the best‐case scenario,
the NPV of the company is $10.5 million. This corresponds to a ROI for a series A investor of 22% in
the worst‐case scenario and 47% in the best‐case scenario.
SynthSeq has applied cutting edge technologies in a novel way to create a process that
performs better than any other on the market. We developed a genome sequencing process that
provides an affordable, reliable product in a short period of time. SynthSeq has presented an
attractive business plan that is poised to provide considerable returns on investment for its
financial backers. Further, SynthSeq has developed a technology and a business plan that could help
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revolutionize medical care by facilitating the average consumer’s access to this crucial information.
We firmly believe that the technology we have presented herein will significantly further
medicine’s ability to predict, prevent and treat disease.

139

A CKNOWLEDGEMENTS
We would like to take this opportunity to thank all of the people who contributed to our
senior design project. Thanks especially to Dr. John C. Crocker for his sage advice and patience over
the course of this endeavor. His extensive knowledge about DNA sequencing technology was vital
to our understanding of the project details and its successful completion. We greatly appreciate Dr.
Daeyeon Lee showing us his layer‐by‐layer laboratory, which helped us nail down the fundamentals
of flow cell preparation. Thanks also to Parijat Sarkar, who was instrumental in helping us develop
a simulation to model the efficiency of our random array. Finally, we would like to thank Professors
Leonard A. Fabiano and Warren D. Seider for their involvement in the senior design process, as well
as the industrial consultants who devoted their time to attend our weekly team meetings.

140

APPENDIX A: REAGENT SPECIFICATIONS
__________________________________________________________________________________________________________________

141

A.1. S AMPLE P REP R EAGENTS
Species

Formula

Manufacturer

Price

PB buffer

N/A

Qiagen

100mL for $68.00

N/A

Qiagen

100mL for $68.00

EB buffer

N/A

Qiagen

250mL for $27.00

T4 DNA Ligase buffer

N/A

New England BioLabs

100,000 units* for

(concentrated)
PE buffer
(concentrated)

with 10mM ATP

$252.00

dNTP mix

N/A

Qiagen

800µL for $153.00

T4 DNA Polymerase

Protein Structure**

New England BioLabs

750 units*** for
$244.00

Klenow Enzyme

Protein Structure+

New England BioLabs

1000 units++ for
$224.00

T4 Polynucleotide

Protein Structure+++

New England BioLabs

Kinase
Klenow exo(3’to 5’ exo

2500 units++++ for
$212.00

N/A

Fisher Scientific

100 units for $53.27

minus)
* One unit is defined as the amount of enzyme required to give 50% ligation of HindIII fragments of
λ DNA (5´ DNA termini concentration of 0.12 µM, 300‐ µg/ml) in a total reaction volume of 20 μl in
30 minutes at 16°C in 1X T4 DNA Ligase Reaction Buffer.
** T4 Polymerase Structure:
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*** One unit is defined as the amount of enzyme that will incorporates 10 nmol of dNTP into acid‐
precipitable material in a total reaction volume of 50 μl in 30 minutes at 37°C (5) in 1X T4 DNA
Polymerase Reaction Buffer with 33 µM dNTPs including [3H]‐dTTP, 70 µg/ml denatured herring
sperm DNA and 50 µg/ml BSA.
+ Klenow Enzyme Structure:

++

One unit is defined as the amount of enzyme required to convert 10 nmol of dNTPs to an acid‐

insoluble form in 30 minutes at 37°C.
+++T4 Polynucleotide Kinase Structure:

++++ One

Richardson unit is defined as the amount of enzyme catalyzing the incorporation of 1 nmol

of acid‐insoluble [32P] in a total reaction volume of 50 μl in 30 minutes at 37°C in 1X T4
Polynucleotide Kinase Reaction Buffer with 66 µM [γ‐32P] ATP (5 x 106 cpm/µmol) and 0.26 mM 5´‐
hydroxyl‐terminated salmon sperm DNA (1).
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A.2. F LOW C ELL P REP R EAGENTS
Species

Manufacturer

Price

Poly(acrylic acid)

Sigma‐Aldrich

10 g for
$219

Poly(acrylamide)

Sigma‐Aldrich

N/A

Fisher

125mL

Scientific

for

MES buffer, pH 6

Formula /Structure

C6H13NO4S

$45.00
Magnesium Chloride

MgCl2

Sigma‐ Aldrich

1 mL for
$37.70

1ethyl3(3

Sigma‐ Aldrich

N/A

Sigma‐Aldrich

1 g for

dimethylaminopropyl)carbodiimide

Nhydroxysulfosuccinimide

C4H4NNaO6S

$323.00
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polydT tails

Acros

5 g for

Organics

$102.20

A.3. N UCLEOTIDE A DDITION R EAGENTS

Species

Formula

Manufacturer

Price

dNTPs

TriLink

ACES buffer

Different for each tagged
nucleotide
C4H10N2O4S

Fisher Scientific

$20,000 custom
synthesis
600g for $643.81

Potassium Acetate

CH3COOK

Fisher Scientific

2.5kg for $633.23

Dithiothreitol

HSCH2CH(OH)CH(OH)CH2SH

Fisher Scientific

5 g for $107.20

Manganese Acetate

C4H6MnO4

Fisher Scientific

100g for $191.21

Phi29 Polymerase

Protein structure*

New England
BioLabs

1250 units** at
10,000units/mL for
$244.00

* Phi29 Polymerase Structure:

** One unit is defined as the amount of enzyme that will incorporate 0.5 pmol of dNTP into acid
insoluble material in 10 minutes at 30°C.
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A.4. F LUOROPHORE C LEAVE R EAGENTS

Species

Formula

Manufacturer

Price

Thermopol I buffer

N/A

6mL for $14.00

Sodium

Na2PdCl4

New England
BioLabs
Sigma‐Aldrich

P(PhSO3Na)3

N/A

N/A

N/A

Tris HCl buffer

HSCH2CH(OH)CH(OH)CH2SH

Fisher Scientific

1100mL for $308.40

1 g for $102.50

tetrachloropalladate
(II)
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S AMPLE P REPARATION E QUIPMENT

PSS BioInstruments Magtration 12GC

Size

500(W) x 500(D) x 570(H) mm

Samples on board

1 to 12

Sample Volumes

100 or 200 µL for DNA

Elution Volumes

50, 100 or 200µl

Purification time (1 ・12 samples)

30 minutes for DNA

Unit Price

$40,000
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Covaris s2 Shearer

Operating

• Temperature: 15°C–25°C

Environment

• Maximum humidity: 80% at 31°C; 50% at 40°C

System

When purchased through Applied Biosystems, the Covaris S2 System

Components

consists of the following components:
• Covaris S2 Machine
• Covaris 2‐series machine holder for (one) 1.5 mL microfuge tube
• Covaris 2‐series machine holder for (one) 0.65 mL microfuge tube
• Covaris 2‐series machine holder for (one) tube(13 x 65 mm)
• Dell™ Latitude laptop computer
• VWR® Compact Chiller, Model 117‐612

Power

• US: 120 V (+/‐ 10%), 60 Hz (+/‐ 10%)

Requirements for

• Japan: 100 V, 50–60 Hz

Covaris S2 Machine

• International: 220–240 V, 50–60 Hz
• Power: ~300 W

Unit Price

$55,000
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F LOW C ELL P REPARATION E QUIPMENT

DS‐50 SLIDE STAINER

Input Line Pressure

FlowThrough Rate
Recirculation Rate
Wash Tank Capacity

10‐100 psia

Factory set via regulator Approx. 1L/min.
Approximately 3.5L/min.
Approximately 1.750 mL
115VAC nominal, 50/60 Hz220‐240 VAC

Electrical Power

Power Consumption
Unit Price

nominal
3.6A peak
$16,734
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CiDRA® Precision Services SlipStream

Optical Flatness (all surfaces)

Less than 500nm/mm

Bottom & Top Plate Thickness

100um to 1cm

Top & Bottom Plate Thickness Tolerance

Less than +/‐20um

Top & Bottom Plate Parallelism Tolerance

Less than +/‐10um

Channel Thickness

25um to 700um

Channel Width

50um to >1cm

Channel Dimensional Accuracy

+/‐30um

Surface Roughness (Ra) for All Optical
Surfaces
Maximum Operational Temperature

<2nm
200°C

Maximum Pressure
Maximum Size

20psi
2,000cm2

Unit Price

$75.00
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S TATION A SSEMBLY E QUIPMENT

Harvard Apparatus Pump 22 Infusion Only
Syringe Pump

# of Syringes
Accuracy
Average Linear Force
Communications
Communications Level
Depth English
Depth Metric
Display
Flow Rate Maximum
Flow Rate Minimum
Height English
Height Metric
Input Power
Motor
Motor Stepper 1 Revolution of Lead Screw
Net Weight English
Net Weight Metric
Non Volatile Memory
Pressure
Pump Configuration
Pump Function
Unit Price

2
0.35 %
47 lbs
RS‐232, TTL
2
5.5 in
14 cm
LED, 3‐1/2 digit, numeric
55.1 ml/min
0.002 µl/hr
11 in
28 cm
0.5 A, 30 W
1/4 microstepping, 0.9° micro step angle motor
3,200 at 1/4 stepping
10 lb
4.5 kg
Storage of all settings
Standard
Standard
Infusion Only
$3,006
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ThorLabs MAX201 Motorized X/Y Stage

75 mm x 50 mm (3" x 2")

Travel

10 mm/s

Maximum Speed
Accuracy

1 μm

Repeatability (Unidirectional)

1 μm

Resolution (micro step size)

40 nm
5 kg

Load Capacity (max)

3 m Long

Cable Included
Compatible w/ Olympus IX71
Compatible w/ Zeiss Axiovert
200
Compatible w/ Nikon TE2000

$6,460

Unit Price
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ThorLabs Microscan Piezo XYZ Controller SCXYZ100B

X and YAxis Travel

100 μm

ZAxis Travel

80 μm

Positioning Resolution

25 nm

Feedback

Strain Gauges

Load Capacity

100 g on Top Surface

Stiffness

0.4 N/μm in X or Y

Resonant Frequency

>70 Hz

Max Voltage

75 V

Unit Price

$9,990
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Olympus IX81 Motorized Inverted Microscope
with TIRFM Capabilities

Objective Lens

APO 60x
Oil Immersion
NA = 1.49
Magnification Changer = 0.5

TIRF

4 line lasers corresponding to four
nucleotide analog excitation
wavelengths

Unit Price

$200,000
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Andor iXonEM +888 Back‐Illuminated EMCCD

Active Pixels

1024 x 1024

Pixel Size (W x H; µm)

13 x 13

mage Area (mm)

13.3 x 13.3

Active Area Pixel Well Depth (e, typical)

80,000

Gain Register pixel well depth (e, typical)

730,000 2

Max Readout Rate (MHz)

10

Frame Rates (frames per sec)

8.9 (full frame)

Read Noise (e)
Unit Price

< 1 to 47 @ 10 MHz
$44,574

163

164

G ENOME A SSEMBLY

IBM Power 750 Express Server

POWER7 processor modules –
one per processor card

Sockets
Level 2 (L2) cache
Level 3 (L3) cache
Memory
Solid State Drives (SSD)
Disk drives
Disk capacity
Media bays
PCI Adapter slots
Unit Price

6‐core 3.3 GHz or
8‐core 3.0 GHz or
8‐core 3.3 GHz or
8‐core 3.55 GHz1
1 to 4
256 KB per core
4 MB per core
8 GB2 to 512 GB of RDIMM DDR3
Active Memory Expansion
Up to eight SFF drives
Up to eight SFF SAS drives
Up to 2.4 TB
Slimline for DVD‐RAM
Half height for tape drive or removable disk
Two PCI‐X 2.0; Three PCI Express 8x
$101,953
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Netdisk 9010N Storage Server

Processor
Main Memory
Flash
LAN
Network Service

Storage/RAID
USB
Dimension
System Power
Software

Unit Price

Dual Core Intel processor running at 2GHz +
DDR2 1GB (Optional 2GB to 4GB)
2GB with NAS and OS (Optional for MS
HomeServer)
Two Gigabit LAN ports
DHCP client/server (default is DHCP
client/Static)
Network Protocol: CIFS/SMB, NFS, FTP
iSCSI (optional)
Twelve 3.5" SATA/SATA‐II Hot‐Swap Drive
500GB, 1TB, 1.5TB or 2TB
RAID 5, 6, 10, 1 and 0 with Hot Spare supported
2x USB 2.0 connectors
202mm x 424mm x 490mm
(W)8.27" x (H)17.32" x (D)20"
400W PSU (Redundant P/S is optional)
Operating System: Linux/FreeBSD, (Optional
Microsoft Home Server)
Backup and Recovery Client Support: Supports
MS Windows 2000, Windows XP and Windows
2003, Linux and Mac
$1,999
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Dell PowerConnect 6224 24 Port Switch

Port Attributes

24 10/100/1000BASE‐T auto‐sensing Gigabit
Ethernet switching ports
4 SFP combo ports for fiber media support
10 Gigabit Ethernet uplink modules (optional)
48Gbps Stacking module (optional)
Auto‐negotiation for speed, duplex mode and flow
control
Auto MDI/MDIX
Port mirroring
Flow‐based port mirroring
Broadcast storm control

Performance

Switch Fabric Capacity 136 Gb/s
Forwarding Rate 95 Mpps
Up to 8,000 MAC Addresses
256MB of CPU SDRAM
32MB of Flash Memory

Availability

Unit Price

Spanning Tree (IEEE 802.1D) and Rapid Spanning
Tree (IEEE 802.1w) with Fast Link Support
Multiple spanning trees (IEEE 802.1s)
Supports Virtual Redundant Routing Protocol (VRRP)
External redundant power support with
PowerConnect EPS‐470 (sold separately)
Cable diagnostics
Optical transceiver diagnostics
$1,400
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J AVA C ODE
import java.util.Random;
public class RandomInteger1{
public static void main(String [] args){
// a x b = dimensions of the 2D arrays
int a = 1024;
int b = 1024;
// d is the number of templates
int d = 1100*1100;
//c = # of little boxes per big box
int c = 50;
//r = radius
int r = 15;
int [][] x = new int [a][b];
//y is the second 2D array, 0.25 um shifted over
int [][] y = new int [a][b+25];
double count = 0;
Random randomGenerator = new Random();
for (int i = 1; i <= d; i++)
{ int rint1 = randomGenerator.nextInt(a*c);
int rint2 = randomGenerator.nextInt(a*c);
if(!(rint1%c<r‐2&&rint2%c<r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<r‐2)&&!(rint1%c<r‐
2&&rint2%c<c‐r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<c‐r‐2)&&x[rint1/c][rint2/c]==0)
{ x[rint1/c][rint2/c] = 1;
if(rint1%c<r‐2&&rint1/c‐1>=0)
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{ x[rint1/c‐1][rint2/c] = ‐1;}
if(rint1%c>c‐r‐2&&rint1/c+1<a)
{ x[rint1/c+1][rint2/c] = ‐1;}
if(rint2%c<r‐2&&rint2/c‐1>=0)
{ x[rint1/c][rint2/c‐1] = ‐1;}
if(rint2%c>c‐r‐2&&rint2/c+1<a)
{ x[rint1/c][rint2/c+1] = ‐1;}
}
else{
if(!(rint1%c<r‐2&&rint2%c<r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<r‐2)&&!(rint1%c<r‐
2&&rint2%c<c‐r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<c‐r‐2)&&x[rint1/c][rint2/c]==1)
{ x[rint1/c][rint2/c] = ‐1;}
else{
if(rint1%c<(r/1.412)&&rint2%c<(r/1.412)&&rint1/c‐1>=0&&rint2/c‐1>=0)
{x[rint1/c‐1][rint2/c‐1] = ‐1;}
if(rint1%c<(r/1.412)&&rint2%c>(c‐r/1.412)&&rint1/c‐1>=0&&rint2/c+1<a)
{x[rint1/c‐1][rint2/c+1] = ‐1;}
if(rint1%c>(c‐r/1.412)&&rint2%c<(r/1.412)&&rint1/c+1<a&&rint2/c‐1>=0)
{x[rint1/c+1][rint2/c‐1] = ‐1;}
if(rint1%c>(c‐r/1.412)&&rint2%c>(c‐r/1.412)&&rint1/c+1<a&&rint2/c+1<a)
{x[rint1/c+1][rint2/c+1] = ‐1;}
}}
rint2 += 25;
if(!(rint1%c<r‐2&&rint2%c<r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<r‐2)&&!(rint1%c<r‐
2&&rint2%c<c‐r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<c‐r‐2)&&y[rint1/c][rint2/c]==0)
{ if(rint2/c>=25)
{y[rint1/c][rint2/c] = 1;}
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if(rint1%c<r‐2&&rint1/c‐1>=0)
{ y[rint1/c‐1][rint2/c] = ‐1;}
if(rint1%c>c‐r‐2&&rint1/c+1<a)
{ y[rint1/c+1][rint2/c] = ‐1;}
if(rint2%c<r‐2&&rint2/c‐1>=0)
{ y[rint1/c][rint2/c‐1] = ‐1;}
if(rint2%c>c‐r‐2&&rint2/c+1<a)
{ y[rint1/c][rint2/c+1] = ‐1;}
}
else{
if(!(rint1%c<r‐2&&rint2%c<r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<r‐2)&&!(rint1%c<r‐
2&&rint2%c<c‐r‐2)&&!(rint1%c<c‐r‐2&&rint2%c<c‐r‐2)&&y[rint1/c][rint2/c]==1)
{ y[rint1/c][rint2/c] = ‐1;}
else{
if(rint1%c<(r/1.412)&&rint2%c<(r/1.412)&&rint1/c‐1>=0&&rint2/c‐1>=0)
{y[rint1/c‐1][rint2/c‐1] = ‐1;}
if(rint1%c<(r/1.412)&&rint2%c>(c‐r/1.412)&&rint1/c‐1>=0&&rint2/c+1<a)
{y[rint1/c‐1][rint2/c+1] = ‐1;}
if(rint1%c>(c‐r/1.412)&&rint2%c<(r/1.412)&&rint1/c+1<a&&rint2/c‐1>=0)
{y[rint1/c+1][rint2/c‐1] = ‐1;}
if(rint1%c>(c‐r/1.412)&&rint2%c>(c‐r/1.412)&&rint1/c+1<a&&rint2/c+1<a)
{y[rint1/c+1][rint2/c+1] = ‐1;}
} }}
for(int j=0; j<=a‐1;j++)
{ for(int k=0;k<=b‐1; k++)
{ if(x[j][k]==1)
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count++;}
}
for(int j=0; j<=a‐1;j++)
{ for(int k=25;k<=b+24; k++)
{ if(y[j][k]==1&&x[j][k‐1]!=1)
count++;}
}
System.out.println(count);
System.out.println(count/(a*b));
}}

172

173

APPENDIX E: FINANCIAL PRO FORMA
__________________________________________________________________________________________________________________

174

175

176

177

178

179

180

181

182

183

184

185

186

REFERENCES
187

1

Nyren, P., “The History of Pyrosequencing.” Methods Mol Biol., 2006; 373:1‐14

2

Shendure, Jay, and Hanlee Ji. "Next‐generation DNA Sequencing." Nature Biotechnology 26.10

(2008): 1135‐145.
3

Cass, Stephen. "Technology Review: Cheap DNA Sequencing Will Drive a Revolution in Health

Care." Technology Review: The Authority on the Future of Technology. MIT, Mar.‐Apr. 2010. Web. 21
Mar. 2010. <http://www.technologyreview.com/biomedicine/24587/>.
4

Shastry, BS. "Pharmacogenetics and the Concept of Individualized Medicine." The

Pharmacogenomics Journal 16.21 (2006): 16‐21.
5

"Pharmacogenomics: Medicine and the New Genetics." Oak Ridge National Laboratory. Web. 13

Apr. 2010. <http://www.ornl.gov/sci/techresources/Human_Genome/medicine/pharma.shtml>.
6

Ndegwa S. “Pharmacogenomics and warfarin therapy.” Issues Emerg Health Technol. 2007

Oct;(104):1‐8.
7

Cass, Stephen. "Technology Review: Cheap DNA Sequencing Will Drive a Revolution in Health

Care." Technology Review: The Authority on the Future of Technology. MIT, Mar.‐Apr. 2010. Web. 21
Mar. 2010. <http://www.technologyreview.com/biomedicine/24587/>.
8

BRCA1 and BRCA2: Cancer Risk and Genetic Testi ‐ National Cancer Institute." NCI Fact Sheet.

National Cancer Institute. Web. 01 Apr. 2010.
<http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA>.
9

Saglio G, Morotti A, Mattioli G, Messa E, Giugliano E, Volpe G, Rege‐Cambrin G, Cilloni D. “Rational

approaches to the design of therapeutics targeting molecular markers: the case of chronic
myelogenous leukemia.” Ann N Y Acad Sci. 2004 Dec;1028:423‐31.
10

Van't Veer, Laura J., and Rene Bernards. "Enabling Personalized Cancer Medicine through

Analysis of Gene‐expression Patterns." Nature 452 (2008): 564‐70.
11

Leary, Rebecca J. et al."Development of Personalized Tumor Biomarkers Using Massively Parallel

Sequencing." Science Translational Medicine 2.20 (2010): 1‐7.

188

12

Ng, Pauline C., Sarah S. Murray, Samuel Levy, and J. Craig Venter. "An Agenda for Personalized

Medicine." Nature 461 (2009): 724‐26.
13

"Phase 3 Clinical Trial Costs Exceed $26,000 per Patient." Life Sciences World. 13 Oct. 2006. Web.

11 Apr. 2010. <http://www.lifesciencesworld.com/life‐science‐news/view/11080?page=16>.
14

Wolinsky, Howard. “The Thousand‐dollar Genome: Genetic Brinkmanship or

Personalized Medicine?”. Science and Society. 8: 10, 900‐903. (2007).
15

Mardis, Elaine R. “Anticipating the $1,000 Genome”. Genome Biology. (2006).

7:112 , p. 1‐4.
16

Shendure, Jay, and Hanlee Ji. "Next‐generation DNA Sequencing." Nature Biotechnology 26.10

(2008): 1135‐145
17

Schuster, Stephan C. "Next‐generation Sequencing Transforms Today’s Biology." Nature Methods

5.1 (2008): 16‐18
18

Gupta, Pushpendra K. "Single‐molecule DNA Sequencing Technologies for Future Genomics

Research." Cell Press 26.11 (2008): 602‐11
19

Michael, Metzker L. "Sequencing Technologies ‐ the next Generation." Nature Reviews 11 (2010):

31‐46
20

“Introducing HiSeq2000”. Illumina, Inc. 2010.

21

Goren, Alon et al. “Chromatin Profiling by Directly Sequencing Small Quantities of

Immunoprecipitated DNA”. Nature Methods. 2009. DOI:10.1038, 1‐5.
22

Shendure, Jay and Hanlee Ji. “Next‐generation DNA Sequencing”. Nature

Biotechnology. 26:10, 1135‐1145 (2008).
23

“Genome Sequencer FLX System: More Applications, More Publications”. Roche Diagnostics / 454

Life Sciences. www.roche‐applied‐science.com.

189

24

Palmer, Roxanne. “Knome Offers Thriftier Gene Sequencing”. 5/18/2009.

http://www.xconomy.com/boston/2009/05/18/knome‐offers‐thriftier‐gene‐sequencing/
25

Knome Website. 4/2/2010. http://www.knome.com/home/service/process.html

26

McBride, Ryan. “Knome Challenged to Keep in Step with Falling Genetic

Sequencing Prices”. 1/20/2010.
http://www.xconomy.com/boston/2010/01/20/knome‐challenged‐to‐keep‐in‐step‐with‐falling‐
genetic‐sequencing‐prices/2/
27

Ju, Jingyue et al. "Four‐color DNA Sequencing by Synthesis Using Cleavable Fluorescent

Nucleotide Reversible Terminators." Proceedings of the National Academy of Science 103.52 (2006):
19635‐9640.
28

Nanoink Inc. DPN 5000 Desktop NanoFabrication System. Nanoink. 28 Feb. 2010.

<http://www.nanoink.net/d/DPN5000Brochure.pdf>
29

"High‐Throughput DNA Purification with the Magtration 12GC." Oragene DNA. DNA Genotek.

Web. 2 Feb. 2010. <http://www.dnagenotek.com/pdf_files/MKAN007_Magtration.pdf>.
30

"Covaris DNA Shearing." K Biosciences. Web. 3 Feb. 2010.

<http://www.kbioscience.co.uk/instrumentation/acoustics/acoustics‐DNA_shear.htm>.
31

“QIAquick Spin Handbook.” QIAGEN, Mar. 2008. Web. 12 Feb. 2010.

<http://www1.qiagen.com/>.
32

"SureSelect Target Enrichment System Protocol." Agilent Technologies. Web. 5 Feb. 2010.

<http://www.opengenomics.com/Upload/file/PDF/Product_Literature/G336090010_SureSelect_P
rotocol_v1_2.pdf>.
33

"MinElute Handbook." QIAGEN, Mar. 2008. Web. 12 Feb. 2010. <http://www1.qiagen.com/>.

190

34

Yang, Sun Y., Jonas D. Mendelsohn, and Michael F. Rubner. "New Class of Ultrathin, Highly Cell‐

Adhesion‐Resistant Polyelectrolyte Multilayers with Micropatterning Capabilities."
Biomacromolecules 4.4 (2003)
35

Laib, Stephan, and Brian D. MacCraith. "Immobilization of Biomolecules on Cycloolefin Polymer

Supports." Analytical Chemistry 79.16 (2007): 6264‐270
36

"Protocol for Annealing Oligonucleotides." Sigma Aldrich. Web. 01 Apr. 2010.

<http://www.sigmaaldrich.com/life‐science/custom‐oligos/custom‐dna/learning‐
center/annealing‐oligos.html>.
37

Kim, Pilnam, and Keon Woo Kwon. "Soft Lithography for Microfluidics: a Review." BIOCHIP

JOURNAL 2.1 (2008): 1‐11. Web.
38

"CiDRA Precision Services | SlipStream Flow Cell." Precision Services | Custom Machining Services

& Flow Cell Manufacturing. Web. 06 Apr. 2010. <http://www.cidraprecisionservices.com/flow‐
cell/technologies‐capabilities/slipstream.html>.
39

Eddings, Mark A., and Michael A. Johnson. "Determining the Optimal PDMS–PDMS Bonding

Technique for Microfluidic Devices." J. Micromech. Microeng. 18 (2008). Web.
40

Alberts, Bruce. Molecular Biology of the Cell. New York: Garland Science, 2008. Print.

41

"Pfam: Family: DNA_pol_B (PF00136)." Pfam: Home Page. Web. 10 Apr. 2010.

<http://pfam.sanger.ac.uk/family/PF00136>.
42

Blanco, Luis, and Margharita Salas. "Relating Structure to Function." THE JOURNAL OF

BIOLOGICAL CHEMISTRY 271.15 (1996): 8509‐512. Web.
43

Tasara, T., B. Angerer, M. Damond, and H. Winter. "Incorporation of Reporter Molecule‐labeled

Nucleotides by DNA Polymerases. II. High‐density Labeling of Natural DNA." Nucleic Acids Res. 10.31
(2003): 2636‐646. Web.
44

Guo, Jia, Lin Yu, and Jingyue Ju. "An Integrated System for DNA Sequencing by Synthesis Using

Novel Nucleotide Analogues." Acc. Chem. Res. 10 (2009).

191

45

Phillips, Rob, Jane Kondev, and Julie Theriot. Physical Biology of the Cell. New York: Garland

Science, 2009. Print.
46

Nucl. Acids Res. ‐‐ Datta and LiCata 31 (19): 5590 Figure KG774TB1." Oxford Journals | Life

Sciences | Nucleic Acids Research. Web. 06 Apr. 2010. <http://nar.oxfordjournals.org/cgi/content‐
nw/full/31/19/5590/GKG774TB1>.
47

"Highly Efficient DNA Synthesis by the Phage Phi 29 DNA Polymerase. Symmetrical Mode of DNA

Replication. — JBC." The Journal of Biological Chemistry. Web. 06 Apr. 2010.
<http://www.jbc.org/content/264/15/8935.abstract>.
48

"Exponential Distribution ‐‐ from Wolfram MathWorld." Wolfram MathWorld: The Web’s Most

Extensive Mathematics Resource. Web. 06 Apr. 2010.
<http://mathworld.wolfram.com/ExponentialDistribution.html>.
49

Bowers, Jayson et al. "Virtual Terminator Nucleotides for Next‐generation DNA Sequencing."

Nature Methods 6.8 (2009): 593‐95.
50

Bowers, Jayson et al. "Virtual Terminator Nucleotides for Next‐generation DNA Sequencing."

Nature Methods 6.8 (2009): 593‐95.
51

Lanrong, Bi, Dae Hyun Kim, and Jingyue Ju. "Design and Synthesis of a Chemically Cleavable

Fluorescent Nucleotide, 3′‐O‐Allyl‐dGTP‐allyl‐Bodipy‐FL‐510, as a Reversible Terminator for DNA
Sequencing by Synthesis." Journal of the American Chemical Society 128.8 (2006): 2542‐543.
52

Ju, Jingyue et al. "Four‐color DNA Sequencing by Synthesis Using Cleavable Fluorescent

Nucleotide Reversible Terminators." Proceedings of the National Academy of Science 103.52 (2006):
19635‐9640.
53

"Phi29 DNA Polymerase(M0269), Mesophilic DNA Polymerases, NEB." New England Biolabs

Homepage. Web. 11 Apr. 2010. <http://www.neb.com/nebecomm/products/productM0269.asp>.
54

Eid, J., and Et. Al. "Real‐time DNA Sequencing from Single Polymerase Molecules." Science

5910.323 (2009). Web.
55

“ScanArray Express Specifications Sheet”. PerkinElmer Life Sciences.

192

www.perkinelmer.com/lifesciences.
56

Encyclopedia of Laser Physics and Technology ‐ Refractive Index, Index of Refraction." RP

Photonics Consulting  Laser and Amplifier Design, Nonlinear Optics, Fiber Optics, Fiber Lasers and
Amplifiers, Ultrashort Pulses, Optoelectronics, Consultant, Training. Web. 06 Apr. 2010.
<http://www.rp‐photonics.com/refractive_index.html>.
57

Tothova, J., B. Brutovsky, and V. Lisy. "Monomer Motion in Single‐ and Double‐stranded DNA

Coils." Web.
58

"Specialized Microscopy Techniques ‐ Total Internal Reflection Fluorescence (TIRF)." Olympus

Microscopy Resource Center. Web. 06 Apr. 2010.
59

Snedeker, Joseph. "TIRFM Estimate." Message to the author. E‐mail

60

"What Is EMCCD Technology And How Is It Used." EMCCD  Electron Multiplying Charge Coupled

Device. Web. 06 Apr. 2010. <http://www.emccd.com/what_is_emccd/>.
61"IXon

888 EMMCD Camera ‐ 1024 X 1024 Frame Transfer CCD Sensor." Andor Technology 

EMCCD SCMOS ICCD CCD Scientific Cameras, Spectrographs and Microscopy Systems. Web. 13 Apr.
2010. <http://www.andor.com/scientific_cameras/ixon/models/default.aspx?iProductCodeID=2>.
62

Ju, Jingyue et al. “Four‐color DNA Sequencing by Synthesis Using Cleaable

Fluorescent Nucleotide Reversible Terminators”. PNAS. (2006). 103:52, 19635‐19640.
63

Reichman, Jay. Handbook of Optical Filters for Fluorescence Microscopy. Chroma

Technology Corp, 2001.
64

"Rhodamine 6G." Laser Photomedicine and Biomedical Optics at the Oregon Medical Laser Center.

Web. 06 Apr. 2010. <http://omlc.ogi.edu/spectra/PhotochemCAD/html/rhodamine6G.html>.
65

"Unravelling Sensitivity ‐ Signal‐To‐Noise." EMCCD  Electron Multiplying Charge Coupled Device.

Web. 06 Apr. 2010.
<http://www.emccd.com/what_is_emccd/unraveling_sensitivity/Signal_to_Noise_in_CCDs/>.

193

66

Zondervan, Rob, Kulzer Florian, Sergei B. Orlinski, and Michel Orrit. "Photoblinking of Rhodamine

6G in Poly(vinyl Alcohol): Radical Dark State Formed through the Triplet." Journal of Physical
Chemistry A 107.35 (2003): 6770‐776
67

Pawley, James B. "Photobleaching." Handbook of Biological Confocal Microscopy. 3rd ed. New

York, NY: Springer, 2006. 690‐702
68

Ju, Jingyue et al. "Four‐color DNA Sequencing by Synthesis Using Cleavable Fluorescent

Nucleotide Reversible Terminators." Proceedings of the National Academy of Science 103.52 (2006):
19635‐9640.
69

Pop, Mihai, et. al. (2004) Comparative genome assembly. Briefings in Bioinformatics, 5(3):237‐

248
70

Eid, J., Turner, S., et al. (2009). Real‐Time DNA Sequencing from Single Polymerase Molecules.

Science 323: 133‐138.
71

Avak Kahvejian, PhD. Director of Business Development. Helicos BioSciences

Corporation. Personal Communication. 3/26/2010
72

Homer, Nils et al. “BFAST: An Alignment Tool for Large Scale Genome

Resequencing”. PLoS ONE. 2009. 4:11, e7767.
73

"SourceForge.net: Bfast." SourceForge.net: Find and Develop Open Source Software. Web. 06 Apr.

2010. <http://sourceforge.net/apps/mediawiki/bfast/index.php?title=Main_Page>.
74

Pushkarev, Dmitry et al. “Single‐molecule Sequencing of an Individual Human

Genome”. Nature Biotechnology. 2009. 27:9, 847‐850.
75

"Archon Genomics X Prize." X Prize Foundation. Web. 16 Mar. 2010.

<http://genomics.xprize.org/>.
76

Loth, Richard. "What You Should Know About Inflation." Investopedia.org. Investopedia. Web. 2

Apr. 2010. <http://www.investopedia.com/articles/01/021401.asp>.

194

77

Cummings Properties. Advertisement. Cummings Properties. Web. 30 Mar. 2010.

<http://www.cummings.com/directory.html#sitedir>.
78

"Prime Loan Interest Rate Forecast." The Financial Forecast Center, 29 Mar. 2010. Web. 30 Mar.

2010. <http://www.forecasts.org/prime.htm>.
79

"Forecast of 6 Month U.S. Treasuury Bill Yield." The Financial Forecast Center, 7 Feb. 2010. Web.

30 Mar. 2010. <http://www.forecasts.org/6mT.htm>.
80

"Knome Lowers Price of Full Genome From $350,000 to $99,000." The Genetic Geneologist. Nov.

2007. Web. Feb.‐Mar. 2010. <http://www.thegeneticgenealogist.com/2009/04/11/knome‐lowers‐
price‐of‐full‐genomefrom‐350000‐to‐99000/>.
81

Knome Challenged to Keep in Step with Falling Genetic Sequencing Prices." Xconomy. Web. 2 Apr.

2010. <http://www.xconomy.com/boston/2010/01/20/knome‐challenged‐to‐keep‐in‐step‐with‐
falling‐geneticsequencing‐prices/>.
82

Diamond, Scott L. "Drug Discovery and Development." University of Pennsylvania, Philadelphia. 8

Dec. 2009. Lecture.

195

